<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for preventing ophthalmia neonatorum - Kapoor, VS - 2020 | Cochrane Library</title> <meta content="Interventions for preventing ophthalmia neonatorum - Kapoor, VS - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001862.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for preventing ophthalmia neonatorum - Kapoor, VS - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001862.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001862.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for preventing ophthalmia neonatorum" name="citation_title"/> <meta content="Vimal Scott Kapoor" name="citation_author"/> <meta content="University of Toronto" name="citation_author_institution"/> <meta content="vimal.kapoor@utoronto.ca" name="citation_author_email"/> <meta content="Jennifer R Evans" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="S Swaroop Vedula" name="citation_author"/> <meta content="Johns Hopkins University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD001862.pub4" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/09/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001862.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001862.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001862.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Infective Agents [*administration &amp; dosage]; Bias; Blindness [prevention &amp; control]; Erythromycin [administration &amp; dosage]; Ophthalmia Neonatorum [*prevention &amp; control]; Povidone-Iodine [administration &amp; dosage]; Randomized Controlled Trials as Topic; Silver Nitrate [administration &amp; dosage]; Tetracycline [administration &amp; dosage]; Trachoma [prevention &amp; control]; Vision Disorders [prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001862.pub4&amp;doi=10.1002/14651858.CD001862.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="KUoIaN9D";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001862\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001862\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001862.pub4",title:"Interventions for preventing ophthalmia neonatorum",firstPublishedDate:"Sep 21, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001862.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001862.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001862.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001862.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001862.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001862.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001862.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001862.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001862.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001862.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10627 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001862.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0177"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-sec-0171"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/appendices#CD001862-sec-0182"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/supinfo/CD001862StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/supinfo/CD001862StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for preventing ophthalmia neonatorum</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information#CD001862-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Vimal Scott Kapoor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information#CD001862-cr-0005">Jennifer R Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information#CD001862-cr-0006">S Swaroop Vedula</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information/en#CD001862-sec-0193">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 September 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001862.pub4">https://doi.org/10.1002/14651858.CD001862.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001862-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001862-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001862-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001862-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001862-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD001862-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001862-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001862-abs-0001" lang="en"> <section id="CD001862-sec-0001"> <h3 class="title" id="CD001862-sec-0001">Background</h3> <p>Ophthalmia neonatorum is an infection of the eyes in newborns that can lead to blindness, particularly if the infection is caused by <i>Neisseria gonorrhoeae.</i> Antiseptic or antibiotic medication is dispensed into the eyes of newborns, or dispensed systemically, soon after delivery to prevent neonatal conjunctivitis and potential vision impairment. </p> </section> <section id="CD001862-sec-0002"> <h3 class="title" id="CD001862-sec-0002">Objectives</h3> <p>1. To determine if any type of systemic or topical eye medication is better than placebo or no prophylaxis in preventing ophthalmia neonatorum. </p> <p>2. To determine if any one systemic or topical eye medication is better than any other medication in preventing ophthalmia neonatorum. </p> </section> <section id="CD001862-sec-0003"> <h3 class="title" id="CD001862-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, LILACS, and three trials registers, date of last search 4 October 2019. We also searched references of included studies and contacted pharmaceutical companies.  </p> </section> <section id="CD001862-sec-0004"> <h3 class="title" id="CD001862-sec-0004">Selection criteria</h3> <p>We included randomised and quasi‐randomised controlled trials of any topical, systemic, or combination medical interventions used to prevent ophthalmia neonatorum in newborns compared with placebo, no prophylaxis, or with each other. </p> </section> <section id="CD001862-sec-0005"> <h3 class="title" id="CD001862-sec-0005">Data collection and analysis</h3> <p>We used standard methods expected by Cochrane. Outcomes were: blindness or any adverse visual outcome at 12 months, conjunctivitis at 1 month (gonococcal (GC), chlamydial (CC), bacterial (BC), any aetiology (ACAE), or unknown aetiology (CUE)), and adverse effects.  </p> </section> <section id="CD001862-sec-0006"> <h3 class="title" id="CD001862-sec-0006">Main results</h3> <p>We included 30 trials with a total of 79,198 neonates. Eighteen studies were conducted in high‐income settings (the USA, Europe, Israel, Canada), and 12 were conducted in low‐ and middle‐income settings (Africa, Iran, China, Indonesia, Mexico). Fifteen of the 30 studies were quasi‐randomised. We judged every study to be at high risk of bias in at least one domain. Ten studies included a comparison arm with no prophylaxis. There were 14 different prophylactic regimens and 12 different medications in the 30 included studies. </p> <p><i>Any prophylaxis compared to no prophylaxis </i> </p> <p>Unless otherwise indicated, the following evidence comes from studies assessing one or more of the following interventions: tetracycline 1%, erythromycin 0.5%, povidone‐iodine 2.5%, silver nitrate 1%. None of the studies reported data on the primary outcomes: blindness or any adverse visual outcome at any time point. There was only very low‐certainty evidence on the risk of GC with prophylaxis (4/5340 newborns) compared to no prophylaxis (5/2889) at one month (risk ratio (RR) 0.79, 95% confidence interval (CI) 0.24 to 2.65, 3 studies). Low‐certainty evidence suggested there may be little or no difference in effect on CC (RR 0.96, 95% CI 0.57 to 1.61, 4874 newborns, 2 studies) and BC (RR 0.84, 95% CI 0.37 to 1.93, 3685 newborns, 2 studies). Moderate‐certainty evidence suggested a probable reduction in risk of ACAE at one month (RR 0.65, 95% 0.54 to 0.78, 9666 newborns, 8 studies assessing tetracycline 1%, erythromycin 0.5%, povidone‐iodine 2.5%, silver nitrate 1%, colostrum, bacitracin‐phenacaine ointment). There was only very low‐certainty evidence on CUE  (RR 1.75, 95% CI 0.37 to 8.28, 330 newborns, 1 study). Very low‐certainty evidence on adverse effects suggested no increased nasolacrimal duct obstruction (RR 0.93, 95% CI 0.68 to 1.28, 404 newborns, 1 study of erythromycin 0.5% and silver nitrate 1%) and no increased keratitis (single study of 40 newborns assessing silver nitrate 1% with no events).    </p> <p><i>Any prophylaxis compared to another prophylaxis</i> </p> <p>Overall, evidence comparing different interventions did not suggest any consistently superior intervention. However, most of this evidence was of low‐certainty and was extremely limited. </p> </section> <section id="CD001862-sec-0007"> <h3 class="title" id="CD001862-sec-0007">Authors' conclusions</h3> <p>There are no data on whether prophylaxis for ophthalmia neonatorum prevents serious outcomes such as blindness or any adverse visual outcome. Moderate‐certainty evidence suggests that the use of prophylaxis may lead to a reduction in the incidence of ACAE in newborns but the evidence for effect on GC, CC or BC was less certain. Comparison of individual interventions did not suggest any consistently superior intervention, but data were limited. A trial comparing tetracycline, povidone‐iodine (single administration), and chloramphenicol for GC and CC could potentially provide the community with an effective, universally applicable prophylaxis against ophthalmia neonatorum.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001862-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001862-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001862-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001862-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001862-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001862-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001862-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001862-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001862-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001862-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001862-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001862-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001862-abs-0002" lang="en"> <h3>Medication to prevent infection of the eye in newborns</h3> <p><b>What was the aim of the review?</b><br/>The aim of this Cochrane Review was to determine if any medication is better than placebo or no preventive action in preventing ophthalmia neonatorum. Cochrane Review authors collected and analysed all relevant studies to answer this question and found 30 studies.  </p> <p><b>Key messages</b><br/>There are no data on whether prophylaxis for ophthalmia neonatorum prevents serious outcomes such as blindness or visual impairment. Moderate‐certainty evidence suggests that the use of prophylaxis may lead to a reduction in the incidence of any conjunctivitis of any cause in newborns but the evidence for effect on gonococcal or chlamydial conjunctivitis was of low to very‐low certainty. Comparison of individual interventions did not suggest any consistently superior intervention, but data were limited. </p> <p><b>What was studied in the review?</b><br/>Ophthalmia neonatorum, also known as neonatal conjunctivitis, is an infection of the eye surface that affects newborn babies within the first month of life. It is usually caused by infection (bacterial or viral) picked up during birth. If left untreated, it can lead to blindness. The World Health Organization (WHO) recommends the following treatments to prevent ophthalmia neonatorum: </p> <p>• tetracycline hydrochloride 1% eye ointment;<br/>• erythromycin 0.5% eye ointment;<br/>• povidone‐iodine 2.5% solution (water‐based);<br/>• silver nitrate 1% solution;<br/>• chloramphenicol 1% eye ointment. </p> <p>Cochrane Review authors considered these treatments and others to prevent the development of conjunctivitis in newborns. They assessed the two main types of conjunctivitis separately ‐ gonococcal conjunctivitis (caused by <i>Neisseria gonorrhoeae</i> ) and chlamydial conjunctivitis (caused by <i>Chlamydia trachomatis</i> ) <i>‐</i> as well as conjunctivitis due to any bacteria (including <i>Neisseria gonorrhoeae </i> and<i> Chlamydia trachomatis</i>), conjunctivitis due to any cause or conjunctivitis of unknown cause.  </p> <p><b>What are the main results of the review?</b><br/>Cochrane Review authors identified 30 studies with a total of 79,198 newborns. Eighteen studies took place in high‐income settings (the USA, Europe, Israel, Canada), and 12 were conducted in low‐ and middle‐income settings (Africa, Iran, China, Indonesia, Mexico). The main preventive medications evaluated in the included studies were: tetracycline 1%, erythromycin 0.5%, povidone‐iodine 2.5%, and silver nitrate 1%. </p> <p>Newborns given preventive medication are likely to have a lower chance of conjunctivitis within one month of birth compared with newborns not given preventive medication (moderate‐certainty evidence). The evidence for specific causes of conjunctivitis (gonococcal, chlamydial) was less certain as these occurred less frequently in the included studies. None of the studies collected data on blindness or adverse vision outcomes. </p> <p><b>How up‐to‐date is the review?</b><br/>Cochrane Review authors searched for studies published up to 4 October 2019. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001862-sec-0177" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001862-sec-0177"></div> <h3 class="title" id="CD001862-sec-0178">Implications for practice</h3> <section id="CD001862-sec-0178"> <p>Overall, evidence comparing different interventions did not suggest any consistently superior intervention as most of the available evidence was of low‐certainty and was limited.   </p> <p>Our findings lead to the following implications for practice.</p> <p> <ol id="CD001862-list-0011"> <li> <p>Prophylaxis for ophthalmia neonatorum reduces risk of neonatal clinical conjunctivitis (any conjunctivitis of any aetiology (ACAE), based on moderate‐certainty evidence. </p> </li> <li> <p>Our analyses did not identify any medication as effective against gonococcal conjunctivitis (GC), but in general studies were underpowered for this rare outcome and we judged the evidence to be low‐certainty. Thus practice should be based on knowledge about known sensitivity of <i>Neisseria gonorrhoeae</i> to antibiotics. This is especially relevant in the context of world‐wide concern regarding anti‐microbial resistance. </p> </li> <li> <p>Silver nitrate and tetracycline may be considered for prophylaxis of GC, although it seems that silver nitrate is no longer manufactured. Low‐certainty evidence including data from all available comparisons (i.e., povidone‐iodine versus any prophylaxis, silver nitrate, and erythromycin), suggests that povidone‐iodine appears to be effective for prophylaxis against chlamydial conjunctivitis (CC). Although some have suggested that povidone‐iodine may be associated with an elevated risk of chemical conjunctivitis (<a href="./references#CD001862-bbs2-0153" title="MooreDL , MacDonaldNE , Canadian Paediatric Society, Infections Diseases and Immunization Committee. Preventing ophthalmia neonatorum. Paediatric Child Health2015;20(2):93-6.">Moore 2015</a>), our findings indicate that it is in fact associated with a lower risk of chemical conjunctivitis. </p> </li> <li> <p>While chloramphenicol appeared to be more effective than povidone‐iodine for prophylaxis against CC based on low‐certainty evidence, data on its effectiveness for preventing GC were limited. Similarly, tetracycline may be an alternative for povidone‐iodine against CC based on low‐certainty evidence, but the data were insufficient in this regard. </p> </li> <li> <p>Finally, there are no data on whether prophylaxis for ophthalmia neonatorum prevents serious outcomes such as blindness or any adverse visual outcome. </p> </li> </ol> </p> <p>Although moderate‐certainty statistically significant evidence in this review suggests that prophylaxis with antibiotics is more effective than silver nitrate for neonatal clinical conjunctivitis (ACAE), instituting antibiotic prophylaxis may be erroneous. Studies demonstrate an increasing prevalence of antibiotic resistance across the globe, specifically for <i>N gonorrhoeae</i> (<a href="./references#CD001862-bbs2-0147" title="LewisDA . Global resistance of Neisseria gonorrhoeae: when theory becomes reality. Current Opinion in Infectious Disease2014;27(1):62-7.">Lewis 2014</a>). Furthermore, this resistance appeared to be specific against antibiotics found to be more effective than silver nitrate for ACAE in our review, including erythromycin, tetracycline, sulfacetamide, and penicillin (<a href="./references#CD001862-bbs2-0176" title="UnemoM , Del RioC , ShaferWM . Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiology Spectrum2016;4(3):10.1128/microbiolspec. EI10-0009-2015.">Unemo 2016</a>). Policy regarding prophylaxis should thus also be informed by the prevalence of <i>Neisseria</i> and <i>Chlamydia</i> , their resistance profile against specific antibiotics, as well as access to prenatal screening and care. In areas of high prevalence of <i>N gonorrhoeae</i> infection in pregnant women, low access to antenatal maternal screening, and low access to high‐quality care, ophthalmia neonatorum prophylaxis may be considered an effective strategy to prevent blindness. A recent systematic review has found that <i>N gonorrhoeae</i> prevalence in pregnancy can be as high as 4.6% (95% CI 4.0% to 5.2%) in low‐income countries (<a href="./references#CD001862-bbs2-0114" title="DaveyDL , ShullHI , BillingsJD , WangD , AdachiK , KlausnerJD . Prevalence of curable sexually transmitted infections in pregnant women in low- and middle-income countries from 2010 to 2015. A systematic review. Sexually Transmitted Diseases2016;43(7):450-8.">Davey 2016</a>). UNICEF statistics further indicate that only 42% of pregnant women in least‐developed countries attended at least four antenatal care visits, and only 77% attended at least one visit, suggesting that 23% women did not receive any antenatal care (<a href="./references#CD001862-bbs2-0177" title="UNICEF. Antenatal care. data.unicef.org/maternal-health/antenatal-care.html (accessed 13 December 2019).">UNICEF </a>). Considering that neonates born to untreated <i>N gonorrhoeae</i>‐infected mothers have a 30% to 50% risk of developing gonococcal ophthalmia, the risk of blindness in endemic areas is therefore high (<a href="./references#CD001862-bbs2-0145" title="LagaM , MeheusA , PlotP . Epidemiology and control of gonococcal ophthalmia neonatorum. Bulletin of the World Health Organization1989;67(5):471-7.">Laga 1989</a>). In areas where rates of <i>N gonorrhoeae</i> are low in pregnancy, rates of antenatal screening are high, and there is good access to high‐quality care, resource utilisation concerns may render ophthalmia neonatorum prophylaxis a relatively less attractive strategy to prevent blindness. </p> </section> <h3 class="title" id="CD001862-sec-0179">Implications for research</h3> <section id="CD001862-sec-0179"> <p>Our findings lead to the following implications for research.</p> <p> <ol id="CD001862-list-0012"> <li> <p>A trial comparing tetracycline, povidone‐iodine (single administration), and chloramphenicol for GC and CC is likely to provide the community with an effective, universally applicable prophylaxis against ophthalmia neonatorum. Our findings suggest that silver nitrate is more effective than erythromycin and povidone‐iodine for GC with limited evidence against tetracycline and chloramphenicol (<a href="#CD001862-fig-0013">Figure 13</a>). In addition, povidone‐iodine appeared to be more effective than silver nitrate and erythromycin but less effective than chloramphenicol for CC (<a href="#CD001862-fig-0014">Figure 14</a>). Well‐designed trials to determine whether povidone‐iodine is more effective than tetracycline and whether chloramphenicol is more effective than povidone‐iodine for GC and CC will thus yield a universally applicable prophylaxis for ophthalmia neonatorum. </p> </li> <li> <p>Although the eventual goal for prophylaxis for ophthalmia neonatorum is to prevent vision loss and blindness, it is unlikely that trials may be designed to address these outcomes. This is because the outcomes are rare, necessitating large sample sizes to detect meaningful effects. It is also imperative that infections such as gonorrhoea and chlamydia be effectively treated when prenatally diagnosed in the mother. A realistic approach to determine the effect of prophylaxis for preventing GC, and the relative effectiveness of medications to do so, is thus to conduct well‐designed randomised controlled trials in targeted settings, for example in populations with high risk or prevalence of infections such as gonorrhoea and chlamydia. The design of such trials should emphasise procedures to minimise losses to follow‐up and prompt treatment of positive gonococcal or chlamydial cultures with the goal of avoiding severe adverse visual outcomes. </p> </li> <li> <p>A control group with no intervention or placebo is not acceptable in future trials on prophylaxis for ophthalmia neonatorum. </p> </li> <li> <p>Any future trials on the effectiveness of colostrum for prophylaxis of ophthalmia neonatorum must adequately justify the rationale for why colostrum may potentially prevent ophthalmia neonatorum, particularly GC and CC. </p> </li> <li> <p>Gonococcal and chlamydial infections in the newborn may affect and manifest within organs other than the eye. It is possible that prophylaxis for ophthalmia neonatorum may inadvertently mask such infection in non‐ocular sites, but subsequently manifest with non‐ocular symptoms and complications. This hypothesis may be addressed in future trials on prophylaxis for ophthalmia neonatorum by following up neonates for non‐ocular manifestations of gonococcal and chlamydial infections despite successful prevention of ophthalmia neonatorum. </p> </li> <li> <p>Finally, in this review, we did not address the relative effectiveness of available medications as prophylaxis for ophthalmia neonatorum. Whilst we included some pairwise comparisons, a network meta‐analysis is needed to address the relative effects of different interventions using both direct and indirect evidence. Our findings suggest that the data available from the trials identified in this systematic review may be sufficient for a network meta‐analysis for some outcomes such as ACAE, but not for others such as GC. </p> </li> </ol> </p> <p>Finally, some have suggested that strategies other than prophylaxis at birth may be effective to prevent ophthalmia neonatorum, for example screening and treating pregnant women for gonococcal or chlamydial infections (<a href="./references#CD001862-bbs2-0153" title="MooreDL , MacDonaldNE , Canadian Paediatric Society, Infections Diseases and Immunization Committee. Preventing ophthalmia neonatorum. Paediatric Child Health2015;20(2):93-6.">Moore 2015</a>). However, randomised controlled trials may not be the optimal study design to obtain evidence on the relative effects of different strategies for preventing ophthalmia neonatorum due to ethical reasons, for example withholding treatment from women infected with chlamydia or gonorrhoea. Other study designs such as interrupted time series may be optimal to determine the relative effect of different strategies to prevent ophthalmia neonatorum in different settings, for example defined by levels of prenatal screening, baseline risk of maternal gonorrhoeal and chlamydial infections, or access to prenatal care and treatment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001862-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001862-sec-0008"></div> <div class="table" id="CD001862-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> any prophylaxis, including povidone‐iodine, erythromycin, tetracycline, silver nitrate, bacitracin‐phenacaine, colostrum </p> <p><b>Comparison:</b> no prophylaxis (none of the studies used a placebo or sham treatment) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with any prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.79<br/>(0.24 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>8229<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>In 2 of these 3 studies there were no cases of gonococcal conjunctivitis in either study arm. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 3) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(10 to 142) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.96<br/>(0.57 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4874<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="15" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(3 to 8) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 1000<br/>(57 to 161) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.84<br/>(0.37 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3685<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/>(19 to 97) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.65<br/>(0.54 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>9666<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 2) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000<br/>(162 to 134) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75<br/>(0.37 to 8.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/>(7 to 166) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>In a single study (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>), any prophylaxis (erythromycin 0.5% or silver nitrate 1%) did not appear to be associated with an increased risk of nasolacrimal duct obstruction compared with no prophylaxis (RR 0.93, 95% CI 0.68 to 1.28). </p> <p>A single study of 40 newborns comparing silver nitrate 1% with control reported that no events of keratitis were observed in the prophylaxis and no‐prophylaxis groups (<a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded (‐1) for risk of bias: studies were at high or unclear risk of bias.<br/><sup>2</sup>Downgraded (‐2) for imprecision: sparse data. </p> <p><sup>3</sup>Downgraded (‐1) for imprecision: 95% confidence interval includes no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001862-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001862-sec-0009"></div> <section id="CD001862-sec-0010"> <h3 class="title" id="CD001862-sec-0010">Description of the condition</h3> <p>Ophthalmia neonatorum, also called neonatal conjunctivitis, is an inflammatory disorder of the eye surface in newborns in the first month of life (<a href="./references#CD001862-bbs2-0187" title="World Health Organization. Conjunctivitis of the newborn: prevention and treatment at the primary health care level. apps.who.int/iris/bitstream/10665/39482/1/9241560886_eng.pdf (accessed 23 March 2016).">WHO 1986</a>). In Europe in the late 1800s, a significant percentage of blind people were blind due to gonococcal ophthalmia neonatorum. Specifically, it was reported that the percentage of blindness from ophthalmia neonatorum was 8% in Copenhagen, 20% in Berlin, 30% in Vienna, and 45% in Paris (<a href="./references#CD001862-bbs2-0104" title="BullerF . Gonorrhoea in its relation to diseases of the eye. Montreal Medical Journal1900;29(3):185-7.">Buller 1900</a>; <a href="./references#CD001862-bbs2-0133" title="Haussman. Hygiene and public health. Ophthalmia neonatorum. Canadian Practitioner Journal1895;20:697.">Haussman 1895</a>; <a href="./references#CD001862-bbs2-0151" title="MilotJ . Ophthalmia neonatorum of the newborn and its treatments in Canadian medical publications: 1872-1985. Canadian Bulletin of Medical History2008;25(2):499-514.">Milot 2008</a>). It has been estimated that during the same period 20% to 80% of children in blind institutions in Germany were blind due to ophthalmia neonatorum caused by <i>Neisseria gonorrhoeae</i> (<a href="./references#CD001862-bbs2-0142" title="KonigsteinL . For the prophylaxis of blenorrhea neonatorum [Zur Prophylaxe der blenorrhea neonatorum]. Arch Kinderheik1882;2:341-69.">Konigstein 1882</a>). In the USA, amongst new admissions into schools for the blind between 1906 and 1911, approximately 24% were due to ophthalmia neonatorum caused by <i>N gonorrhoeae</i>, with a range of 8% to 45% (<a href="./references#CD001862-bbs2-0101" title="BarsamPC . Specific prophylaxis of gonorrheal ophthalmia neonatorum. A review. New England Journal of Medicine1966;274(13):731-4.">Barsam 1966</a>). In 1918, St Margaret's Hospital in London (UK) was opened specifically for the treatment of neonates with ophthalmia neonatorum (<a href="./references#CD001862-bbs2-0099" title="Anonymous. Hospital for ophthalmia neonatorum. British Journal of Ophthalmology1918;2(11):574.">Anonymous 1918</a>; <a href="./references#CD001862-bbs2-0100" title="Anonymous. The early treatment of ophthalmia neonatorum. British Journal of Ophthalmology1919;3(8):365.">Anonymous 1919</a>). </p> <p>To this day, ophthalmia neonatorum remains a significant cause of childhood corneal blindness in low‐ and middle‐income countries, mainly from <i>N gonorrhoeae</i> (<a href="./references#CD001862-bbs2-0186" title="WhitcherJP , SrinivasanM , UpadhyayMP . Corneal blindness: a global perspective. Bulletin of the World Health Organization2001;79(3):214-21.">Whitcher 2001</a>). There are major epidemiological challenges in determining the prevalence and incidence of blindness from ophthalmia neonatorum. Notwithstanding these limitations, cross‐sectional surveys have estimated the percentage of blindness or severe visual impairment due to ophthalmia neonatorum to be 3% in Ethiopia (<a href="./references#CD001862-bbs2-0140" title="KelloAB , GilbertCE . Causes of severe visual impairment and blindness in schools for the blind in Ethiopia. British Journal of Ophthalmology2003;87(5):526-30.">Kello 2003</a>), 0.7% in Bangladesh (<a href="./references#CD001862-bbs2-0155" title="MuhitMA , ShahSP , GlibertCE . Causes of severe visual impairment and blindness in Bangladesh: a study of 1935 children. British Journal of Ophthalmology2007;91(8):1000-4.">Muhit 2007</a>), 0.4% in Malaysia (<a href="./references#CD001862-bbs2-0141" title="KoayCL , PatelDK , TajunisahI , SubrayanV , LansinghVC . A comparative analysis of avoidable causes of childhood blindness in Malaysia with low income, middle income and high income countries. International Ophthalmology2015;35(2):201-7.">Koay 2015</a>), 5% in East Africa (<a href="./references#CD001862-bbs2-0124" title="FosterA , GilbertC . Community efforts in the reduction of corneal blindness in developing countries. Refractive and Corneal Surgery1991;7(6):445-8.">Foster 1991</a>), 0.8% in India (<a href="./references#CD001862-bbs2-0165" title="RahiJS , SripathiS , GilbertCE , FosterA . Childhood blindness in India: causes in 1318 blind school students in nine states. Eye1995;9(5):545-50.">Rahi 1995</a>), and 2% in Tanzania (<a href="./references#CD001862-bbs2-0123" title="FosterA , SommerA . Corneal ulceration, measles, and childhood blindness in Tanzania. British Journal of Ophthalmology1987;71(5):331-43.">Foster 1987</a>). </p> <p>Gonococcal ophthalmia neonatorum is associated with the most severe consequences. Gonococcal ophthalmia neonatorum is mainly contracted from the mother's infected birth canal during delivery, but can also be contracted in utero by ascending infections. Neonates born to gonorrhoea‐infected mothers have a 30% to 50% risk of developing gonococcal conjunctivitis (<a href="./references#CD001862-bbs2-0145" title="LagaM , MeheusA , PlotP . Epidemiology and control of gonococcal ophthalmia neonatorum. Bulletin of the World Health Organization1989;67(5):471-7.">Laga 1989</a>). Untreated or inappropriately treated gonococcal conjunctivitis can result in corneal perforation and vision loss in 24 hours (<a href="./references#CD001862-bbs2-0119" title="DonhamBP , GiblerWB . Images in emergency medicine. Gonococcal conjunctivitis. Annals of Emergency Medicine2008;52(1):11.">Donham 2008</a>; <a href="./references#CD001862-bbs2-0120" title="Duke-ElderS . Diseases of the outer eye. In: System of Ophthalmology. Vol. 8 (Part 1). St Louis: CV Mosby Co, 1965:167-74.">Duke‐Elder 1965</a>). In one case series, the mean duration of corneal perforation from untreated gonococcal conjunctivitis was 11 days (<a href="./references#CD001862-bbs2-0139" title="KawashimaM , KawakitaT , DenS , TomitaM , ShimazakiJ . Surgical management of corneal perforation secondary to gonococcal keratoconjunctivitis. Eye2009;23(2):339-44.">Kawashima 2009</a>). In areas with low incidence of gonococcal ophthalmia neonatorum or limited access to appropriate health care, appropriate clinical diagnosis and appropriate therapy may be delayed, which can lead to loss of vision (<a href="./references#CD001862-bbs2-0102" title="BastionML , PrakashK , SiowYC , LohSS . Bilateral corneal perforation in a sexually active adult male with gonococcal conjunctivitis. Medical Journal of Malaysia2006;61(3):366-8.">Bastion 2006</a>; <a href="./references#CD001862-bbs2-0150" title="McElneaE , StapletonP , KhanS , StokesJ , HigginsG . Challenges in the management of Neisseria gonorrhoeae keratitis. International Ophthalmology2015;35(1):135-40.">McElnea 2015</a>; <a href="./references#CD001862-bbs2-0170" title="SchwabL , TizazuT . Destructive epidemic of Neisseria gonorrhea in African adults. British Journal of Ophthalmology1985;69(7):525-8.">Schwab 1985</a>; <a href="./references#CD001862-bbs2-0184" title="WanWL , FarkasGC , MayWN . The clinical characteristics and course of adult gonococcal conjunctivitis. American Journal of Ophthalmology1986;102(5):575-83.">Wan 1986</a>). After historical declines in rates of gonorrhoea, it made a resurgence in some high‐income countries In 2012, amongst adults aged 15 to 49 years, it is estimated there were 27 million cases of gonorrhoea globally (<a href="./references#CD001862-bbs2-0159" title="NewmanL , RowleyJ , Vander HoornS , WijesooriyaNS , UnemoM , LowN , et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLOS ONE2015;10(12):e0143304.">Newman 2015</a>). Furthermore, there is increasing incidence of drug‐resistant strains of <i>N gonorrhoeae</i> globally (<a href="./references#CD001862-bbs2-0149" title="MartinI , SawatzkyP , LiuG , MulveyMR . Antimicrobial resistance to Neisseria gonorrhoeae in Canada: 2009-2013. Canadian Communicable Diseases Report2015;41(2):35-41.">Martin 2015</a>; <a href="./references#CD001862-bbs2-0180" title="Van de LaarM , SpiteriG . Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. European Surveillance2012;17(29):202-25.">Van de Laar 2012</a>; <a href="./references#CD001862-bbs2-0189" title="World Health Organization. Baseline report on global sexually transmitted infection surveillance. apps.who.int/iris/bitstream/10665/85376/1/9789241505895_eng.pdf (accessed 24 March 2016).">WHO 2012</a>). The pooled mean prevalence of <i>N gonorrhoeae</i> was estimated at 3.7% (95% confidence interval (CI) 2.8% to 4.6%) in pregnant women in Eastern and Southern Africa, and 2.7% (95% CI 1.7% to 3.7%) in pregnant women in West and Central Africa (<a href="./references#CD001862-bbs2-0108" title="ChicoRM , MayaudP , AritiC , MabeyD , RonsmansC , ChandramohanD . Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA2012;307(19):2079-86.">Chico 2012</a>).  </p> <p>Chlamydial ophthalmia neonatorum is also associated with a high risk of corneal and conjunctival scarring, haemorrhagic conjunctivitis, and rarely, loss of vision if left untreated (<a href="./references#CD001862-bbs2-0106" title="ChangK , ChengVY , KwongNS . Neonatal haemorrhagic conjunctivitis: a specific sign of chlamydial infection. Hong Kong Medical Journal2006;12(1):27-32.">Chang 2006</a>; <a href="./references#CD001862-bbs2-0113" title="DarvilleT . Chlamydia trachomatis infections in neonates and young children. Seminars in Pediatric Infectious Diseases2005;16(4):235-44.">Darville 2015</a>; <a href="./references#CD001862-bbs2-0186" title="WhitcherJP , SrinivasanM , UpadhyayMP . Corneal blindness: a global perspective. Bulletin of the World Health Organization2001;79(3):214-21.">Whitcher 2001</a>). It is caused by transmission of <i>Chlamydia trachomatis</i> from the mother to the newborn during delivery. The risk of chlamydial transmission from an infected mother to newborns is 15% on average (range = 8% to 44%; <a href="./references#CD001862-bbs2-0077" title="RosenmanMB , MohanBE , DownsSM , KleimanMB . Oral erythromycin prophylaxis vs watchful waiting in caring for newborns exposed to Chlamydia trachomatis. Archives of Pediatrics and Adolescent Medicine2003;157(6):565-71. ">Rosenman 2003</a>). Furthermore, an increased prevalence of chlamydial infection in some high‐income countries is associated with a commensurate rise in risk of chlamydial conjunctivitis (<a href="./references#CD001862-bbs2-0163" title="QuirkeM , CullinaneA . Recent trends in chlamydial and gonococcal conjunctivitis among neonates and adults in an Irish hospital. International Journal of Infectious Diseases2008;12(4):371-3.">Quirke 2008</a>). Chlamydial ophthalmia neonatorum is much more prevalent than gonococcal ophthalmia neonatorum, and has historically been underdiagnosed due to lack of accurate diagnostic techniques (<a href="./references#CD001862-bbs2-0113" title="DarvilleT . Chlamydia trachomatis infections in neonates and young children. Seminars in Pediatric Infectious Diseases2005;16(4):235-44.">Darville 2015</a>; <a href="./references#CD001862-bbs2-0193" title="YipPP , ChanWH , YipKT , QueTL , KwongNS , HoCK . The use of polymerase chain reaction assay versus conventional methods in detecting neonatal chlamydial conjunctivitis. Journal of Pedatric Ophthalmology and Strabismus2008;45(4):234-9.">Yip 2008</a>). Pooled mean prevalence of <i>C trachomatis</i> was higher at 6.9% (95% CI 5.1% to 8.6%) in pregnant women in Eastern and Southern Africa, and 6.1% (95% CI 4.0% to 8.3%) in pregnant women in West and Central Africa (<a href="./references#CD001862-bbs2-0108" title="ChicoRM , MayaudP , AritiC , MabeyD , RonsmansC , ChandramohanD . Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA2012;307(19):2079-86.">Chico 2012</a>). </p> <p>Ophthalmia neonatorum may be caused by bacteria other than <i>Neisseria</i> and <i>Chlamydia</i>. The relative frequencies of bacterial causes of ophthalmia neonatorum reported in the literature vary by study and geographic location (<a href="./references#CD001862-bbs2-0098" title="AminiE , GhasemiM , DaneshjouK . A five-year study in Iran of ophthalmia neonatorum: prevalence and etiology. Medical Science Monitor2008;14(2):90-6.">Amini 2008</a>; <a href="./references#CD001862-bbs2-0107" title="ChhabraMS , MotleyWW , MortensenJE . Eikenella corrodens as a causative agent for neonatal conjunctivitis. Journal of AAPOS2008;12(5):524-5.">Chhabra 2008</a>; <a href="./references#CD001862-bbs2-0117" title="Di BartolomeoS , MirtaDH , JanerM , Rodríguez FermepinMR , SaukaD , MagariñosF , et al. Incidence of Chlamydia trachomatis and other potential pathogens in neonatal conjunctivitis. International Journal of Infectious Diseases2015;5(3):139-43.">Di Bartolomeo 2001</a>; <a href="./references#CD001862-bbs2-0118" title="Di BartolomeoS , HigaM , JanerM , PennisiA , BalbinG , PrioreG . Neonatal conjunctivitis in a hospital at Gran Buenos Aires. Last 5 years update. Revista Argentina de Microbiologia2005;37(3):139-41.">Di Bartolomeo 2005</a>; <a href="./references#CD001862-bbs2-0132" title="HammerschlagMR . Neonatal conjunctivitis. Pediatric Annals1993;22(6):346-51.">Hammerschlag 1993</a>; <a href="./references#CD001862-bbs2-0152" title="MohileM , DeorariAK , SatpathyG , SharmaA , SinghM . Microbiological study of neonatal conjunctivitis with special reference to Chlamydia trachomatis. Indian Journal of Ophthalmology2002;50(4):295-9.">Mohile 2002</a>; <a href="./references#CD001862-bbs2-0168" title="SandströmKI , BellTA , ChandlerJW , KuoCC , WangSP , GraystonJT , et al. Microbial causes of neonatal conjunctivitis. Journal of Pediatrics1984;105(5):706-11.">Sandström 1984</a>). Even though certain bacteria are frequently cultured from neonates with conjunctivitis (e.g. <i>Staphylococcus aureus</i>), their role as the causative agent of conjunctivitis is uncertain because these bacteria may be frequently cultured from the eyes of asymptomatic neonates (<a href="./references#CD001862-bbs2-0098" title="AminiE , GhasemiM , DaneshjouK . A five-year study in Iran of ophthalmia neonatorum: prevalence and etiology. Medical Science Monitor2008;14(2):90-6.">Amini 2008</a>; <a href="./references#CD001862-bbs2-0126" title="FransenL , vanden BergheP , MertensA . Incidence and bacterial aetiology of neonatal conjunctivitis. European Journal of Pediatrics1987;146(2):152-5.">Fransen 1987</a>; <a href="./references#CD001862-bbs2-0144" title="KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. American Journal of Epidemiology1993;138(5):326-32.">Krohn 1993</a>). </p> <p>Finally, some viruses such as herpes simplex and adenovirus can cause ophthalmia neonatorum (<a href="./references#CD001862-bbs2-0097" title="AlbertDM , Jakobiec FA (editors). Principles and Practice of Ophthalmology: Clinical Practice. Philadelphia: W.B. Saunders Company, 1994.">Albert 1994</a>). Often, no causative pathogen can be found in newborns with ophthalmia neonatorum due to methods for obtaining and culturing for bacteria, or due to causes other than bacteria such as chemical conjunctivitis or nasolacrimal duct obstruction (<a href="./references#CD001862-bbs2-0169" title="SandströmI . Etiology and diagnosis of neonatal conjunctivitis. Acta Paediatrica Scandinavica1967;76(2):221-7.">Sandström 1987</a>). </p> <p>While most micro‐organisms that cause ophthalmia neonatorum are acquired during passage through the birth canal, others are acquired after birth from caregivers or the nasopharyngeal passages of the newborn (<a href="./references#CD001862-bbs2-0144" title="KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. American Journal of Epidemiology1993;138(5):326-32.">Krohn 1993</a>). The relative importance of intrapartum versus postpartum sources of infection varies based on extraneous factors such as socioeconomic status of mothers (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>; <a href="./references#CD001862-bbs2-0181" title="VedanthamV . Prophylaxis of ophthalmia neonatorum. British Journal of Ophthalmology2004;88(10):1352.">Vedantham 2004</a>; <a href="./references#CD001862-bbs2-0182" title="VermaM , ChhatwalJ , VarughesePV . Neonatal conjunctivitis: a profile. Indian Pediatrics1994;31(11):1357-61.">Verma 1994</a>). </p> </section> <section id="CD001862-sec-0011"> <h3 class="title" id="CD001862-sec-0011">Description of the intervention</h3> <p>There are four strategies to achieve the public health goal of eliminating ophthalmia neonatorum and its adverse vision consequences: </p> <p> <ol id="CD001862-list-0001"> <li> <p>preventing spread of sexually transmitted infections;</p> </li> <li> <p>screening women who are pregnant for genital infection;</p> </li> <li> <p>administering prophylaxis to newborns soon after birth;</p> </li> <li> <p>diagnosing and treating eye infections in newborns at an early stage (<a href="./references#CD001862-bbs2-0125" title="FosterA , VolkerK . Ophthalmia neonatorum in developing countries. New England Journal of Medicine1995;332(9):600-1.">Foster 1995</a>; <a href="./references#CD001862-bbs2-0145" title="LagaM , MeheusA , PlotP . Epidemiology and control of gonococcal ophthalmia neonatorum. Bulletin of the World Health Organization1989;67(5):471-7.">Laga 1989</a>). </p> </li> </ol> </p> <p>German‐born obstetrician and gynaecologist Carl Siegmund Franz Credé introduced the third strategy, ophthalmia neonatorum prophylaxis (<a href="./references#CD001862-bbs2-0111" title="CredeCSF . Die Verhütung der Augenentzündung der Neugeborenen (Ophthalmoblennorrhoea neonatorum) der häufigsten und wichtigsten Ursache der Blindheit. Berlin: Hirschwald, 1884.">Crede 1884</a>; <a href="./references#CD001862-bbs2-0121" title="DunnPM . Dr. Carl Credé (1819-1892) and the prevention of ophthalmia neonatorum. Archives of Disease in Children. Fetal and Neonatal Edition2000;83(2):F158-9.">Dunn 2000</a>; <a href="./references#CD001862-bbs2-0160" title="OrielJD . Eminent venereologists 5: Carl Credé. Genitourin Medicine1991;67(1):67-9.">Oriel 1991</a>). In a seminal study, albeit a case series, Credé showed that silver nitrate administered to newborns reduced the incidence of ophthalmia neonatorum from 13.6% to 0.05% (<a href="./references#CD001862-bbs2-0110" title="CredeCS . Ophthalmia neonatorum in newborn children [Die verhürtung der augenentzündung der neugeborenen]. Archiv fur Gynaekologie1881;17:50-3.">Crede 1881</a>). The relevance of prophylaxis for ophthalmia neonatorum and debate about the optimal medication has since evolved in response to the discovery of new antibiotics; concerns about side effects with silver nitrate such as chemical conjunctivitis and impact on maternal‐infant bonding; and the declining prevalence of <i>N gonorrhoeae</i> in some countries and increased reporting rates of chlamydial ophthalmia neonatorum in others (<a href="./references#CD001862-bbs2-0158" title="NapchanBM , MoralesRP , CarvalhoML , CunhaKV , FiguerasA . From suspicion to action: the chemical conjunctivitis and silver nitrate connexion example in Brazilian hospitals. Pharmacoepidemiology and Drug Safety2005;14(8):555-9.">Napchan 2005</a>; <a href="./references#CD001862-bbs2-0029" title="WahlbergV . Crede's prevention method has lost its justification today [Credeprofylax - en metod som idag saknar berattigande]. Nordisk Medicin1982;97(2):36-7. WahlbergV . Reconsideration of Crede prophylaxis. A study of maternity and neonatal care. Acta Paediatrica Scandinavica1982;295(Suppl):1-73. ">Wahlberg 1982</a>). </p> <p>Initially, studies looking for alternatives to silver nitrate mainly examined penicillin as ophthalmia neonatorum prophylaxis. Later, erythromycin and tetracycline were studied in comparison to silver nitrate, and more recently, povidone‐iodine. There have been studies of other prophylactic agents, but the majority of jurisdictions in the world today appear to use either erythromycin or povidone‐iodine as ophthalmia neonatorum prophylaxis. However, there remains a high degree of variability in the agents used for ophthalmia neonatorum prophylaxis, with some jurisdictions using prophylactic medications that are uncommon or not well‐studied (<a href="./references#CD001862-bbs2-0130" title="GualaA , GuarinoR , ZaffaroniM , MartanoC , FabrisC , PastoreG , et al. The impact of national and international guidelines on newborn care in the nurseries of Piedmont and Aosta Valley. BMC Pediatrics2005;5:45. [DOI: 10.1186/1471-2431-5-45]">Guala 2005</a>; <a href="./references#CD001862-bbs2-0194" title="ZlotoO , GharaibehA , MezerE , StankovicB , IsenbergS , Wygnanski-JaffeT . Ophthalmia neonatorum treatment and prophylaxis: IPOSC global study. Graefe's Archive for Clinical and Experimental Ophthalmology2016;254(3):577-82.">Zloto 2016</a>). </p> <p>Erythromycin and tetracycline gained acceptance as prophylactic agents in the 1980s because of their allegedly superior activity against <i>C trachomatis</i> and because they lacked some of the side effects of silver nitrate, such as chemical conjunctivitis (<a href="./references#CD001862-bbs2-0135" title="Isenberg SJ (editor). The Eye in Infancy. 2nd edition. St Louis: Mosby, 1994.">Isenberg 1994a</a>). However, it remains unresolved whether these antibiotic agents are, in fact, any more effective than silver nitrate in preventing chlamydial conjunctivitis. Furthermore, the emergence of beta‐lactamase‐producing <i>N gonorrhoeae</i> has reduced the prophylactic effectiveness of erythromycin and tetracycline (<a href="./references#CD001862-bbs2-0137" title="IsonA , DillonJR , TapsallJW . The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi. Lancet1998;351(Suppl):SM8-11.">Ison 1998</a>; <a href="./references#CD001862-bbs2-0149" title="MartinI , SawatzkyP , LiuG , MulveyMR . Antimicrobial resistance to Neisseria gonorrhoeae in Canada: 2009-2013. Canadian Communicable Diseases Report2015;41(2):35-41.">Martin 2015</a>; <a href="./references#CD001862-bbs2-0180" title="Van de LaarM , SpiteriG . Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. European Surveillance2012;17(29):202-25.">Van de Laar 2012</a>; <a href="./references#CD001862-bbs2-0189" title="World Health Organization. Baseline report on global sexually transmitted infection surveillance. apps.who.int/iris/bitstream/10665/85376/1/9789241505895_eng.pdf (accessed 24 March 2016).">WHO 2012</a>). Povidone‐iodine, introduced in studies in the 1960s as a surgical antiseptic and disinfectant agent, has been used relatively more recently as a candidate for ophthalmia neonatorum prophylaxis. It allegedly has many advantages over silver nitrate, erythromycin, and tetracycline, including economic feasibility, broader antibacterial spectrum, lack of generation of bacterial resistance, and no reports of anaphylaxis (<a href="./references#CD001862-bbs2-0129" title="GrzybowskiA , KanclerzP , MyersWG . The use of povidone-iodine in ophthalmology. Current Opinion in Ophthalmology2018;29(1):19-32.">Grzybowski 2018</a>; <a href="./references#CD001862-bbs2-0136" title="IsenbergSJ , AptL , YoshimoriR , LeakeR , RichR . Povidone-iodine for ophthalmia neonatorum prophylaxis. American Journal of Ophthalmology1994;118(6):701-6.">Isenberg 1994b</a>). Other prophylactic measures that have been used beyond antimicrobial or antiseptic agents include cleansing the eyelids with sterile swabs; cleansing the eyes with distilled water and wiping dry; and physiological saline. </p> <p>Credé’s original procedure for ophthalmic prophylaxis called for administration “directly after birth” (<a href="./references#CD001862-bbs2-0110" title="CredeCS . Ophthalmia neonatorum in newborn children [Die verhürtung der augenentzündung der neugeborenen]. Archiv fur Gynaekologie1881;17:50-3.">Crede 1881</a>). Timing of prophylaxis of ophthalmia neonatorum after birth has been addressed by one small study (<a href="./references#CD001862-bbs2-0154" title="MuheL , TafariN . Is there a critical time for prophylaxis against neonatal gonococcal ophthalmia?Genitourinary Medicine1986;62(5):356-7.">Muhe 1986</a>). This study suggested that increasing delay in administration of prophylaxis after birth can lead to a trend to increasing failure of the intervention (<a href="./references#CD001862-bbs2-0154" title="MuheL , TafariN . Is there a critical time for prophylaxis against neonatal gonococcal ophthalmia?Genitourinary Medicine1986;62(5):356-7.">Muhe 1986</a>). This study also suggested that a delay in prophylaxis greater than four hours can lead to a four‐ to five‐fold risk of gonococcal ophthalmia neonatorum (<a href="./references#CD001862-bbs2-0145" title="LagaM , MeheusA , PlotP . Epidemiology and control of gonococcal ophthalmia neonatorum. Bulletin of the World Health Organization1989;67(5):471-7.">Laga 1989</a>; <a href="./references#CD001862-bbs2-0154" title="MuheL , TafariN . Is there a critical time for prophylaxis against neonatal gonococcal ophthalmia?Genitourinary Medicine1986;62(5):356-7.">Muhe 1986</a>). Three guidelines have suggested optimal timing of prophylaxis, but cited no evidence: In 2002, the Canadian Pediatric Society Guideline suggested prophylaxis administration within one hour after birth (<a href="./references#CD001862-bbs2-0109" title="Canadian Paediatric Society. Recommendations for the prevention of neonatal ophthalmia. Paediatric Child Health2002;7(7):480-8.">CPS 2002</a>); in 2011, the United States Preventive Services Task Force recommendation suggested timing of prophylaxis administration no later than 24 hours after birth (<a href="./references#CD001862-bbs2-0178" title="US Preventive Services Task Force (USPSTF). Ocular prophylaxis for gonococcal ophthalmia neonatorum: U.S. Preventive Services Task Force reaffirmation recommendation statement. Agency for Healthcare Research and Quality2011.">USPSTF 2011</a>); and in 2017, the World Health Organization (WHO) suggested timing of prophylaxis to be “immediately after birth” (<a href="./references#CD001862-bbs2-0192" title="World Health Organization. WHO recommendations on newborn health: guidelines approved by the WHO Guidelines Review Committee. Vol. WHO/MCA/17.07. Geneva: World Health Organization, 2017. [CC BY-NC-SA 3.0 IGO]">WHO 2017</a>). </p> </section> <section id="CD001862-sec-0012"> <h3 class="title" id="CD001862-sec-0012">How the intervention might work</h3> <p>Ophthalmia neonatorum prophylaxis agents used around the world are antimicrobial or antiseptic agents, which, when administered topically, or rarely systemically, destroy or inhibit micro‐organisms in the eye to prevent conjunctivitis and keratitis (<a href="./references#CD001862-bbs2-0143" title="KramerA , Behrens-Baumann W (editors). Antiseptic Prophylaxis and Therapy in Ocular Infections. Vol. 33. Developments in Ophthalmology. Basel: Karger, 2000.">Kramer 2002</a>). The micro‐organisms may be acquired from the mother’s infected birth canal, in utero by ascending infections, or from the hospital or home environment. </p> </section> <section id="CD001862-sec-0013"> <h3 class="title" id="CD001862-sec-0013">Why it is important to do this review</h3> <p>Launched in 1999, Vision 2020 is a global initiative of the WHO and the International Agency for the Prevention of Blindness with the goal to eliminate avoidable blindness by 2020 (<a href="./references#CD001862-bbs2-0188" title="World Health Organization. What is VISION 2020?www.who.int/blindness/partnerships/vision2020/en/ (accessed 24 March 2016).">WHO 1999</a>). Vision 2020 was updated by the WHO in 2013 to develop a Global Action Plan from 2014 to 2019 “to reduce the prevalence of avoidable visual impairment by 25% by 2019” (<a href="./references#CD001862-bbs2-0190" title="World Health Organization. Universal eye health: a global action plan 2014–2019. www.who.int/blindness/actionplan/en/ (accessed 23 March 2016).">WHO 2013</a>). Controlling childhood blindness is a high priority of this plan, as it has been estimated that 4% of all global blindness is due to childhood blindness, and that 45% of all childhood blindness is avoidable. Corneal scarring is one of five childhood blindness conditions prioritised for control. While vitamin A and measles are responsible for the majority of corneal scarring, ophthalmia neonatorum is a significant cause of corneal blindness, mainly in low‐ and middle‐income countries such as those in sub‐Saharan Africa (<a href="./references#CD001862-bbs2-0127" title="GilbertC , RahiJ . Visual impairment and blindness in children – magnitude and causes. In: JohnsonG , MinassianD , WealeW , WestS , editors(s). Epidemiology of Eye Disease. London: Imperial College Press, 2012.">Gilbert 2012</a>; <a href="./references#CD001862-bbs2-0166" title="RobaeiD , WatsonS . Corneal blindness: a global problem. Clinical and Experimental Ophthalmology2014;42(3):213-4.">Robaei 2014</a>; <a href="./references#CD001862-bbs2-0186" title="WhitcherJP , SrinivasanM , UpadhyayMP . Corneal blindness: a global perspective. Bulletin of the World Health Organization2001;79(3):214-21.">Whitcher 2001</a>; <a href="./references#CD001862-bbs2-0190" title="World Health Organization. Universal eye health: a global action plan 2014–2019. www.who.int/blindness/actionplan/en/ (accessed 23 March 2016).">WHO 2013</a>). </p> <p>In sub‐Saharan Africa, the two major agents responsible for corneal blindness and scarring, <i>N gonorrhoeae</i> and <i>C trachomatis</i>, have high prevalence in pregnant women. </p> <p>The WHO, in conjunction with the United Nations Children’s Fund and the United Nations Population Fund, has developed guidelines through its Integrated Management of Pregnancy and Childbirth (IMPAC) strategy to reduce child and maternal mortality and morbidity. The IMPAC approach includes preventative and curative elements, targeting health systems, health workers, families, and communities. The <i>Pregnancy, Childbirth, Postpartum and Newborn Care</i> guide’s evidence‐based recommendations include eye prophylaxis for prevention of ophthalmia neonatorum. Evidence on this intervention and the relative effectiveness of different prophylactic regimens is therefore essential to this intervention (<a href="./references#CD001862-bbs2-0191" title="WHO, UN Population Fund, UNICEF. Integrated Management of Pregnancy and Childbirth. Pregnancy, Childbirth, Postpartum and Newborn Care: a Guide for Essential Practice. 3rd edition. Geneva: WHO, 2015.">WHO 2015</a>). </p> <p>There is considerable global variability in recommendations on whether to use ophthalmia neonatorum prophylaxis, and the prophylactic agent used. Certain jurisdictions still carry out ophthalmia neonatorum prophylaxis, including Brazil (<a href="./references#CD001862-bbs2-0105" title="CaligarisLS , MedinaNH , DurkinSR , Haro-MunozE , ChinenNH . Assessment of the current ocular health practices within neonatal units in the City of São Paulo, Brazil. Ophthalmic Epidemiology2010;17(5):333-7.">Caligaris 2010</a>), the USA (<a href="./references#CD001862-bbs2-0178" title="US Preventive Services Task Force (USPSTF). Ocular prophylaxis for gonococcal ophthalmia neonatorum: U.S. Preventive Services Task Force reaffirmation recommendation statement. Agency for Healthcare Research and Quality2011.">USPSTF 2011</a>), Italy (<a href="./references#CD001862-bbs2-0130" title="GualaA , GuarinoR , ZaffaroniM , MartanoC , FabrisC , PastoreG , et al. The impact of national and international guidelines on newborn care in the nurseries of Piedmont and Aosta Valley. BMC Pediatrics2005;5:45. [DOI: 10.1186/1471-2431-5-45]">Guala 2005</a>), Spain (<a href="./references#CD001862-bbs2-0148" title="LunaMS , AlonsoCR , MussonsFB , UrcelayIE , CondeJR , NarbonaE , et al. Recommendations for the care of the healthy normal newborn at delivery and during the first postnatal hours. Anales de Pediatria2009;71(4):349-61.">Luna 2009</a>), Canada (<a href="./references#CD001862-bbs2-0153" title="MooreDL , MacDonaldNE , Canadian Paediatric Society, Infections Diseases and Immunization Committee. Preventing ophthalmia neonatorum. Paediatric Child Health2015;20(2):93-6.">Moore 2015</a>), Slovenia (<a href="./references#CD001862-bbs2-0138" title="Jug DošlerA , PetročnikP , MivšekAP , ZakšekT , SkubicM . Neonatal prophylaxis: prevention of Vitamin K deficiency haemorrhage and neonatal ophthalmia. Zdravstveno Varstvo2015;54(3):184-93.">Jug Došler 2015</a>), France (<a href="./references#CD001862-bbs2-0112" title="DagevilleC . Is prophylaxis against ophthalmia neonatorum justified in French maternity wards?Archives of Pediatrics2015;22(2):128-9.">Dageville 2015</a>), Turkey (<a href="./references#CD001862-bbs2-0122" title="EserI , BozaciM . A nationwide survey of prophylaxis against ophthalmia neonatorum in Turkey. Turkish Journal of Medical Sciences2009;39(5):771-4.">Eser 2009</a>), certain areas of Central America, some countries in Africa, parts of the Far East, areas of the Middle East, and sections of Central Asia (<a href="./references#CD001862-bbs2-0194" title="ZlotoO , GharaibehA , MezerE , StankovicB , IsenbergS , Wygnanski-JaffeT . Ophthalmia neonatorum treatment and prophylaxis: IPOSC global study. Graefe's Archive for Clinical and Experimental Ophthalmology2016;254(3):577-82.">Zloto 2016</a>). Norway, Great Britain, Sweden, the Netherlands (<a href="./references#CD001862-bbs2-0167" title="RoursIG , HammerschlagMR , OttA , De FaberTJ , VerbrughHA , deGrootR , et al. Chlamydia trachomatis as a cause of neonatal conjunctivitis in Dutch infants. Pediatrics2008;121(2):e321-6.">Rours 2008</a>; <a href="./references#CD001862-bbs2-0183" title="Volksgezondheid (Leidschendam) Geneeskundige Hoofdinspectie van de. Methode van Crede, ja of nee?: staatstoezicht op de volksgezondheid. Geneeskundigen Hoofdinspectie van de Volksgezondheid, 1980.">Volksgezondheid 1980</a>), Australia (<a href="./references#CD001862-bbs2-0171" title="ShawEB . Questions need for prophylaxis with silver nitrate. Pediatrics1977;59(5):792.">Shaw 1977</a>), Belgium (<a href="./references#CD001862-bbs2-0175" title="TriboletS , GillardP , LefèvreA , RigoV . Gonococcal ophthalmia neonatorum: clinical illustration, prevention, and future prospects. Archives of Pediatrics2016;23(3):297-300.">Tribolet 2016</a>), and Denmark (<a href="./references#CD001862-bbs2-0161" title="PandeH . When the custom goes blind - 25 years without Credé's prophylaxis [Når sedvane gjør blind – 25 år uten Credés lapisprofylakse]. Tidsskr Nor Lægeforen2006;8(126):1087-90.">Pande 2006</a>), discontinued ophthalmia neonatorum prophylaxis several years ago (<a href="./references#CD001862-bbs2-0143" title="KramerA , Behrens-Baumann W (editors). Antiseptic Prophylaxis and Therapy in Ocular Infections. Vol. 33. Developments in Ophthalmology. Basel: Karger, 2000.">Kramer 2002</a>). As recently as 2010, England and Wales removed ophthalmia neonatorum from the list of notifiable diseases, even though there is some evidence of significant under‐reporting of the incidence of ophthalmia neonatorum (<a href="./references#CD001862-bbs2-0115" title="Department of Health. Explanatory memorandum to the health protection (part 2a orders) regulations, 2010. No. 658. www.legislation.gov.uk/uksi/2010/658/pdfs/uksiem_20100658_en.pdf (accessed 25 November 2013).">Department of Health, UK 2010</a>; <a href="./references#CD001862-bbs2-0116" title="DharmasenaA , HallN , GoldacreR , GoldacreMJ . Time trends in ophthalmia neonatorum and dacryocystitis of the newborn in England, 2000-2011: database study. Sexually Transmitted Infections2015;91(5):342-5.">Dharmasena 2015</a>). In Canada, there have been recent recommendations that ophthalmia neonatorum be discontinued, although no legislative changes have been made in the country as yet (<a href="./references#CD001862-bbs2-0153" title="MooreDL , MacDonaldNE , Canadian Paediatric Society, Infections Diseases and Immunization Committee. Preventing ophthalmia neonatorum. Paediatric Child Health2015;20(2):93-6.">Moore 2015</a>). Some groups in Canada oppose this recommendation (<a href="./references#CD001862-bbs2-0156" title="MulhollandC , GardinerJ . Ophthalmia neonatorum prophylaxis. Canadian Journal of Ophthalmology2015;50(4):328-9.">Mulholland 2015</a>), and others question whether the alternative strategy of prenatal screening is an optimal sole substitute for prophylaxis (<a href="./references#CD001862-bbs2-0162" title="PoliquinV , WylieJ , ColeR , YudinMH , Van CaesseeleP . Preparedness for implementing change in neonatal ocular prophylaxis policies. Journal of Obstetrics and Gynaecology Canada2016;38(1):7-8.">Poliquin 2015</a>). The Canadian recommendation to discontinue prophylaxis has been made in spite of the fact that the rate of chlamydia in Canada has increased 57.6% (<a href="./references#CD001862-bbs2-0173" title="TottenS , MacLeanR , PayneE , SeveriniA . Chlamydia and lymphogranuloma venereum in Canada: 2003-2012 Summary Report. Canadian Communicable Diseases Report2015;41(2):20-25.">Totten 2015a</a>), and the rate of gonorrhoea has increased 38.9% from 2003 to 2012, mainly in women (<a href="./references#CD001862-bbs2-0174" title="TottenS , MacLeanR , PayneE . Gonorrhea in Canada: 2003-2012. Canadian Communicable Diseases Report2015;41(2):26-29.">Totten 2015b</a>). In France, ophthalmia neonatorum prophylaxis is no longer universally recommended. Ocular prophylaxis is only recommended for neonates where there is a risk of sexually transmitted infections in the mother, and where the mother has had poor prenatal care (<a href="./references#CD001862-bbs2-0096" title="Agence Française de Sécurité Sanitaire. Prophylaxis of conjunctival infections of newborn children [Prophylaxie des infections conjonctivales du nouveau-né]. ansm.sante.fr/var/ansm_site/storage/original/application/8d7b81471c088327d5343c5c102feafa.pdf (accessed 23 March 2016).">AFSSAPS 2010</a>). Still, other jurisdictions are looking to implement ophthalmia neonatorum prophylaxis (<a href="./references#CD001862-bbs2-0024" title="AlexandreI , JustelM , MartinezP , Ortiz de LejarazuR , PastorJC . First attempt to implement ophthalmia neonatorum prophylaxis in Angola: microorganisms, efficacy, and obstacles. Journal of Ophthalmology2015;2015:Article ID 326526. [DOI: 10.1155/2015/326526]">Pastor 2015</a>). </p> <p>The global variability in practices regarding prophylaxis for ophthalmia neonatorum may be explained by the following: </p> <p> <ol id="CD001862-list-0002"> <li> <p>there is uncertainty about the evidence of effectiveness and risk‐benefit ratio of the various prophylactic agents, particularly against <i>C trachomatis</i> and <i>N gonorrhoeae</i>; </p> </li> <li> <p>the prevalence and distribution of <i>N gonorrhoeae</i> and <i>C trachomatis </i>is variable, and has evolved over time, raising the possibility that universal prophylaxis may no longer be justified; </p> </li> <li> <p>the relative effectiveness of different medications for prophylaxis of ophthalmia neonatorum remains to be determined. </p> </li> </ol> </p> <p>In this systematic review, we aimed to synthesise the available evidence to inform care and policy regarding prophylaxis for ophthalmia in the newborn. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001862-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001862-sec-0014"></div> <p>1. To determine if any type of systemic or topical eye medication is better than placebo or no prophylaxis in preventing ophthalmia neonatorum. </p> <p>2. To determine if any one systemic or topical eye medication is better than any other medication in preventing ophthalmia neonatorum. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001862-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001862-sec-0015"></div> <section id="CD001862-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001862-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised and quasi‐randomised controlled trials.</p> </section> <section id="CD001862-sec-0018"> <h4 class="title">Types of participants</h4> <p>Trials that enrolled newborn infants were eligible for inclusion in the review.</p> </section> <section id="CD001862-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing any topical, systemic, or combination medical interventions with placebo, no prophylaxis, or with each other. </p> </section> <section id="CD001862-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We considered the following outcomes: </p> <section id="CD001862-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001862-list-0003"> <li> <p>Proportion of infants developing blindness, defined as a visual acuity of 20/200 or worse measured, e.g., using a Teller visual acuity card at 12 months. </p> </li> <li> <p>Proportion of infants developing any adverse visual outcome measured, e.g., with a Teller visual acuity card at 12 months. </p> </li> <li> <p>Proportion of neonates developing gonococcal conjunctivitis (GC) within 28 days of birth, where diagnosis was made with a laboratory‐based method to identify the infecting organism. We anticipated that most studies would not have studied blindness as an outcome. Because severe GC is associated with a substantial risk for loss of vision, we considered this outcome as a substitute for the more important measure of blindness. </p> </li> </ol> </p> </section> <section id="CD001862-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001862-list-0004"> <li> <p>Proportion of neonates developing chlamydial conjunctivitis (CC) within 28 days of birth. </p> </li> <li> <p>Proportion of neonates developing bacterial conjunctivitis (BC) within 28 days of birth: this includes cases of conjunctivitis confirmed to be of bacterial origin by culture or Gram stain, or both. In addition to conjunctivitis cases of other bacterial aetiology, this category includes GC and CC. </p> </li> <li> <p>Proportion of neonates developing any clinical conjunctivitis within 28 days of birth, referred to as any conjunctivitis cases of any aetiology (ACAE): this includes all cases of conjunctivitis clinically diagnosed, irrespective of aetiology. This would include infectious and non‐infectious conjunctivitis. Infectious conjunctivitis includes BC, mycoplasma conjunctivitis, chlamydial or viral conjunctivitis. Non‐infectious conjunctivitis includes chemical, toxic, or mechanical conjunctivitis. In cases where there was selective outcome reporting, and all cases of clinical conjunctivitis were not reported, this outcome was not included in comparisons. </p> </li> <li> <p>Proportion of neonates developing conjunctivitis of unknown aetiology (CUE) within 28 days of birth: this includes cases of conjunctivitis that are culture‐negative, where the aetiology is unknown. These may be infectious, but showing no growth of pathogenic agents on culture media, or on other methods to identify microbiologic aetiology. This may include non‐infectious conjunctivitis, such as chemical conjunctivitis. Finally, it may be a mix of the aforementioned causes of conjunctivitis. In many cases, it is calculated by subtracting the total conjunctivitis cases of any aetiology from the conjunctivitis cases proven to be of bacterial origin. </p> </li> <li> <p>Proportion of neonates developing the following adverse effects of ophthalmia neonatorum prophylaxis: </p> <ol id="CD001862-list-0005"> <li> <p>keratitis within 28 days of birth;</p> </li> <li> <p>nasolacrimal duct obstruction within 60 days of birth.</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD001862-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001862-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases for randomised controlled trials and controlled clinical trials. There were no restrictions to language or year of publication. The databases were last searched on 4 October 2019. </p> <p> <ul id="CD001862-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 10) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched 4 October 2019) (<a href="./appendices#CD001862-sec-0183">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to 4 October 2019) (<a href="./appendices#CD001862-sec-0184">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to 4 October 2019) (<a href="./appendices#CD001862-sec-0185">Appendix 3</a>). </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database (1982 to 4 October 2019) (<a href="./appendices#CD001862-sec-0186">Appendix 4</a>). </p> </li> <li> <p>ISRCTN registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched 4 October 2019) (<a href="./appendices#CD001862-sec-0187">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>; searched 4 October 2019) (<a href="./appendices#CD001862-sec-0188">Appendix 6</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>; searched 4 October 2019) (<a href="./appendices#CD001862-sec-0189">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD001862-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of identified trial reports and existing review articles and contacted pharmaceutical companies to locate additional trials. </p> </section> </section> <section id="CD001862-sec-0026"> <h3 class="title" id="CD001862-sec-0026">Data collection and analysis</h3> <section id="CD001862-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened titles and abstracts of records retrieved from the searches, categorising each record as either include, exclude, or unclear. We retrieved full‐text articles of records that any of the review authors marked as include or unclear. Two review authors independently assessed the full‐text articles and marked them as include or exclude. We reported reasons for full‐text articles excluded in this process. The review authors resolved disagreements through discussion and consensus. In cases where additional information was needed before a decision could be made on the eligibility of full‐text articles, we attempted to obtain this information from the study investigator. </p> </section> <section id="CD001862-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For each eligible study (using all reports from the study), two review authors independently extracted information on methods, participants, interventions, outcomes, and funding sources using data forms developed for this review. We contacted the study authors for information missing from available reports. </p> </section> <section id="CD001862-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias in each included study according to methods described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001862-bbs2-0134" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). We assessed risk of bias for generation and concealment of the allocation sequence; masking of participants, caregivers/study personnel, and outcome assessors; completeness of follow‐up; reporting biases (selective outcome reporting); and other sources of potential bias such as funding. </p> <p>The review authors judged the risk of bias for each item as high, low, or unclear. We contacted study authors if the information in the available reports was insufficient to make an assessment. We used the available information if study authors did not respond within six weeks. </p> </section> <section id="CD001862-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We computed the risk ratio for dichotomous outcomes.</p> </section> <section id="CD001862-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We considered the individual as the unit of analysis. The assigned intervention was typically administered to both eyes, and we considered infants to be infected if at least one eye was affected. We excluded studies in which each eye within an infant was randomised to a different intervention, even if data were reported separately for each eye. No cluster‐randomised or cross‐over randomised controlled trials were identified and indeed they are not anticipated in this topic area. </p> </section> <section id="CD001862-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of included trials where we identified missing data on risk of bias or outcomes. If authors provided information on risk of bias that was not described in the trial reports, then this information was marked as such in the review. If missing data on an outcome were not available from study authors, then we assessed whether a meta‐analysis was possible using an intention‐to‐treat or available‐case approach. </p> </section> <section id="CD001862-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity in effect estimates from the included trials through a visual examination of the forest plot and based on the I<sup>2</sup> statistic. We considered I<sup>2</sup> values of 60% or greater to indicate substantial heterogeneity. We did not perform a meta‐analysis when we found substantial heterogeneity, and instead provided a narrative summary of the findings. We also considered the nature of interventions and the patient population to evaluate clinical heterogeneity in the included trials. </p> </section> <section id="CD001862-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>For meta‐analyses in which we included more than 10 trials, we planned to construct funnel plots to assess the potential for publication bias. We planned that if a trial protocol was available, we would assess whether all outcomes relevant to this review that were specified in the protocol were also described in the published reports. </p> </section> <section id="CD001862-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We performed a meta‐analysis for comparisons where we found minimal or no clinical heterogeneity and without substantial statistical heterogeneity. We used a random‐effects model, except for comparisons with two eligible studies, when we used a fixed‐effect model. For trials with more than one comparison group, we included the trial in relevant non‐overlapping comparisons. In addition, we collapsed data across intervention groups to include such trials in the comparison of any prophylaxis versus no prophylaxis. We used the number allocated in the denominator for our calculations in all cases except when these data were not available in the trial reports. We did not explicitly consider risk of bias as a factor when determining whether to include eligible trials in meta‐analyses. We considered sensitivity analyses based on risk of bias as discussed below. </p> <p>For outcomes where at least one trial explicitly reported that no events were observed in either the treatment or control arm, we performed a meta‐analysis using the Mantel‐Haenszel method and a continuity correction proportional to the inverse of the opposite arm (<a href="./references#CD001862-bbs2-0172" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine2004;23(9):1351-75.">Sweeting 2004</a>). Specifically, the continuity correction we used was 1/(r + 1) in the treatment arm and r/(r + 1) in the control group, where r is the ratio of sample sizes in the two arms. We used R (version 3.3.2) to conduct meta‐analyses that included the continuity correction (<a href="./references#CD001862-bbs2-0164" title="R: A language and environment for statistical computing. R Core Team. Vienna, Austria: R Foundation for Statistical Computing, 2013. www.R-project.org.">R Core Team 2013</a>). </p> </section> <section id="CD001862-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to consider subgroups by cause of infection, however the available data were insufficient to permit such analyses. We also planned to separately analyse studies conducted in high‐income versus low‐income countries using the classification specified by the United Nations (<a href="./references#CD001862-bbs2-0185" title="United Nations. World economic situation and prospects. www.un.org/en/development/desa/policy/wesp/wesp_current/2016wesp_full_en.pdf (accessed 10 April 2019).">WESP2016</a>). However, this was not possible given the diversity in settings in which the included trials were conducted. </p> </section> <section id="CD001862-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>Where data were available, we excluded studies with high risk of selection bias in sensitivity analyses. </p> </section> <section id="CD001862-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared 'Summary of findings' tables using the GRADE approach for the following eight outcomes (<a href="./references#CD001862-bbs2-0146" title="LangendamMW , AklEA , DahmP , GlasziouP , GuyattG , SchunemannHJ . Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews2013;2:81. [DOI: 10.1186/2046-4053-2-81]">Langendam 2013</a>). </p> <p> <ol id="CD001862-list-0007"> <li> <p>Blindness</p> </li> <li> <p>Any adverse visual outcome</p> </li> <li> <p>Gonococcal conjunctivitis (GC)</p> </li> <li> <p>Chlamydial conjunctivitis (CC)</p> </li> <li> <p>Bacterial conjunctivitis (BC)</p> </li> <li> <p>Any conjunctivitis of any aetiology (ACAE)</p> </li> <li> <p>Conjunctivitis of unknown aetiology (CUE)</p> </li> <li> <p>Adverse effects</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001862-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001862-sec-0039"></div> <section id="CD001862-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD001862-sec-0041"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded a total of 498 records (<a href="#CD001862-fig-0001">Figure 1</a>). After removal of 32 duplicates, we screened the remaining 466 records. We obtained the full‐text reports of 105 records for further assessment. Of these, we included 34 reports of 30 studies (see <a href="./references#CD001862-sec-0199" title="">Characteristics of included studies</a> for details). We excluded 70 reports of 63 studies (see <a href="./references#CD001862-sec-0200" title="">Characteristics of excluded studies</a> for details). One study (<a href="./references#CD001862-bbs2-0094" title="MatinzadehZK , BeiragdarF , KavemaneshZ , AbolgasemiH , AmirsalariS . Efficacy of topical ophthalmic prophylaxis in prevention of ophthalmia neonatorum. Tropical Doctor2007;37(1):47-9. ">Matinzadeh 2007</a>)is currently awaiting classification (see <a href="./references#CD001862-sec-0201" title="">Characteristics of studies awaiting classification</a>); if we receive further information on this study we will assess it for inclusion in future updates of this review. </p> <div class="figure" id="CD001862-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram" data-id="CD001862-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> </div> </section> <section id="CD001862-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD001862-sec-0043"> <h5 class="title">Setting and participants</h5> <p>Specific details on each included study are shown in the <a href="./references#CD001862-sec-0199" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD001862-sec-0044"> <h5 class="title">Design</h5> <p>Half of the included studies were quasi‐randomised (15/30; 50%), and half were randomised (15/30; 50%); see <a href="#CD001862-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD001862-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Table of Trial Settings" data-id="CD001862-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-02.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Table of Trial Settings</p> </div> </div> </div> </section> <section id="CD001862-sec-0045"> <h5 class="title">Sample sizes</h5> <p>The total number of neonates included in the review across all 30 studies was 79,198. The sample size in individual trials ranged from 40 to 32,058 neonates. The average number of neonates in the included studies was 2988, with a median of 654.5. </p> </section> <section id="CD001862-sec-0046"> <h5 class="title">Setting</h5> <p>Of the 30 trials, 18 studies (60%) were conducted in high‐income economies (9 in the USA, 7 in Europe, 1 each in Canada and Israel), and 12 (40%) were conducted in low‐ and middle‐income economies (3 in Kenya, 4 in Iran, 1 each in Zaire, Mexico, Indonesia, China, and Angola). Two studies explicitly reported recruiting participants at high risk, for example inner‐city populations (<a href="#CD001862-fig-0002">Figure 2</a>) (<a href="./references#CD001862-bbs2-0015" title="HammerschlagMR , ChandlerJW , AlexanderER , EnglishM , ChiangWT , KoutskyL , et al. Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. JAMA1980;244(20):2291-3. ">Hammerschlag 1980</a>; <a href="./references#CD001862-bbs2-0016" title="HammerschlagMR , CummingsC , RoblinPM , WilliamsTH , DelkeI . Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. New England Journal of Medicine1989;320(12):769-72. ">Hammerschlag 1989</a>). </p> </section> <section id="CD001862-sec-0047"> <h5 class="title">Time period of trials</h5> <p>A significant number of trials were conducted more than 50 years ago. Of the 30 included trials, seven (23%) trials were conducted between 1940 and 1960, with most of these trials (six) taking place between 1950 and 1960. Four trials (13%) were conducted between 1960 and 1980; eight trials (27%) between 1980 and 2000; seven trials (23%) between 2000 and 2010; and four trials (13%) from 2010 to the present. </p> </section> <section id="CD001862-sec-0048"> <h5 class="title">Interventions</h5> <p>Fourteen different prophylactic regimens and 12 different prophylactic interventions were studied across the 30 included trials (<a href="#CD001862-fig-0003">Figure 3</a>). Silver nitrate was used in the majority of trials (18 out of 30); mainly in older trials up to the early 1990s. Erythromycin was used in 10 trials; tetracycline in 9 trials; and povidone‐iodine in 9 trials. Povidone‐iodine was used mainly in more recent trials from the 1990s to the present. The route of delivery for medications was topical ocular administration, with the exception of two trials that used intramuscular penicillin. No prophylaxis was used as one arm of the study in 10 of the 30 trials. Of all trials that included no prophylaxis in one arm of the study, placebo was used in only one trial: <a href="./references#CD001862-bbs2-0029" title="WahlbergV . Crede's prevention method has lost its justification today [Credeprofylax - en metod som idag saknar berattigande]. Nordisk Medicin1982;97(2):36-7. WahlbergV . Reconsideration of Crede prophylaxis. A study of maternity and neonatal care. Acta Paediatrica Scandinavica1982;295(Suppl):1-73. ">Wahlberg 1982</a> used physiological normal saline in one arm of the trial. </p> <div class="figure" id="CD001862-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Table of Trials, Interventions, Method of Allocation, Settings" data-id="CD001862-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-03.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Table of Trials, Interventions, Method of Allocation, Settings</p> </div> </div> </div> <p>The full list of interventions used in the included studies is as follows.</p> <p> <ol id="CD001862-list-0008"> <li> <p>Silver nitrate solution (18 studies: all 1%)</p> </li> <li> <p>Erythromycin ointment (10 studies: all 0.5%, except for one study in which concentration was not specified) </p> </li> <li> <p>Tetracycline (9 studies: all 1%; 2 studies used solution instead of ointment)</p> </li> <li> <p>Povidone‐iodine:</p> <ol id="CD001862-list-0009"> <li> <p>solution (9 studies: all 2.5%);</p> </li> <li> <p>double application (1 study).</p> </li> </ol> </li> <li> <p>Hexarginum (1 study: 10% solution contains 1 g AgNO3 + 36 g CH3NH2 dissolved in 63 g sterile water) </p> </li> <li> <p>Penicillin:</p> <ol id="CD001862-list-0010"> <li> <p>ointment (2 studies: 1 study: penicillin G 1% ointment; 1 study: penicillin ointment 100,000 units/g); </p> </li> <li> <p>intramuscular injection (IM) (2 studies: 1 study: penicillin 10,000 units per IM injection; 1 study: penicillin G 25,000 to 50,000 units per IM injection depending on birthweight) </p> </li> </ol> </li> <li> <p>Cetyl‐pyridinium chloride solution (2 studies: 1 study: 0.1%; 1 study: 0.05%)</p> </li> <li> <p>Bacitracin‐phenacaine ointment (1 study: bacitracin 500 units/g; 2% phenacaine hydrochloride)</p> </li> <li> <p>Sulphacetimide ointment (1 study: 10% ointment)</p> </li> <li> <p>Chloramphenicol solution (2 studies)</p> </li> <li> <p>Carbethopendecinium bromide solution (1 study)</p> </li> <li> <p>Colostrum (1 study: 2 drops of mother's colostrum in each eye)</p> </li> </ol> </p> </section> <section id="CD001862-sec-0049"> <h5 class="title">Follow‐up time</h5> <p>The included trials varied widely in duration of follow‐up and the time at which outcomes were analysed and reported. Eleven out of 30 (37%) studies followed up neonates for one month. Four trials (13%) followed up neonates for more than one month. In 12 trials (40%), follow‐up was less than one month. In three trials (10%), no follow‐up period was specified. Of the four trials that followed up neonates for more than one month, two trials followed up neonates for three to five months, and two trials for 60 days. Of the two trials that followed up neonates for 60 days, we were able to extract 30‐day data from one trial, and in the other trial, follow‐up was only for the outcome of nasolacrimal duct obstruction. Of the 12 trials that followed up neonates for less than a month, nine trials followed neonates for 10 days or less, and three trials followed neonates for two weeks. </p> </section> <section id="CD001862-sec-0050"> <h5 class="title">Outcomes</h5> <p>Eighteen of the 30 included trials (60%) reported the outcome of gonococcal conjunctivitis (GC). Thirteen of these 18 trials (43%) reported no actual cases of GC in any arm of the study. Consequently, only five studies out of the 30 included trials (17%) reported any cases of neonates with GC. </p> <p>Thirteen of the 30 included studies (43%) reported the outcome of chlamydial conjunctivitis (CC). One of these 13 studies found no cases of CC in either arm of the study. Seven of the 30 trials (23%) were conducted between 1940 to 1960, when methods to detect <i>C trachomatis</i> were not readily available. Ten out of 30 trials (33%) reported rates of bacterial conjunctivitis (BC). Twenty‐four out of 30 trials (80%) reported the outcome of total number of clinical conjunctivitis cases. In 10 of 30 trials (33%), we were able to determine rates of conjunctivitis that were culture‐negative. </p> <p>We were unable to extract outcome data from four studies. In <a href="./references#CD001862-bbs2-0027" title="RichterR , BelowH , KadowI , KramerA , MüllerC , FuschC . Effect of topical 1.25% povidone-iodine eyedrops used for prophylaxis of ophthalmia neonatorum on renal iodine excretion and thyroid-stimulating hormone level. Journal of Pediatrics2006;148(3):401-3. ">Richter 2006</a>, the outcomes of conjunctivitis were not well defined, such that they could not be extracted. In <a href="./references#CD001862-bbs2-0029" title="WahlbergV . Crede's prevention method has lost its justification today [Credeprofylax - en metod som idag saknar berattigande]. Nordisk Medicin1982;97(2):36-7. WahlbergV . Reconsideration of Crede prophylaxis. A study of maternity and neonatal care. Acta Paediatrica Scandinavica1982;295(Suppl):1-73. ">Wahlberg 1982</a>, the outcomes of total conjunctivitis, culture‐negative conjunctivitis, BC, GC, and CC were not presented by allocation group; the denominators did not correspond to allocation groups; and the data were presented as percentages. In <a href="./references#CD001862-bbs2-0003" title="BramantyoT , RoeslaniRD , AndriansjahA , SitorusRS . The efficacy of 1% chloramphenicol eye ointment versus 2.5% povidone-iodine ophthalmic solution in reducing bacterial colony in newborn conjunctivae. Asia-Pacific Journal of Ophthalmology2015;4(3):180-3. ">Bramantyo 2016</a>, there were no conjunctivitis cases; follow‐up time was only 24 hours; and conjunctivitis was not specified in the methods as an outcome. Finally, in <a href="./references#CD001862-bbs2-0024" title="AlexandreI , JustelM , MartinezP , Ortiz de LejarazuR , PastorJC . First attempt to implement ophthalmia neonatorum prophylaxis in Angola: microorganisms, efficacy, and obstacles. Journal of Ophthalmology2015;2015:Article ID 326526. [DOI: 10.1155/2015/326526]">Pastor 2015</a>, there was a high loss to follow‐up, and repeated communications with the study authors failed to clarify confusion over the remaining data, so that we felt the data could not be extracted. </p> </section> </section> <section id="CD001862-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 63 studies (see <a href="#CD001862-fig-0001">Figure 1</a>, <a href="./references#CD001862-sec-0200" title="">Characteristics of excluded studies</a>) </p> </section> </section> <section id="CD001862-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias is summarised in <a href="#CD001862-fig-0004">Figure 4</a> and <a href="#CD001862-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD001862-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001862-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001862-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001862-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001862-sec-0053"> <h4 class="title">Allocation</h4> <p>Of the 15 quasi‐randomised trials, three trials alternated by day, six trials alternated by week, two trials alternated by month, and three trials applied prophylaxis to alternate neonates. In the remaining quasi‐randomised trial, the prophylaxis for each day was selected from a previously prepared random sequence of assignments. Amongst the 15 randomised trials, only four trials reported the method of randomisation; the remaining 11 trials described allocation using the word “random” or “randomised” but did not provide any further information on how the random sequence was generated. </p> <p>We assessed 15 out of the 30 included trials (50%) as having a high risk of selection bias based on random sequence generation. These 15 trials were generally quasi‐randomised studies using alternation by neonate or by day, week, or month. Eleven of the 30 included trials (37%) used the word “random” or “randomised” in the methods, but provided no further information on the random sequence generation process. We found only four trials (13%) to have a low risk of selection bias based on random sequence generation. </p> <p>Similarly, amongst the 30 included trials, we assessed 15 trials (50%) as having a high risk of selection bias based on inadequate concealment of allocations prior to assignment. Again, these 15 trials were generally quasi‐randomised studies as mentioned above. Twelve of the 30 included trials (40%) used the word “random” or “randomised” in the methods, but provided no further information on the allocation concealment. We found only five trials (17%) to have a low risk of selection bias based on the fact that participants or investigators could not foresee the assignment. </p> </section> <section id="CD001862-sec-0054"> <h4 class="title">Blinding</h4> <p>We assessed masking (blinding) of participants, personnel, and outcome assessors for studies in this review. We further categorised “personnel” into three subcategories: 1. mothers of infants; 2. people administering prophylaxis; and 3. people involved in postnatal care. </p> <p>In none of the trials was there any explicit mention of any attempt to make the interventions look the same, or dispense them from containers that made them indistinguishable from the other interventions. In only one trial, <a href="./references#CD001862-bbs2-0029" title="WahlbergV . Crede's prevention method has lost its justification today [Credeprofylax - en metod som idag saknar berattigande]. Nordisk Medicin1982;97(2):36-7. WahlbergV . Reconsideration of Crede prophylaxis. A study of maternity and neonatal care. Acta Paediatrica Scandinavica1982;295(Suppl):1-73. ">Wahlberg 1982</a>, it may have been the case that the interventions looked the same, and were dispensed from containers that looked the same, but this was not explicit. The ophthalmic medications used in each of the included studies did not look the same, except possibly in <a href="./references#CD001862-bbs2-0029" title="WahlbergV . Crede's prevention method has lost its justification today [Credeprofylax - en metod som idag saknar berattigande]. Nordisk Medicin1982;97(2):36-7. WahlbergV . Reconsideration of Crede prophylaxis. A study of maternity and neonatal care. Acta Paediatrica Scandinavica1982;295(Suppl):1-73. ">Wahlberg 1982</a>. For instance, silver nitrate is a clear solution; erythromycin is an ointment; and povidone‐iodine is an orange‐red solution. The physical characteristics of the interventions studied in the included trials are described in <a href="#CD001862-tbl-0002">Table 1</a>. </p> <div class="table" id="CD001862-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Physical characteristics of interventions studied in included trials</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions studied in included trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Physical characteristics/method of delivery</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver nitrate solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Translucent/white ointment, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Light‐yellow ointment, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline hydrochlorate solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown colour/consistency, aqueous solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orange‐red, clear solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hexarginum solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colour unknown, solution with 1 g silver nitrate + 36 g methylamine dissolved in 63 g sterile water, topical application </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin G ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear/white ointment, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin G intramuscular injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear, aqueous solution, intramuscular injection</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cetyl‐pyridinium chloride solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solution of unknown colour/consistency, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacitracin‐phenacaine ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ointment of unknown colour, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfacetamide ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ointment of unknown colour, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear, colourless to slightly yellow solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colourless ointment; topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colostrum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yellowish, white or clear liquid, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbethopendecinium bromide solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yellowish to white powder in solution, solution colour unknown, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mechanical cleansing</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyes swabbed with clear, distilled water and wiped dry</p> </td> </tr> </tbody> </table> </div> <p>In all but five of the 30 included trials, the medications would have looked strikingly different, either because of colour or consistency. The difference in appearance of the medication would prevent masking for the person administering the medication and could lead to bias, which could influence the outcome. In fact, one study, <a href="./references#CD001862-bbs2-0010" title="FischerPR , RetaBB . Prevention of neonatal conjunctivitis in Zaire. Annals of Tropical Paediatrics1988;8(2):85-6. ">Fischer 1988</a>, demonstrated lack of adherence to application of medication secondary to lack of masking, which influenced rates of conjunctivitis in one arm of the study. </p> <p>Masking is further affected by the fact that the majority of the medications leave a stain on the eyes after dispensing. Silver nitrate leaves lid stains that may last 30 to 48 hours. Povidone‐iodine may stain periocular skin for minutes to hours. Antibiotic ointments such as erythromycin, tetracycline, and penicillin can leave a residue that may last for hours. In four of the five above‐mentioned trials in which the medications may have looked the same, one of the interventions was silver nitrate, which would have affected masking of mothers and people involved in postnatal care due to silver nitrate’s propensity to cause lid stains. In the remaining trial in which the medications may have looked the same, there were three intervention arms, with two arms using erythromycin and tetracycline ointment, and the last arm having no prophylaxis. In this trial the ointment allocation groups could therefore be distinguished from the no‐prophylaxis group. In fact, in only one of the 10 trials where no prophylaxis was one of the arms of the study was any placebo used; hence, there was lack of masking for the person administering the medication in the remaining nine trials with a no‐prophylaxis arm. </p> <p>To summarise, in no studies was it possible to mask the person administering the prophylaxis for ophthalmia neonatorum. There are also risks of compromising masking in mothers of neonates and people involved in postnatal care due to the presence of prophylaxis staining and residue. Finally, for outcome assessments conducted soon after prophylaxis administration, particularly for the interventions of silver nitrate, antibiotic ointments, and povidone‐iodine, masking could be compromised. </p> <p>In spite of the performance bias and detection bias introduced by the appearance and residual staining of the prophylaxis medications, trials were scored on these categories, by subjective and objective outcome. We classified clinical conjunctivitis as a subjective outcome, and BC, CC and GC as an objective outcome. We considered CUE, which was essentially culture‐negative conjunctivitis, as objective, given that it was derived from subtracting BC cases from total clinical conjunctivitis cases. Our 'risk of bias' assessment for masking essentially found that there was much similarity in the classifications between the subjective and objective outcomes of conjunctivitis. In summary, the vast majority of studies had a high or unclear risk of performance bias, and unclear risk of detection bias, across most outcomes. </p> <p>There is an additional aspect of silver nitrate that introduces a form of detection bias. Sixteen of the 30 included trials (53%) used silver nitrate. In 13 of these trials, there was an outcome derived from eye culture results. In any trial with silver nitrate, there could be biased outcome assessment. Silver nitrate causes a chemical conjunctivitis in the first 72 hours. As a result, more neonates in the silver nitrate allocation group could be referred for culture in the first 72 hours. Finding bacteria in the culture does not necessarily prove that the bacteria caused the conjunctivitis. The conjunctivitis could be chemical, but growing normal flora of the eye. Alternatively, the conjunctivitis could be chemical with a chlamydial carrier. Finally, the conjunctivitis could very well be caused by the bacteria or chlamydia. Considerations about incubation periods, and assessing for carriers and normal flora with asymptomatic cases, could have assisted with differential diagnosis, but no trial made an attempt to distinguish these possible outcomes. </p> </section> <section id="CD001862-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed eight of the 24 studies that reported the outcome of total clinical conjunctivitis cases as at high risk of bias due to the high proportion of missing outcome data in proportion to event rates. We judged 13 of these 24 studies to be at unclear risk of bias due to poor reporting in the study. We graded only three studies as at low risk of attrition bias. Of the 20 studies that reported BC, CC or GC we assessed 10 as at high risk and 10 as at unclear risk of attrition bias. The two studies reporting nasolacrimal duct obstruction as an outcome had a high risk of attrition bias. We graded the single study that reported the outcome of keratitis as at low risk of attrition bias. </p> </section> <section id="CD001862-sec-0056"> <h4 class="title">Selective reporting</h4> <p>We did not have access to the protocols for any of the included studies, therefore we compared the outcomes listed in the methods section of the trial with those reported in the results. We judged 19 of the 30 included trials to be at high risk of bias for selective outcome reporting. We assessed seven studies as at unclear risk and only four studies as at low risk of reporting bias. </p> </section> <section id="CD001862-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>More than half of the included studies (18/30; 60%) did not specify a source of funding. Of the remaining 12 studies (40%), nine studies were funded by a non‐governmental organisation, charitable foundation, government agency, hospital, or medical school; funding sources that would seem unlikely to have biased the methodology or results. Three studies were funded by pharmaceutical companies, which supplied one of the interventions in the trial (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>; <a href="./references#CD001862-bbs2-0015" title="HammerschlagMR , ChandlerJW , AlexanderER , EnglishM , ChiangWT , KoutskyL , et al. Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. JAMA1980;244(20):2291-3. ">Hammerschlag 1980</a>; <a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>). In all three studies, outcomes favoured the intervention supplied and funded by the pharmaceutical company. We were unable to determine if any aspect of the methodology may have been affected to the point of risk of bias by any pharmaceutical funding. </p> <p>Only five of the 30 included trials (17%) made a declaration of interest, specifying there was no conflict of interest. The remaining 25 trials (83%) made no reference to any declaration of interest. </p> <p>Only three of the 30 included trials (10%) provided sufficiently detailed information in the study report to enable ruling out other potential sources of bias. </p> <p>We contacted the study authors if the information in the available reports was insufficient to permit assessment. Some authors were not contacted due to the age of the studies. We contacted the study authors of 14 of the 30 included trials, of which authors of nine studies provided a response. </p> </section> </section> <section id="CD001862-sec-0058"> <h3 class="title" id="CD001862-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD001862-tbl-0001"><b>Summary of findings 1</b> Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</a> </p> <p>None of the trials reported any data on two of the primary outcomes specified for this review: incidence of blindness and visual impairment. Data on the remaining outcomes are discussed below (<a href="#CD001862-tbl-0003">Table 2</a>). In this review, we did not attempt to rank the relative effectiveness of the various interventions; this has to be addressed in a subsequent network meta‐analysis. Instead, we discuss our findings for important pairwise comparisons of interventions along with an overall comparison of any prophylaxis versus no prophylaxis. The individual pairwise comparisons are organised as follows: interventions compared with silver nitrate; interventions compared with erythromycin; interventions compared with tetracycline; and other comparisons. </p> <div class="table" id="CD001862-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary results</span></div> <tbody> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Gonococcal conjunctivitis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Chlamydial conjunctivitis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Bacterial conjunctivitis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Any conjunctivitis of any aetiology</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Conjunctivitis of unknown aetiology</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any prophylaxis vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.24 to 2.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.57 to 1.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.37 to 1.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.54 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75 (0.37 to 8.28)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver nitrate vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.55 to 2.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.52 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.49 to 1.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.22 to 2.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.51 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.26 to 8.80)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.42 to 1.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.55 to 0.94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00 (0.18 to 21.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.30 to 3.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.18 to 0.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00 (0.37 to 10.70)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacitracin‐phenacaine vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 (0.20 to 2.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colostrum vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.45 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28 (0.88 to 5.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.51 to 1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.69 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.21 to 2.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.40 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.66 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfacetamide vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.45 to 1.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.32 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.11 to 0.66)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cetyl‐pyridinium chloride vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.79 (0.59 to 5.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.40 to 2.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 2; IM penicillin: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 0.34 (0.18 to 0.65); IM penicillin: 0.75 (0.46 to 1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 2; IM penicillin: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin:* <a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>: 0.15 (0.12 to 0.20); <a href="./references#CD001862-bbs2-0017" title="HarrisST . Silver nitrate in ophthalmia neonatorum prophylaxis. Sight Saving Review1957;27(3):152-3. ">Harris 1957</a>: 0.78 (0.35 to 1.70); IM penicillin: 0.26 (0.21 to 0.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 1; IM penicillin: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 0.13 (0.10 to 0.18); IM penicillin: 0.21 (0.17 to 0.27)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94 (0.60 to 6.29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52 (0.38 to 0.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.61 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.63 to 0.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.55 to 0.89)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline vs erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.18 to 2.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.42 to 1.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>: 0.75 (0.54 to 1.02); <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a>: 1.38 (0.76 to 2.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colostrum vs erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (0.80 to 2.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.36 to 2.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.54 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.71 to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.68 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.58 to 0.93)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin IM vs tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.48 to 1.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04 (0.99 to 4.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.01 (1.52 to 5.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs chloramphenicol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.77 (0.97 to 3.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs carbethopendecinium bromide</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (0.15 to 1.35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine twice vs povidone‐iodine once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.27 (0.26 to 6.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.69 (0.59 to 4.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.32 (0.99 to 1.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.29 (0.95 to 1.74)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin IM vs topical penicillin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.19 (1.14 to 4.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71 (1.26 to 2.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.58 (1.12 to 2.25)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>IM:</b> intramuscular </p> <p>*Indicates statistically significant heterogeneity precluding a meta‐analysis.</p> </div> </div> <section id="CD001862-sec-0059"> <h4 class="title">Any prophylaxis versus no prophylaxis</h4> <p>See <a href="./full#CD001862-tbl-0001">summary of findings Table 1</a>. </p> <p>Any prophylaxis was associated with a statistically significant reduction in risk for any conjunctivitis of any aetiology (ACAE) but not for GC, BC, CC, or conjunctivitis of unknown aetiology (CUE). The certainty of evidence was moderate for ACAE but low for all other outcomes. For the sake of clarity in the narrative, within each outcome under the overall comparison of any prophylaxis versus no prophylaxis, we will describe effects for individual medications versus no prophylaxis (see <a href="#CD001862-tbl-0004">Table 3</a>; <a href="#CD001862-tbl-0005">Table 4</a>; <a href="#CD001862-tbl-0006">Table 5</a>; <a href="#CD001862-tbl-0007">Table 6</a>; <a href="#CD001862-tbl-0008">Table 7</a>; <a href="#CD001862-tbl-0009">Table 8</a>). </p> <div class="table" id="CD001862-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> silver nitrate<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2225<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in this study.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.06<br/>(0.55 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2225<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(3 to 10) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(55 to 202) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>2 of the 3 studies did not measure or report bacterial conjunctivitis (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>; <a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). 1 study measured bacterial conjunctivitis but did not report this outcome by study arm (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.67<br/>(0.52 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2713<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 per 1000<br/>(156 to 261) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>2 of the 3 studies did not measure did not measure or report conjunctivitis of unknown aetiology (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>; <a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). 1 study measured conjunctivitis of unknown aetiology but did not report this outcome by trial arm (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In a single study (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>), silver nitrate prophylaxis appeared to be associated with an increased risk of nasolacrimal duct obstruction compared with no prophylaxis, but the variance in the estimate was imprecise with wide confidence intervals (RR 1.28, 95% CI 0.40 to 4.02). </p> <p>A single study comparing silver nitrate with control reported that no events of keratitis were observed in the prophylaxis and no‐prophylaxis groups (<a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study with high risk of selection bias, unclear and high risk of performance bias, unclear risk of detection bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm of trial; study underpowered to assess relative effects of treatment on this outcome.<br/><sup>3</sup>Downgraded for imprecision (‐1): 95% confidence interval includes no effect.<br/><sup>4</sup>Downgraded for risk of bias (‐1): largest trial has high or unclear risk of bias; second‐largest trial has low risk of selection bias, but higher risk of performance or detection bias.<br/><sup>5</sup>Downgraded (‐2) for imprecision: sparse data. </p> </div> </div> <div class="table" id="CD001862-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> erythromycin<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2526<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in these studies.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.93<br/>(0.49 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2526<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(2 to 9) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/>(49 to 177) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain.<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.80<br/>(0.22 to 2.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 9) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> <p>(11 to 145)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.68<br/>(0.51 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3509<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> <p>(153 to 267)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/>(0.26 to 8.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(5 to 160) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In a single study of 269 people, there was no clear relationship between erythromycin and nasolacrimal duct obstruction (RR 0.83, 95% CI 0.56 to 1.23). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies were at high risk or unclear risk of bias. High loss to follow‐up in one trial, and unclear if follow‐up time is two weeks or one month in same trial. No placebo used in either trial.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm of trial.<br/><sup>3</sup>Downgraded for imprecision (‐1): 95% confidence interval includes no effect; very few events; one study; small sample size.<br/><sup>4</sup>Downgraded for risk of bias (‐1): study has high or unclear risk of bias with high loss to follow‐up. No placebo used.<br/><sup>5</sup>Downgraded for imprecision (‐2): very wide confidence intervals. </p> </div> </div> <div class="table" id="CD001862-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> tetracycline<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2299<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in this study.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.82<br/>(0.42 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2299<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(7 to 26) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> <p>(42 to 163)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>1 study did not measure or report bacterial conjunctivitis (<a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a>), whilst the other study measured bacterial conjunctivitis but did not report by allocation group (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.72<br/>(0.55 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2519<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> <p>(1165 to 282)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>1 study did not measure or report conjunctivitis of unknown aetiology (CUE) (<a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a>), whilst the other study measured CUE but did not report by allocation group (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (‐3): no events in this trial.<br/><sup>2</sup>Downgraded for risk of bias (‐1): single trial with high risk of bias for sequence generation, allocation concealment, and masking, and unclear risk of bias for detection and attrition bias, which could affect outcomes considering the low event rates.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size not met, and confidence interval overlaps no effect in this single study.<br/><sup>4</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias. </p> </div> </div> <div class="table" id="CD001862-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Povidone‐iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in this study.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 2.00<br/>(0.18 to 21.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 109) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> <p>(18 to 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain.<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.00<br/>(0.30 to 3.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 10) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> <p>(15 to 168)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.38<br/>(0.18 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(1 to 2) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> <p>(54 to 231)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.00<br/>(0.37 to 10.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(7 to 195) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (‐3): no events in either arm of this study.<br/><sup>2</sup>Downgraded for risk of bias (‐1): the study is unclear regarding sequence generation and allocation concealment. Masking is a concern as there was no placebo. Very high losses to follow‐up.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> <p><sup>4</sup>Downgraded for imprecision (‐2): very wide confidence intervals. </p> </div> </div> <div class="table" id="CD001862-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Bacitracin‐phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Bacitracin‐phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> bacitracin‐phenacaine<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bacitracin‐phenacaine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.76<br/>(0.20 to 2.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3355<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> <p>(20 to 283 per 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The 1 study does not seem to have measured or reported cases of chlamydial conjunctivitis (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>). Diagnostic methods for chlamydia would not have been readily available in 1959. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>It is unknown if bacterial conjunctivitis was measured in the 1 study (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>), as it categorises conjunctivitis only as "nonspecific conjunctivitis" and "gonorrhoeal ophthalmia". </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>It is unknown if all conjunctivitis were measured in the 1 study (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>), as it categorises conjunctivitis only as "nonspecific conjunctivitis" and "gonorrhoeal ophthalmia". </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The category of "nonspecific conjunctivitis" reported in the 1 study is undefined and may or may not also include bacterial conjunctivitis cases (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>). </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial with high risk of selection bias, unclear risk of performance and detection bias, high risk of selective outcome reporting.<br/><sup>2</sup>Downgraded for imprecision (‐2): very wide confidence intervals, which include no effect. </p> </div> </div> <div class="table" id="CD001862-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> colostrum<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with colostrum</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No discussion of gonococcal conjunctivitis in this study (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). The trial excluded culture‐positive neonates before application of prophylaxis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No discussion of chlamydial conjunctivitis in this 1 study (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). It is unknown if it was measured. Chlamydial conjunctivitis cases were not reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The 1 trial trial does not report bacterial conjunctivitis cases as distinguished from all conjunctivitis cases (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). It is unknown if bacterial conjunctivitis was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.72<br/>(0.45 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>186<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> <p>(135 to 342)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The 1 trial only reports all conjunctivitis cases, and does not distinguish bacterial conjunctivitis cases from cases of conjunctivitis of unknown aetiology (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study at high or unclear risk of performance, detection, and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): 95% confidence interval includes no effect. </p> </div> </div> <section id="CD001862-sec-0060"> <h5 class="title">Gonococcal conjunctivitis </h5> <p>There was only very low‐certainty evidence on the risk of GC with prophylaxis (4/5340 newborns) compared to no prophylaxis (5/2889) at one month (risk ratio (RR) 0.79, 95% confidence interval (CI) 0.24 to 2.65, 3 studies, I<sup>2</sup> = 0%; <a href="#CD001862-fig-0006">Figure 6</a>).  </p> <div class="figure" id="CD001862-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Any prophylaxis versus no prophylaxis, outcome: 1.1 Gonococcal conjunctivitis" data-id="CD001862-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Any prophylaxis versus no prophylaxis, outcome: 1.1 Gonococcal conjunctivitis </p> </div> </div> </div> <p>Data on GC were available for the following medications individually compared with no prophylaxis: silver nitrate, erythromycin, tetracycline, povidone‐iodine, and bacitracin. For all these medications, a single trial provided data on comparison with no prophylaxis except erythromycin for which data were provided by two trials. No events of GC were observed when silver nitrate (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>), erythromycin (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>; <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>), tetracycline (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>), or povidone‐iodine (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>), were compared with no prophylaxis. It was thus not possible to estimate the effect of prophylaxis with these medications against GC. Bacitracin was associated with a RR of 0.76 for GC but with very wide CIs (RR 0.76, 95% CI 0.20 to 2.83) (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>). </p> </section> <section id="CD001862-sec-0061"> <h5 class="title">Chlamydial conjunctivitis </h5> <p>In a meta‐analysis of two trials, any prophylaxis did not appear to reduce the incidence of CC (RR 0.96, 95% CI 0.57 to 1.61, 4874 participants, 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0018" title="">Analysis 1.1</a>). GRADE certainty of the evidence was low. </p> <p>Data on CC were available for the following medications individually compared with no prophylaxis: silver nitrate, erythromycin, tetracycline, and povidone‐iodine. For all these medications, a single trial provided data on comparison with no prophylaxis except erythromycin for which data were provided by two trials. There was little or no difference with the risk of CC for silver nitrate (RR 1.06, 95% CI 0.55 to 2.02; <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>) . Povidone‐iodine was associated with an increased risk of CC (RR 2.00, 95% CI 0.18 to 22.74; <a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>), but this association was not statistically significant. There was little or no difference in CC with erythromycin (RR 0.93, 95% CI 0.49 to 1.77, 2526 participants, 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0030" title="">Analysis 3.2</a>) and tetracycline (RR 0.82, 95% CI 0.42 to 1.63)  compared with no prophylaxis (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> </section> <section id="CD001862-sec-0062"> <h5 class="title">Bacterial conjunctivitis </h5> <p>In a meta‐analysis of two trials, any prophylaxis did not appear to reduce the incidence of BC (RR 0.84, 95% CI 0.37 to 1.93, 3685 participants, 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0019" title="">Analysis 1.2</a>). GRADE certainty of the evidence was low. </p> <p>Data on BC were available for the following medications individually compared with no prophylaxis: erythromycin and povidone‐iodine. A single trial provided data on BC for both these medications (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). There was no evidence that erythromycin was associated with a reduced risk of BC compared with no prophylaxis (RR 0.80, 95% CI 0.22 to 2.90) (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). Povidone‐iodine did not appear to reduce the incidence of BC compared with no prophylaxis (RR 1.00, 95% CI 0.30 to 3.36) (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). </p> </section> <section id="CD001862-sec-0063"> <h5 class="title">Any conjunctivitis of any aetiology </h5> <p>In a meta‐analysis of eight trials, any prophylaxis was associated with a 35% (95% CI 22% to 46%) reduction in risk of ACAE compared with no prophylaxis (RR 0.65, 95% CI 0.54 to 0.78, 9666 participants, 8 studies; I<sup>2</sup> = 11%; <a href="./references#CD001862-fig-0020" title="">Analysis 1.3</a>). GRADE certainty of the evidence was moderate. </p> <p>Data on ACAE were available for the following medications individually compared with no prophylaxis: silver nitrate, erythromycin, tetracycline, povidone‐iodine, and colostrum. In a meta‐analysis of three trials, silver nitrate was associated with a reduced risk of ACAE compared with no prophylaxis (RR 0.67, 95% CI 0.52 to 0.87, 2713 participants, 3 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0026" title="">Analysis 2.3</a>). In a meta‐analysis of six trials, erythromycin was associated with a reduced risk of ACAE compared with no prophylaxis (RR 0.68, 95% CI 0.51 to 0.89, 3509 participants, 6 studies; I<sup>2</sup> = 38%; <a href="./references#CD001862-fig-0032" title="">Analysis 3.4</a>). Similarly, in a meta‐analysis of two trials, tetracycline was associated with a reduced risk of ACAE compared with no prophylaxis (RR 0.72, 95% CI 0.55 to 0.94, 2519 participants, 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0037" title="">Analysis 4.3</a>). Data from a single trial suggest that povidone‐iodine reduces the risk of ACAE compared with no prophylaxis (RR 0.38, 95% CI 0.18 to 0.77) (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). Finally, a single trial indicates colostrum is associated with a reduction in risk of ACAE compared with no prophylaxis that was not statistically significant (RR 0.72, 95% CI 0.45 to 1.14) (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). </p> </section> <section id="CD001862-sec-0064"> <h5 class="title">Conjunctivitis of unknown aetiology </h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>), any prophylaxis was associated with an increased risk of CUE compared with no prophylaxis, but the CIs were very wide (RR 1.75, 95% CI 0.37 to 8.28). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0065"> <h5 class="title">Adverse events</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>), any prophylaxis (erythromycin 0.5% or silver nitrate 1%) did not appear to be associated with an increased risk of nasolacrimal duct obstruction compared with no prophylaxis (RR 0.93, 95% CI 0.68 to 1.28). GRADE certainty of the evidence was very low. A single trial of silver nitrate 1% in 40 newborn children reported that no events of keratitis were observed in the prophylaxis and no‐prophylaxis groups (<a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). </p> </section> </section> <section id="CD001862-sec-0066"> <h4 class="title">Erythromycin versus silver nitrate</h4> <p>See summary of findings in <a href="#CD001862-tbl-0010">Table 9</a>. </p> <div class="table" id="CD001862-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> erythromycin<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.28<br/>(0.88 to 5.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,855<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In 2 of the 4 trials, there were no cases of gonococcal conjunctivitis in either study arm. </p> <p>Follow‐up: range 8 days to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 6) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.51 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13,472<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: range 4 weeks to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(11 to 23) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.69 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6333<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: range 9 days to 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(39 to 58) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9021<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A meta‐analysis was not conducted considering the considerable statistical heterogeneity (I<sup>2</sup> = 90%). Therefore, there was no pooled effect. </p> <p>Follow‐up: range 9 days to 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment of conjunctivitis</p> <p>follow‐up: 1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.80 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4729<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After excluding 1 study (<a href="./references#CD001862-bbs2-0006" title="ChristianJR . Comparison of ocular reactions with the use of silver nitrate and erythromycin ointment in ophthalmia neonatorum prophylaxis. Journal of Pediatrics1960;57(1):55-60. ">Christian 1960</a>), I<sup>2</sup> declined to 51%, but was still moderate. A pooled effect was then presented for these 3 remaining studies. </p> <p>Follow‐up: range 9 days to 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/>(136 to 221) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.77 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2041<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/>(107 to 165) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In 1 study, erythromycin was associated with a reduced risk of nasolacrimal duct obstruction compared with silver nitrate. This association was not statistically significant (RR 0.81, 95% CI 0.55 to 1.20). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): very wide 95% confidence intervals including no effect.<br/><sup>3</sup>Downgraded for imprecision (‐1): 95% confidence intervals include no effect.<br/><sup>4</sup>Downgraded for risk of bias (‐1): one of the four studies, the smallest one (<a href="./references#CD001862-bbs2-0015" title="HammerschlagMR , ChandlerJW , AlexanderER , EnglishM , ChiangWT , KoutskyL , et al. Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. JAMA1980;244(20):2291-3. ">Hammerschlag 1980</a>), was funded by the pharmaceutical company that produces erythromycin (Dista Pharmaceuticals). That trial favoured erythromycin, and was the only trial amongst four trials with no chlamydial conjunctivitis in the erythromycin arm (12 cases in the silver nitrate arm). There were 36 infants in the silver nitrate arm and only 24 in the erythromycin arm. Furthermore, 7 of 67 chlamydia‐positive mothers remained unaccounted for. Their distribution in the allocation arms is unknown. With a transmission rate of about 30%, low event rates, and small sample size, these missing mothers could have a significant effect on the results.<br/><sup>5</sup>Downgraded for inconsistency (‐1): confidence intervals do not overlap; point estimates vary widely and on either side of no effect; I<sup>2</sup> is 90%; and Chi<sup>2</sup> P &lt; 0.001. Heterogeneity could be explained by one older trial that did not define conjunctivitis, and review authors applied definition to eye reaction classifications. </p> </div> </div> <section id="CD001862-sec-0067"> <h5 class="title">Gonococcal conjunctivitis </h5> <p>In a meta‐analysis of four trials, two of which reported no incidence of GC, erythromycin was associated with a 2.28‐fold increase in risk of GC compared with silver nitrate (RR 2.28, 95% CI 0.88 to 5.90, 14,855 participants, 4 studies; I<sup>2</sup> = 0%; <a href="#CD001862-fig-0007">Figure 7</a>). GRADE certainty of the evidence was very low. The wide CIs indicate that the estimate is compatible with a 12% reduction in risk and a 5.9‐fold increase in risk. </p> <div class="figure" id="CD001862-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.1 Gonococcal conjunctivitis." data-id="CD001862-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.1 Gonococcal conjunctivitis. </p> </div> </div> </div> </section> <section id="CD001862-sec-0068"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a meta‐analysis of four trials, erythromycin was associated with a 25% reduction (95% CI 49% reduction to 9% increase) in risk of CC compared with silver nitrate (RR 0.75, 95% CI 0.51 to 1.09, 13,472 participants, 4 studies; I<sup>2</sup> = 30%;  <a href="./references#CD001862-fig-0045" title="">Analysis 8.1</a>; <a href="#CD001862-fig-0008">Figure 8</a>). GRADE certainty of the evidence was low. </p> <div class="figure" id="CD001862-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.2 Chlamydial conjunctivitis." data-id="CD001862-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.2 Chlamydial conjunctivitis. </p> </div> </div> </div> </section> <section id="CD001862-sec-0069"> <h5 class="title">Bacterial conjunctivitis </h5> <p>In a meta‐analysis of two trials, erythromycin was associated with a lower incidence of BC compared with silver nitrate (RR 0.83, 95% CI 0.69 to 1.01, 6333 participants; 2 studies; I<sup>2</sup> = 55%; <a href="./references#CD001862-fig-0046" title="">Analysis 8.2</a>). GRADE certainty of the evidence was low. The two trials had considerable differences in study design, which explains the observed I<sup>2</sup> of 55%. The trials were conducted about 35 years apart. While both trials allocated infants by alternation and were thus at high risk of selection bias, <a href="./references#CD001862-bbs2-0006" title="ChristianJR . Comparison of ocular reactions with the use of silver nitrate and erythromycin ointment in ophthalmia neonatorum prophylaxis. Journal of Pediatrics1960;57(1):55-60. ">Christian 1960</a> alternated infants and reported inadequate alternation for the first two months of the trial. </p> </section> <section id="CD001862-sec-0070"> <h5 class="title">Any conjunctivitis of any aetiology </h5> <p>There was considerable statistical heterogeneity (I<sup>2</sup> = 90%) amongst the four trials that compared erythromycin versus silver nitrate and reported data for this outcome (<a href="./references#CD001862-fig-0047" title="">Analysis 8.3</a>), thus we did not conduct a meta‐analysis of the four trials. The protective effect of erythromycin in <a href="./references#CD001862-bbs2-0006" title="ChristianJR . Comparison of ocular reactions with the use of silver nitrate and erythromycin ointment in ophthalmia neonatorum prophylaxis. Journal of Pediatrics1960;57(1):55-60. ">Christian 1960</a> was about three orders of magnitude higher than that seen in the remaining three trials, which may be explained by its high risk of selection bias. GRADE certainty of the evidence was very low. In a sensitivity analysis excluding <a href="./references#CD001862-bbs2-0006" title="ChristianJR . Comparison of ocular reactions with the use of silver nitrate and erythromycin ointment in ophthalmia neonatorum prophylaxis. Journal of Pediatrics1960;57(1):55-60. ">Christian 1960</a>, which was at a high risk of selection bias, there was no evidence that erythromycin reduced the risk of ACAE any more than silver nitrate (RR 1.02, 95% CI 0.80 to 1.30). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0071"> <h5 class="title">Conjunctivitis of unknown aetiology </h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>), there was little evidence of any difference between erythromycin and silver nitrate for risk of CUE (RR 0.96, 95% CI 0.77 to 1.19). GRADE certainty of the evidence was low (<a href="./references#CD001862-fig-0048" title="">Analysis 8.4</a>). </p> </section> <section id="CD001862-sec-0072"> <h5 class="title">Adverse events</h5> <p>In one trial, erythromycin was associated with a reduced risk of nasolacrimal duct obstruction compared with silver nitrate. This association was not statistically significant (RR 0.81, 95% CI 0.55 to 1.20; <a href="./references#CD001862-fig-0049" title="">Analysis 8.5</a>) (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>). GRADE certainty of the evidence was low. </p> <p>Overall, we rated the certainty of the evidence for erythromycin versus silver nitrate to be moderate for GC, CC, and BC (see <a href="#CD001862-tbl-0010">Table 9</a>). We considered the certainty of the evidence for ACAE to be very low, owing to heterogeneous estimates in the included studies. </p> </section> </section> <section id="CD001862-sec-0073"> <h4 class="title">Tetracycline versus silver nitrate</h4> <p>See summary of findings in <a href="#CD001862-tbl-0011">Table 10</a>. </p> <div class="table" id="CD001862-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> tetracycline<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.21 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,501<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Amongst the 5 included trials, 3 had no events in either study arm.</p> <p>Range 4 weeks to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 2) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.40 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,142<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Range 4 weeks to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(3 to 7) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst 5 studies, 4 measured bacterial conjunctivitis but did not report the results (2) or the data could not be extracted (2). 1 study did not measure or report bacterial conjunctivitis. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.66 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6229<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(42 to 63) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst 5 trials, 4 measured conjunctivitis of unknown aetiology (CUE) but did not report the results (2) or the data could not be extracted (2). 1 trial did not measure or report CUE. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In 1 trial, tetracycline appeared to be associated with a higher risk of nasolacrimal duct obstruction, but the estimate was imprecise and included no effect (RR 1.57, 95% CI 0.63 to 3.91). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias.<br/><sup>2</sup>Downgraded for inconsistency (‐1): I<sup>2</sup> is 60%, Chi<sup>2</sup> P value is 0.11. Two trials had no events in either arm. Downgraded due to variable methods and length of follow‐up.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size is not met, but large sample size (7721 neonates in tetracycline group and 6780 neonates in silver nitrate group) with low baseline risk; however, confidence intervals are quite wide around relative effects, but around absolute effects relatively narrow. Outcome of gonococcal conjunctivitis is of critical significance and can affect vision. Therefore, downgraded one level for imprecision.<br/><sup>4</sup>Downgraded for imprecision (‐1): optimal information size is not met, but large sample size (7598 neonates in tetracycline group and 6544 neonates in silver nitrate group) with low baseline risk; confidence intervals are wide around relative effects, but around absolute effects relatively narrow. Confidence interval overlaps no effect. RR of 60% with tetracycline versus RR increase of 2% with tetracycline. Confidence interval fails to exclude important benefit. Chlamydial conjunctivitis outcome is important. Downgraded for imprecision.<br/><sup>5</sup>Downgraded for imprecision (‐1): confidence intervals include benefit and harm </p> </div> </div> <section id="CD001862-sec-0074"> <h5 class="title">Gonococcal conjunctivitis </h5> <p>In a meta‐analysis of five trials, tetracycline was associated with a 34% reduction in risk of GC when compared with silver nitrate, but this effect was consistent with both a 79% reduction in risk and a 2.05‐fold increase in risk (RR 0.66, 95% CI 0.21 to 2.05, 14,501 participants, 5 studies; I<sup>2</sup> = 0%; <a href="#CD001862-fig-0009">Figure 9</a>). GRADE certainty of the evidence was very low. While the statistical heterogeneity was not high, all five trials were at high or unclear risk of bias for all 'Risk of bias' domains assessed. Furthermore, three of the five trials reported no events of GC. We thus considered the overall certainty of evidence for this analysis to be low. </p> <div class="figure" id="CD001862-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.1 Gonococcal conjunctivitis." data-id="CD001862-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.1 Gonococcal conjunctivitis. </p> </div> </div> </div> </section> <section id="CD001862-sec-0075"> <h5 class="title">Chlamydial conjunctivitis </h5> <p>In a meta‐analysis of four trials, tetracycline was associated with a reduced risk of CC, but the effect was not statistically significant (RR 0.64, 95% CI 0.40 to 1.02, 14,142 participants, 4 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0050" title="">Analysis 9.1</a>; <a href="#CD001862-fig-0010">Figure 10</a>). GRADE certainty of the evidence was low. </p> <div class="figure" id="CD001862-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.2 Chlamydia conjunctivitis." data-id="CD001862-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.2 Chlamydia conjunctivitis. </p> </div> </div> </div> </section> <section id="CD001862-sec-0076"> <h5 class="title">Bacterial conjunctivitis </h5> <p>No data were available for BC comparing tetracycline versus silver nitrate.</p> </section> <section id="CD001862-sec-0077"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a meta‐analysis of four trials, tetracycline was associated with a lower risk of ACAE compared with silver nitrate (RR 0.80, 95% CI 0.66 to 0.98, 6229 participants, 4 studies; I<sup>2</sup> = 0%; <a href="#CD001862-fig-0011">Figure 11</a>). One of the four trials included in this meta‐analysis reported no events in infants treated with silver nitrate. GRADE certainty of the evidence was moderate. </p> <div class="figure" id="CD001862-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.3 Any conjunctivitis of any aetiology" data-id="CD001862-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.3 Any conjunctivitis of any aetiology </p> </div> </div> </div> </section> <section id="CD001862-sec-0078"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>No data were available for CUE comparing tetracycline versus silver nitrate.</p> </section> <section id="CD001862-sec-0079"> <h5 class="title">Adverse events</h5> <p>In one trial, tetracycline appeared to be associated with a higher risk of nasolacrimal duct obstruction, but the variance in the estimate was high (RR 1.57, 95% CI 0.63 to 3.91, 145 participants, 1 study) (<a href="./references#CD001862-fig-0051" title="">Analysis 9.2</a>). GRADE certainty of the evidence was low. </p> </section> </section> <section id="CD001862-sec-0080"> <h4 class="title">Sulfacetamide versus silver nitrate</h4> <p>See summary of findings in <a href="#CD001862-tbl-0012">Table 11</a>. </p> <div class="table" id="CD001862-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> sulfacetamide<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sulfacetamide</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study reported no cases of gonococcal conjunctivitis (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>). </p> <p>follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>It is likely that chlamydial conjunctivitis was measured in this 1952 study but not reported in this trial. It is described in other observational studies in the same paper ("virus inclusion bodies"). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.45 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(24 to 92) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.32 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/>(39 to 109) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27<br/>(0.11 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(8 to 46) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study with high risk of selection bias, high risk of performance bias, unclear risk of detection bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm of trial; study was underpowered to assess this outcome.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval overlaps no effect. </p> </div> </div> <section id="CD001862-sec-0081"> <h5 class="title">Gonococcal conjunctivitis </h5> <p>No events of GC were reported in one trial comparing sulfacetamide versus silver nitrate (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0082"> <h5 class="title">Chlamydial conjunctivitis </h5> <p>No data on CC were available in one trial comparing sulfacetamide versus silver nitrate (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>). </p> </section> <section id="CD001862-sec-0083"> <h5 class="title">Bacterial conjunctivitis </h5> <p>In one trial (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>), sulfacetamide was associated with little or no difference in risk of BC compared with silver nitrate (RR 0.88, 95% CI 0.45 to 1.74). This association was not statistically significant. GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0084"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In one trial (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>), sulfacetamide was associated with a lower risk of ACAE than silver nitrate (RR 0.54, 95% CI 0.32 to 0.89). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0085"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In one trial (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>), sulfacetamide was associated with a lower risk of CUE than silver nitrate (RR 0.27, 95% CI 0.11 to 0.66). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0086"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing sulfacetamide versus silver nitrate.</p> </section> </section> <section id="CD001862-sec-0087"> <h4 class="title">Cetyl‐pyridinium chloride versus silver nitrate</h4> <p>See summary of findings in <a href="#CD001862-tbl-0013">Table 12</a>. </p> <div class="table" id="CD001862-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Cetyl‐pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cetyl‐pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> cetyl‐pyridinium chloride<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cetyl‐pyridinium chloride</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis not measured and not reported. Study explicitly reported that there was no culture method used to detect <i>Neisseria gonorrhoeae</i>. </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported the diagnosis of chlamydial conjunctivitis. None of the studies specified if chlamydia was measured, which was unlikely considering publication date of 1965. </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.79<br/>(0.59 to 5.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/>(10 to 92) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.40 to 2.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(11 to 78) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.14<br/>(0.01 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 27) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval overlaps no effect. Confidence intervals very wide.<br/><sup>3</sup>Downgraded for inconsistency (‐1): point estimates on opposite sides of no effect. I<sup>2</sup> is 60%, but confidence intervals overlap and and Chi<sup>2</sup> P value is 0.11. Borderline. Downgraded. </p> </div> </div> <section id="CD001862-sec-0088"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>No data were available on GC comparing cetyl‐pyridinium chloride versus silver nitrate.</p> </section> <section id="CD001862-sec-0089"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>No data were available on CC comparing cetyl‐pyridinium chloride versus silver nitrate.</p> </section> <section id="CD001862-sec-0090"> <h5 class="title">Bacterial conjunctivitis</h5> <p>In a meta‐analysis of two trials, cetyl‐pyridinium chloride was associated with a higher risk of BC compared with silver nitrate; this association was not statistically significant (RR 1.79, 95% CI 0.59 to 5.41, 599 participants, 2 studies; I<sup>2</sup> = 15%). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0091"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a meta‐analysis of two trials, cetyl‐pyridinium chloride was associated with a higher risk of ACAE compared with silver nitrate; this association was not statistically significant (RR 1.08, 95% CI 0.40 to 2.90, 599 participants, 2 studies; I<sup>2</sup> = 60%). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0092"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In a meta‐analysis of two trials, cetyl‐pyridinium chloride was associated with a lower risk of CUE compared with silver nitrate; this association was not statistically significant (RR 0.14, 95% CI 0.01 to 2.71, 599 participants, 2 studies; I<sup>2</sup> = 60%) (<a href="./references#CD001862-bbs2-0021" title="KaivonenM . Prophylaxis of ophthalmia neonatorum. A clinical and bacteriologic study of ophthalmia neonatorum and conjunctival bacterial flora of the newborn. Acta Ophthalmologica1965;79(Suppl):9-70. ">Kaivonen 1965a</a>; <a href="./references#CD001862-bbs2-0022" title="KaivonenM . Prophylaxis of ophthalmia neonatorum. A clinical and bacteriologic study of ophthalmia neonatorum and conjunctival bacterial flora of the newborn. Acta Ophthalmologica1965;79(Suppl):9-70. ">Kaivonen 1965b</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0093"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing cetyl‐pyridinium chloride versus silver nitrate. </p> </section> </section> <section id="CD001862-sec-0094"> <h4 class="title">Penicillin versus silver nitrate</h4> <p>See summary of findings in <a href="#CD001862-tbl-0014">Table 13</a> and <a href="#CD001862-tbl-0015">Table 14</a>. </p> <div class="table" id="CD001862-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2804<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study with this comparison measured gonococcal conjunctivitis but found no cases of gonococcal conjunctivitis in either study arm (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). follow‐up: 10 days </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Studies comparing penicillin to silver nitrate do not report the diagnosis of chlamydial conjunctivitis. They do not specify if chlamydia was measured, which is understandable considering 1950s publication dates. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/>(0.18 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2804<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a> </p> <p>follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(5 to 17) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5228<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Significant statistical heterogeneity, therefore meta‐analysis not conducted. Heterogeneity may be explained by differing definitions of conjunctivitis between trials. </p> <p>follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.13<br/>(0.10 to 0.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2804<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(26 to 47) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial with high risk of selection bias, unclear and high risk of performance bias, and high risk of attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either penicillin or silver nitrate arms of trial. Study was underpowered to assess this outcome.<br/><sup>3</sup>Downgraded for inconsistency (‐1): point estimates vary; confidence intervals do not overlap; I<sup>2</sup> is 93%; Chi<sup>2</sup> P &lt; 0.001. </p> </div> </div> <div class="table" id="CD001862-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin IM </p> <p><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin IM</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study with follow‐up: 10 days measured gonococcal conjunctivitis but found no cases of gonococcal conjunctivitis in either study arm (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>1 study comparing penicillin IM to silver nitrate does not report chlamydial conjunctivitis and does not specify if chlamydia was measured, which is understandable considering the study was published in 1951. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.46 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up 10 days (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(12 to 32) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/>(0.21 to 0.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(61 to 93) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21<br/>(0.17 to 0.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(45 to 71) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>IM:</b> intramuscular; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias: single trial with high risk of selection bias, unclear to high risk of performance bias, and unclear to high risk of attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm, likely not meeting optimal information size criteria.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met; confidence interval wide and crosses null effect. </p> </div> </div> <section id="CD001862-sec-0095"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>One trial reported no events of GC comparing topical and intramuscular (IM) penicillin versus silver nitrate (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0096"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>No data were available on CC comparing topical and IM penicillin versus silver nitrate.</p> </section> <section id="CD001862-sec-0097"> <h5 class="title">Bacterial conjunctivitis</h5> <p>In one trial, topical penicillin was associated with a reduced risk of BC compared with silver nitrate (RR 0.34, 95% CI 0.18 to 0.65) (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was moderate. </p> <p>In one trial, IM penicillin was associated with a reduced risk of BC compared with silver nitrate; this association was not statistically significant (RR 0.75, 95% CI 0.46 to 1.24) (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0098"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>Two trials compared topical penicillin versus silver nitrate for ACAE. While both trials reported that penicillin was associated with a lower risk of ACAE compared with silver nitrate, their estimates were statistically heterogeneous (I<sup>2</sup> = 93%; <a href="./references#CD001862-fig-0061" title="">Analysis 12.3</a>), precluding a meta‐analysis. The RR for ACAE was 0.15 (95% CI 0.12 to 0.20) in <a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a> and 0.78 (95% CI 0.35 to 1.70) in <a href="./references#CD001862-bbs2-0017" title="HarrisST . Silver nitrate in ophthalmia neonatorum prophylaxis. Sight Saving Review1957;27(3):152-3. ">Harris 1957</a>. GRADE certainty of the evidence was very low. Both trials were reported in the 1950s, and were at high risk of selection bias and unclear risk of performance, detection, and attrition biases. Multiple factors may explain the heterogeneity observed in this analysis, including lack of a specific definition of conjunctivitis in <a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>, requiring interpretation by the review authors; and use of wax ampoules that the study authors reported were sometimes defective, leading to evaporation and potentially increased concentration of silver nitrate, and eventually frequency of chemical conjunctivitis. </p> <p>In one trial, IM penicillin was associated with a reduced risk of ACAE compared with silver nitrate (RR 0.26, 95% CI 0.21 to 0.32) (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0099"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In one trial, topical penicillin was associated with a reduced risk of CUE compared with silver nitrate (RR 0.13, 95% CI 0.10 to 0.18) (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was low. </p> <p>In one trial, IM penicillin was associated with a reduced risk of CUE compared with silver nitrate (RR 0.21, 95% CI 0.17 to 0.27) (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0100"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing penicillin versus silver nitrate.</p> </section> </section> <section id="CD001862-sec-0101"> <h4 class="title">Povidone‐iodine versus silver nitrate</h4> <p>See summary of findings in <a href="#CD001862-tbl-0016">Table 15</a>. </p> <div class="table" id="CD001862-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Povidone‐iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.94<br/>(0.60 to 6.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(3 to 25) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/>(0.38 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(40 to 75) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.61 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 per 1000<br/>(107 to 161) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/>(0.63 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226 per 1000<br/>(198 to 264) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.55 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/>(76 to 124) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial has high or unclear risk of selection bias, performance bias, and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> </div> </div> <section id="CD001862-sec-0102"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>), povidone‐iodine was associated with a higher risk of GC than silver nitrate, which was not statistically significant (RR 1.94, 95% CI 0.60 to 6.29). GRADE assessment of the evidence was low. </p> </section> <section id="CD001862-sec-0103"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>), povidone‐iodine was associated with a lower risk of CC than silver nitrate (RR 0.52, 95% CI 0.38 to 0.71). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0104"> <h5 class="title">Bacterial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>), povidone‐iodine was associated with a lower risk of BC than silver nitrate (RR 0.75, 95% CI 0.61 to 0.92). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0105"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>), povidone‐iodine was associated with a lower risk of ACAE than silver nitrate (RR 0.72, 95% CI 0.63 to 0.84). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0106"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>), povidone‐iodine was associated with a lower risk of CUE than silver nitrate (RR 0.70, 95% CI 0.55 to 0.89). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0107"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing povidone‐iodine versus silver nitrate.</p> </section> </section> <section id="CD001862-sec-0108"> <h4 class="title">Tetracycline versus erythromycin</h4> <p>See summary of findings in <a href="#CD001862-tbl-0017">Table 16</a>. </p> <div class="table" id="CD001862-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> tetracycline<br/><b>Comparison:</b> erythromycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/>(0.18 to 2.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,946<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 of 2 included studies did not identify any cases of gonococcal conjunctivitis (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/>(0.42 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,946<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(3 to 8) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst the 3 studies comparing these interventions, <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> measured and reported bacterial conjunctivitis, but data could not be extracted, and <a href="./references#CD001862-bbs2-0016" title="HammerschlagMR , CummingsC , RoblinPM , WilliamsTH , DelkeI . Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. New England Journal of Medicine1989;320(12):769-72. ">Hammerschlag 1989</a> and <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> did not report and outcome was unlikely measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2539<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Data not pooled because of significant heterogeneity. I<sup>2</sup> is 69% and point estimates on opposite side of line of no effect. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst the 3 studies comparing these interventions, <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> measured and reported conjunctivitis of unknown aetiology, but data could not be extracted, and <a href="./references#CD001862-bbs2-0016" title="HammerschlagMR , CummingsC , RoblinPM , WilliamsTH , DelkeI . Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. New England Journal of Medicine1989;320(12):769-72. ">Hammerschlag 1989</a> and <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> did not report and outcome was unlikely measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at unclear or high risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, but sample size is large at 5624 in tetracycline group and 5322 in erythromycin group. However, confidence interval includes no effect, confidence intervals wide, and one trial has no events.<br/><sup>3</sup>Downgraded for inconsistency (‐1): significant statistical heterogeneity. Point estimates on either side of line of no effect. I<sup>2</sup> is 69%. </p> </div> </div> <section id="CD001862-sec-0109"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>In a meta‐analysis of two trials, there was no evidence that tetracycline was associated with a statistically significant reduction in risk of GC compared with erythromycin (RR 0.73, 95% CI 0.18 to 2.95, 10,946 participants, 2 studies; I<sup>2</sup> = 0%). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0110"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a meta‐analysis of two trials, tetracycline was associated with a lower risk of CC than erythromycin, but the reduction in risk was not statistically significant (RR 0.72, 95% CI 0.42 to 1.25, 10,946 participants, 2 studies; I<sup>2</sup> = 0%). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0111"> <h5 class="title">Bacterial conjunctivitis</h5> <p>No data were available on BC comparing tetracycline versus erythromycin.</p> </section> <section id="CD001862-sec-0112"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>There was significant heterogeneity (I<sup>2</sup> = 69%) in estimates for risk of ACAE from two trials comparing tetracycline and erythromycin, which precluded a meta‐analysis (<a href="./references#CD001862-fig-0073" title="">Analysis 15.2</a>). A 25% risk reduction (95% CI 46% reduction to 2% increase) was observed in <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> (RR 0.75, 95% CI 0.54 to 1.02), whilst a 38% increase in risk (95% CI 24% reduction to 2.47‐fold increase) was observed in <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> (RR 1.38, 95% CI 0.76 to 2.47). GRADE certainty of the evidence was very low. The heterogeneity observed between the two trials may be explained by methodological and clinical factors. <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> reported randomly allocating neonates to interventions, whilst <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> alternated the interventions monthly. Furthermore, <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> was described as “single‐blind”, whilst <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> did not involve any masking. Clinically, the causative agents of conjunctivitis in neonates could differ between the two trials. However, only <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> reported culture results, and we are unable to definitively ascertain diversity in aetiology of conjunctivitis as a source of heterogeneity. Separately, the ointments used in the two studies were of identical concentrations, but they were manufactured by different companies. This difference may explain heterogeneous outcomes to the extent that the manufacturing protocols contributed to differential efficacy of the antibiotics. </p> </section> <section id="CD001862-sec-0113"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>No data were available on CUE comparing tetracycline versus erythromycin.</p> </section> <section id="CD001862-sec-0114"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing tetracycline versus erythromycin.</p> </section> </section> <section id="CD001862-sec-0115"> <h4 class="title">Colostrum versus erythromycin</h4> <p>See summary of findings in <a href="#CD001862-tbl-0018">Table 17</a>. </p> <div class="table" id="CD001862-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> colostrum<br/><b>Comparison:</b> erythromycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with colostrum</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Gonococcal conjunctivitis was not reported, and there is no evidence that it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Chlamydial conjunctivitis was not reported, and there is no evidence that it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Bacterial conjunctivitis was reported, but data could not be extracted. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.49<br/>(0.80 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>171<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 per 1000<br/>(127 to 442) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Conjunctivitis of unknown aetiology was not reported, and there was no evidence that it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial at unclear or high risk of performance bias and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> </div> </div> <section id="CD001862-sec-0116"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>No data were available on GC comparing colostrum versus erythromycin.</p> </section> <section id="CD001862-sec-0117"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>No data were available on CC comparing colostrum versus erythromycin.</p> </section> <section id="CD001862-sec-0118"> <h5 class="title">Bacterial conjunctivitis</h5> <p>No data were available on BC comparing colostrum versus erythromycin.</p> </section> <section id="CD001862-sec-0119"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>), colostrum was associated with a higher risk of ACAE compared with erythromycin, but the effect was not statistically significant (RR 1.49, 95% CI 0.80 to 2.78). The trial was at low risk of selection bias but at high risk of attrition bias. GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0120"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>No data were available on CUE comparing colostrum versus erythromycin.</p> </section> <section id="CD001862-sec-0121"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing colostrum versus erythromycin.</p> </section> </section> <section id="CD001862-sec-0122"> <h4 class="title">Povidone‐iodine versus erythromycin</h4> <p>See summary of findings in <a href="#CD001862-tbl-0019">Table 18</a>. </p> <div class="table" id="CD001862-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Povidone‐iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> erythromycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.36 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 of the 2 studies had no cases of gonococcal conjunctivitis in intervention or control arm (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(3 to 18) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.54 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(37 to 70) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/>(0.71 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/>(101 to 152) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.68 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 per 1000<br/>(187 to 248) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.58 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(72 to 115) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): confidence interval overlaps no effect and optimal information size criteria not met.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criterion not met. </p> </div> </div> <section id="CD001862-sec-0123"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>Two trials compared povidone‐iodine with erythromycin and reported data on GC; one of the trials reported no events in both groups (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). The second trial (<a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a>) was larger by about 10 times; only a few events of GC were observed, resulting in high variance in the estimate. Povidone‐iodine was associated with a lower risk of GC compared with erythromycin, but the effect was not statistically significant (RR 0.85, 95% CI 0.36 to 2.01, 2408 participants, 2 studies; I<sup>2</sup> = 0%; <a href="#CD001862-fig-0012">Figure 12</a>). GRADE certainty of the evidence was low. </p> <div class="figure" id="CD001862-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 17 Povidone‐iodine versus erythromycin, outcome: 17.1 Gonococcal conjunctivitis" data-id="CD001862-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 17 Povidone‐iodine versus erythromycin, outcome: 17.1 Gonococcal conjunctivitis </p> </div> </div> </div> </section> <section id="CD001862-sec-0124"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a meta‐analysis of two trials, povidone‐iodine was associated with a lower risk of CC compared with erythromycin, but the effect was not statistically significant (RR 0.74, 95% CI 0.54 to 1.02, 2408 participants, 2 studies; I<sup>2</sup> = 0%; <a href="./references#CD001862-fig-0075" title="">Analysis 17.1</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0125"> <h5 class="title">Bacterial conjunctivitis</h5> <p>Povidone‐iodine was associated with a lower risk of BC compared with erythromycin, but the effect was not statistically significant (RR 0.87, 95% CI 0.71 to 1.07; <a href="./references#CD001862-fig-0076" title="">Analysis 17.2</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0126"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a meta‐analysis of two trials, povidone‐iodine was associated with a lower risk of ACAE compared with erythromycin; there was some statistical heterogeneity (RR 0.78, 95% CI 0.68 to 0.90; I<sup>2</sup> = 45%; <a href="./references#CD001862-fig-0077" title="">Analysis 17.3</a>). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0127"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In a meta‐analysis of two trials, povidone‐iodine was associated with a lower risk of CUE compared with erythromycin (RR 0.74, 95% CI 0.58 to 0.93; <a href="./references#CD001862-fig-0078" title="">Analysis 17.4</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0128"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing povidone‐iodine versus erythromycin.</p> </section> </section> <section id="CD001862-sec-0129"> <h4 class="title">Penicillin IM versus tetracycline</h4> <p>See summary of findings in <a href="#CD001862-tbl-0020">Table 19</a>. </p> <div class="table" id="CD001862-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin IM<br/><b>Comparison:</b> tetracycline </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin IM</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32,058<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study with this comparison measured gonococcal conjunctivitis but reported no cases in either study arm (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>). </p> <p>follow‐up: 41 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.48 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,058<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a> </p> <p>follow‐up: 41 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 4) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>In the 1 study with these 2 interventions (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>), it is uncertain whether all cases of bacterial conjunctivitis were measured. Bacterial conjunctivitis was not reported in this study. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Total conjunctivitis cases of any aetiology (ACAE) was not reported in the 1 study with this comparison (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>). It is uncertain whether ACAE was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>In the 1 study comparing these interventions (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>), conjunctivitis of unknown aetiology was not reported, and it is uncertain if it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>IM:</b> intramuscular; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial has high risk of selection bias, high to unclear risk of performance bias, unclear attrition bias.<br/><sup>2</sup>We did not downgrade for imprecision even though number of events were low, sample sizes are very large (close to 16,000 in each group). Long follow‐up time of 41 months. </p> </div> </div> <section id="CD001862-sec-0130"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>None of the 32,058 participants in a single trial comparing IM penicillin versus tetracycline developed GC (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0131"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>), IM penicillin was associated with a lower risk of CC compared with tetracycline, but the effect was not statistically significant (RR 0.75, 95% CI 0.48 to 1.17). GRADE certainty of the evidence was moderate. </p> </section> <section id="CD001862-sec-0132"> <h5 class="title">Bacterial conjunctivitis</h5> <p>No data were available on BC comparing IM penicillin versus tetracycline.</p> </section> <section id="CD001862-sec-0133"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>No data were available on ACAE comparing IM penicillin versus tetracycline.</p> </section> <section id="CD001862-sec-0134"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>No data were available on CUE comparing IM penicillin versus tetracycline.</p> </section> <section id="CD001862-sec-0135"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing IM penicillin versus tetracycline.</p> </section> </section> <section id="CD001862-sec-0136"> <h4 class="title">Povidone‐iodine versus tetracycline</h4> <p>See summary of findings in <a href="#CD001862-tbl-0021">Table 20</a>. </p> <div class="table" id="CD001862-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Povidone‐iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> tetracycline </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study included in this comparison measured gonococcal conjunctivitis but did not find any cases in either study arm (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study included in this comparison measured chlamydial conjunctivitis but did not identify any cases in either study arm (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.04<br/>(0.99 to 4.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/>(49 to 209) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.01<br/>(1.52 to 5.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149 per 1000<br/>(75 to 296) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 20.4<br/>(1.2 to 345.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There were no cases of conjunctivitis in the comparator group. The value of 1 per 1000 is the risk for tetracycline for illustrative purposes only. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(1 to 346) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): study has unclear or high risk of bias, which could influence outcome.<br/><sup>2</sup>Downgraded for imprecision (‐1): small trial size and lack of detection of any gonorrhoea cases.<br/><sup>3</sup>Downgraded for imprecision (‐1): small trial size and lack of detection of any chlamydia cases.<br/><sup>4</sup>Downgraded for imprecision (‐1): optimal information size criteria not met; confidence interval overlaps no effect; small trial size.<br/><sup>5</sup>Downgraded for imprecision (‐1): optimal information size criteria met, but one trial, wide confidence interval, low event rates, small sample size.<br/><sup>6</sup>Downgraded for imprecision (‐1): optimal information size criteria possibly met, but one trial, wide confidence interval, low event rates, small sample size. </p> </div> </div> <section id="CD001862-sec-0137"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>No incidence of GC was reported in a single trial of 410 infants (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0138"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>No incidence of CC was reported in a single trial of 410 infants (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0139"> <h5 class="title">Bacterial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>), povidone‐iodine was associated with a higher risk of BC compared with tetracycline; the association was not statistically significant (RR 2.04, 95% CI 0.99 to 4.22). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0140"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>), povidone‐iodine was associated with a higher risk of ACAE compared with tetracycline; the association was not statistically significant (RR 3.01, 95% CI 1.52 to 5.98). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0141"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In a single trial comparing povidone‐iodine versus tetracycline (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>), 10 events of CUE were reported with povidone‐iodine but no events of CUE were reported with tetracycline, thus the effect was not estimable. GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0142"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available comparing povidone‐iodine versus tetracycline.</p> </section> </section> <section id="CD001862-sec-0143"> <h4 class="title">Povidone‐iodine versus chloramphenicol</h4> <p>See summary of findings in <a href="#CD001862-tbl-0022">Table 21</a>. </p> <div class="table" id="CD001862-tbl-0022"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Povidone‐iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> chloramphenicol </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chloramphenicol</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 included study measured gonococcal conjunctivitis but did not find any cases in either study arm (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.77<br/>(0.97 to 3.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(16 to 52) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study measured and reported cases of bacterial conjunctivitis, but data could not be extracted (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study measured and reported cases of any conjunctivitis of any aetiology, but data could not be extracted (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study likely measured conjunctivitis of unknown aetiology, but data could not be extracted (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): masking not addressed or unclear; high losses to follow‐up, which can create plausible bias about results.<br/><sup>2</sup>Downgraded for imprecision (‐1): zero event rates, sample size small, and unable to determine relative effects; single trial.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size not met, and confidence interval overlaps no effect; single trial. </p> </div> </div> <section id="CD001862-sec-0144"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>None of the 2004 infants in a single trial comparing povidone‐iodine versus chloramphenicol developed GC (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0145"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>), povidone‐iodine was associated with a higher risk of CC compared with chloramphenicol, but the association was not statistically significant (RR 1.77, 95% CI 0.97 to 3.22). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0146"> <h5 class="title">Bacterial conjunctivitis</h5> <p>No data were available on BC for povidone‐iodine versus chloramphenicol.</p> </section> <section id="CD001862-sec-0147"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>No data were available on ACAE for povidone‐iodine versus chloramphenicol.</p> </section> <section id="CD001862-sec-0148"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>No data were available on CUE for povidone‐iodine versus chloramphenicol.</p> </section> <section id="CD001862-sec-0149"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available for povidone‐iodine versus chloramphenicol.</p> </section> </section> <section id="CD001862-sec-0150"> <h4 class="title">Povidone‐iodine versus carbethopendecinium bromide</h4> <p>See summary of findings in <a href="#CD001862-tbl-0023">Table 22</a>. </p> <div class="table" id="CD001862-tbl-0023"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Povidone‐iodine compared to carbethopendecinium bromide for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to carbethopendecinium bromide for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> carbethopendecinium bromide </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with carbethopendecinium bromide</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make any reference to gonococcal conjunctivitis (GC). There is no reference to culturing. It is unknown if GC was measured. GC cases were not reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make any reference to chlamydial conjunctivitis (CC). It unknown if CC was measured. No reference to culturing. No CC cases were reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make reference to bacterial conjunctivitis (BC). It unknown if BC was measured. No reference to culturing. No BC cases reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/>(0.15 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 trial only (<a href="./references#CD001862-bbs2-0030" title="ZbojanJ , DluholuckyS , ZacharovskaM . Credeization with povidone-iodine - efficiency and a possible influence on thyroid gland in newborns [Kredeizacia povidon-jodidom - ucinnost a mozny vplyv na stitnu zlazu novorodenca]. Cesko Slovenska Pediatrie2004;59(1):11-3. ">Zbojan 2004</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(27 to 243) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make reference to conjunctivitis of unknown aetiology (CUE). It unknown if CUE was measured. No CUE cases were reported and CUE could not be calculated. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial with unclear risk of selection bias, performance bias, detection bias, and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect; small trial. </p> </div> </div> <section id="CD001862-sec-0151"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>No data were available on GC for povidone‐iodine versus carbethopendecinium bromide.</p> </section> <section id="CD001862-sec-0152"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>No data were available on CC for povidone‐iodine versus carbethopendecinium bromide.</p> </section> <section id="CD001862-sec-0153"> <h5 class="title">Bacterial conjunctivitis</h5> <p>No data were available on BC for povidone‐iodine versus carbethopendecinium bromide.</p> </section> <section id="CD001862-sec-0154"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0030" title="ZbojanJ , DluholuckyS , ZacharovskaM . Credeization with povidone-iodine - efficiency and a possible influence on thyroid gland in newborns [Kredeizacia povidon-jodidom - ucinnost a mozny vplyv na stitnu zlazu novorodenca]. Cesko Slovenska Pediatrie2004;59(1):11-3. ">Zbojan 2004</a>), povidone‐iodine was associated with a lower risk of ACAE, but the effect was not statistically significant (RR 0.44, 95% CI 0.15 to 1.35). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0155"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>No data were available on CUE for povidone‐iodine versus carbethopendecinium bromide.</p> </section> <section id="CD001862-sec-0156"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available for povidone‐iodine versus carbethopendecinium bromide. </p> </section> </section> <section id="CD001862-sec-0157"> <h4 class="title">Povidone‐iodine twice versus povidone‐iodine once</h4> <p>See summary of findings in <a href="#CD001862-tbl-0024">Table 23</a>. </p> <div class="table" id="CD001862-tbl-0024"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Double application of povidone‐iodine compared to single application of povidone‐iodine for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Double application of povidone‐iodine compared to single application of povidone‐iodine for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> double application of povidone‐iodine<br/><b>Comparison:</b> single application of povidone‐iodine </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with single application of povidone‐iodine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with double application of povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study measured cases of gonococcal conjunctivitis, but no cases were found in either study arm (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/>(0.26 to 6.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(2 to 44) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.69<br/>(0.59 to 4.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(9 to 72) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(0.99 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/>(182 to 322) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.29<br/>(0.95 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218 per 1000<br/>(161 to 294) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial has high risk of selection bias, unclear risk of performance bias, and unclear risk of attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm. <br/><sup>3</sup>Downgraded for imprecision (‐2): limited number of events in each arm, very wide confidence intervals. <br/><sup>4</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> </div> </div> <section id="CD001862-sec-0158"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>No incidence of GC was reported amongst 719 infants in a single trial comparing povidone‐iodine administered twice versus once (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0159"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>), povidone‐iodine administered twice was associated with a higher risk of CC compared with a single dose of povidone‐iodine, but the variance in the estimate was large (RR 1.27, 95% CI 0.26 to 6.24). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0160"> <h5 class="title">Bacterial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>), povidone‐iodine administered twice was associated with a higher risk of BC compared with a single dose of povidone‐iodine, but the effect was not statistically significant (RR 1.69, 95% CI 0.59 to 4.82). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0161"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>), povidone‐iodine administered twice was associated with a higher risk of ACAE compared with a single dose of povidone‐iodine, but the effect was not statistically significant (RR 1.32, 95% CI 0.99 to 1.75). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0162"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>), povidone‐iodine administered twice was associated with a higher risk of CUE compared with a single dose of povidone‐iodine, but the effect was not statistically significant (RR 1.29, 95% CI 0.95 to 1.74). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0163"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available for povidone‐iodine administered twice versus once. </p> </section> </section> <section id="CD001862-sec-0164"> <h4 class="title">Penicillin IM versus topical penicillin</h4> <p>See summary of findings in <a href="#CD001862-tbl-0025">Table 24</a>. </p> <div class="table" id="CD001862-tbl-0025"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin IM </p> <p><b>Comparison:</b> topical penicillin ointment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with topical penicillin ointment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin IM</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study measured cases of gonococcal conjunctivitis, but no cases were found in either study arm (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>This 1 study from 1951 did not report the diagnosis of chlamydial conjunctivitis, nor did the authors specify if chlamydia was measured. It is unlikely that techniques to detect chlamydia were used in this time period. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.19<br/>(1.14 to 4.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(10 to 38) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/>(1.26 to 2.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(55 to 102) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.58<br/>(1.12 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(39 to 79) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>IM:</b> intramuscular; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study at high risk or unclear risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): optimal information size criteria likely not met; no events.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met. However, confidence interval excludes no effect. </p> </div> </div> <section id="CD001862-sec-0165"> <h5 class="title">Gonococcal conjunctivitis</h5> <p>No incidence of GC was reported amongst 2795 infants in a single trial comparing IM versus topical penicillin (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). GRADE certainty of the evidence was very low. </p> </section> <section id="CD001862-sec-0166"> <h5 class="title">Chlamydial conjunctivitis</h5> <p>No incidence of CC was reported amongst 2795 infants in a single trial comparing IM versus topical penicillin (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </section> <section id="CD001862-sec-0167"> <h5 class="title">Bacterial conjunctivitis</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>), IM penicillin was associated with a higher risk of BC compared with topical penicillin (RR 2.19, 95% CI 1.14 to 4.24). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0168"> <h5 class="title">Any conjunctivitis of any aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>), IM penicillin was associated with a higher risk of ACAE compared with topical penicillin (RR 1.71, 95% CI 1.26 to 2.32). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0169"> <h5 class="title">Conjunctivitis of unknown aetiology</h5> <p>In a single trial (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>), IM penicillin was associated with a higher risk of CUE compared with topical penicillin (RR 1.58, 95% CI 1.12 to 2.25). GRADE certainty of the evidence was low. </p> </section> <section id="CD001862-sec-0170"> <h5 class="title">Adverse events</h5> <p>No adverse events data were available for penicillin IM versus topical penicillin.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001862-sec-0171" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001862-sec-0171"></div> <section id="CD001862-sec-0172"> <h3 class="title" id="CD001862-sec-0172">Summary of main results</h3> <p>No data were available from the included trials for the primary vision outcomes of blindness and any adverse visual outcome. Gonococcal conjunctivitis (GC) may be considered a surrogate for vision outcomes because it is associated with a high risk of blindness. </p> <p>For prophylaxis of GC, the protective effect of none of the interventions we examined was statistically significant, but in general studies were underpowered for this rare outcome and we judged the evidence to be low‐certainty. Based on effect estimates, silver nitrate appeared to be more effective for prophylaxis of GC than erythromycin or povidone‐iodine (<a href="#CD001862-fig-0013">Figure 13</a>). A similar protective effect with silver nitrate was not observed against tetracycline, however. </p> <div class="figure" id="CD001862-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Prophylaxis of GC" data-id="CD001862-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prophylaxis of GC</p> </div> </div> </div> <p>For prophylaxis of chlamydial conjunctivitis (CC), the protective effect of povidone‐iodine relative to silver nitrate was statistically significant, and a consistent effect was seen relative to erythromycin (<a href="#CD001862-fig-0014">Figure 14</a>). There were limited data against tetracycline. However, povidone‐iodine was associated with a higher risk of CC compared with chloramphenicol, which was not statistically significant. </p> <div class="figure" id="CD001862-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Prophylaxis of CC" data-id="CD001862-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prophylaxis of CC</p> </div> </div> </div> <p>For prophylaxis of bacterial conjunctivitis (BC), povidone‐iodine appeared to be more effective than silver nitrate and erythromycin but less effective than tetracycline (<a href="#CD001862-fig-0015">Figure 15</a>). Furthermore, erythromycin, sulfacetamide, and penicillin were associated with a protective effect against BC compared with silver nitrate; only the effect of topical penicillin relative to silver nitrate was statistically significant. Our findings also indicate that administering povidone‐iodine twice was associated with a higher risk of CC, BC, and any conjunctivitis of any aetiology (ACAE) compared with single administration of povidone‐iodine. </p> <div class="figure" id="CD001862-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Prophylaxis of BC" data-id="CD001862-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prophylaxis of BC</p> </div> </div> </div> <p>For prophylaxis of ACAE, any prophylaxis was associated with a lower incidence (<a href="#CD001862-fig-0016">Figure 16</a>). Povidone‐iodine, erythromycin, silver nitrate, and tetracycline had a statistically significant protective effect against ACAE compared with no prophylaxis. However, colostrum did not show a statistically significant protective effect against ACAE. Furthermore, povidone‐iodine, erythromycin, tetracycline, penicillin, and sulfacetamide seemed to be more protective against ACAE compared with silver nitrate and povidone‐iodine appeared to be less protective against ACAE compared with tetracycline. </p> <div class="figure" id="CD001862-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Prophylaxis of ACAE" data-id="CD001862-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prophylaxis of ACAE</p> </div> </div> </div> <p>Finally, our findings demonstrate that silver nitrate is associated with a statistically significant increased risk of chemical conjunctivitis when compared with povidone‐iodine, cetyl‐pyridinium chloride, sulfacetamide, and penicillin (<a href="#CD001862-fig-0017">Figure 17</a>). Povidone‐iodine was associated with a reduced risk of chemical conjunctivitis when compared with erythromycin. There was high variance in the estimates showing an apparent increased risk of chemical conjunctivitis observed with povidone‐iodine relative to no prophylaxis and to tetracycline. </p> <div class="figure" id="CD001862-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Prophylaxis of CUE" data-id="CD001862-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prophylaxis of CUE</p> </div> </div> </div> </section> <section id="CD001862-sec-0173"> <h3 class="title" id="CD001862-sec-0173">Overall completeness and applicability of evidence</h3> <p>No trials included the primary outcome of blindness or any adverse visual outcome. There could be ethical and logistical barriers to conducting such a trial. The very low incidence of blindness following ophthalmia neonatorum means trials must be very large to have adequate power to detect clinically meaningful differences in treatment effects. The low event rate makes it difficult to determine if prophylaxis is effective for GC, and difficult to determine the relative effect of the various prophylactic medications for the critical outcome of GC. </p> <p>This review included studies conducted all over the world, in low‐, middle‐ and high‐income countries, and various settings within countries, with high and low baseline prevalence of sexually transmitted and other infections that may be causal agents of ophthalmia neonatorum. Twelve (40%) of the 30 studies were conducted in low‐ and middle‐income economies, with the majority in Iran and Kenya. Three studies took place in Kenya, four studies in Iran and one each in Zaire, Mexico, Indonesia, China, and Angola). Eighteen studies (60%) were conducted in high‐income countries, with the majority in the USA and Europe. Nine studies were conducted in the USA, seven in European countries, one in Canada, and one in Israel. </p> <p>More than 50% of the trials were conducted more than 20 years ago, and about a third of them were conducted more than 40 years ago. Healthcare systems, the epidemiology of infectious diseases, and drug resistance have changed during this time in many settings, which makes generalisability difficult. </p> <p>The majority of trials studied silver nitrate (61%), erythromycin (38%), tetracycline (35%), povidone‐iodine (27%), and no prophylaxis (31%). Silver nitrate does not appear to be manufactured anymore, and, a limited global survey of agents used for ophthalmia neonatorum prophylaxis found that silver nitrate is no longer used in the world (<a href="./references#CD001862-bbs2-0194" title="ZlotoO , GharaibehA , MezerE , StankovicB , IsenbergS , Wygnanski-JaffeT . Ophthalmia neonatorum treatment and prophylaxis: IPOSC global study. Graefe's Archive for Clinical and Experimental Ophthalmology2016;254(3):577-82.">Zloto 2016</a>). However, a variation containing organically bound silver, and alleged to have a similar effect to silver nitrate, called Targesin (1% silver protein acetyl tannate eye drops) is still used in Slovenia (<a href="./references#CD001862-bbs2-0138" title="Jug DošlerA , PetročnikP , MivšekAP , ZakšekT , SkubicM . Neonatal prophylaxis: prevention of Vitamin K deficiency haemorrhage and neonatal ophthalmia. Zdravstveno Varstvo2015;54(3):184-93.">Jug Došler 2015</a>). The majority of the world seems to use erythromycin or povidone‐iodine for ophthalmia neonatorum prophylaxis. </p> <p>The practice of ophthalmia neonatorum prophylaxis varies globally, with many countries no longer considering it to be an important public health intervention, and some countries continuing with prophylaxis. This review provides some moderate‐certainty evidence on the use of prophylaxis to prevent all‐cause cases of ophthalmia neonatorum, but not specifically gonococcal ophthalmia neonatorum, which has a high risk of blindness, and was the original purpose of prophylaxis. The results provide data on the relative effectiveness of the predominant medications used in the world for ophthalmia neonatorum prophylaxis, but no conclusions on which prophylaxis is most effective for the critical outcome of GC, which leads to an adverse visual outcome. </p> </section> <section id="CD001862-sec-0174"> <h3 class="title" id="CD001862-sec-0174">Quality of the evidence</h3> <p>The certainty of evidence available to address objectives specified for this review was at best moderate, and was low or very low for most of the comparisons studied. Major factors that affected our assessment of the certainty of the evidence included high potential for selection bias (inadequate randomisation), performance/detection bias due to masking that was either insufficient or impossible, and attrition bias. Our assessment of the certainty of the evidence was affected by heterogeneity across trials in only a few instances. </p> </section> <section id="CD001862-sec-0175"> <h3 class="title" id="CD001862-sec-0175">Potential biases in the review process</h3> <p>We conducted an extensive search of the literature; our search may not have identified studies presented at conferences in paediatrics and neonatal medicine. We specified a broad inclusion criteria to encompass quasi‐randomised and randomised studies, therefore we rated several of the included studies to be at high risk of bias and the certainty of the evidence as low. Furthermore, several trials included in this review were published over a period of about six decades. Trial reporting has significantly varied over time. Consequently, there was insufficient information to assess the risk of bias for many of the included trials, which we judged as unclear and moderated our evaluation of the certainty of the evidence. The duration of follow‐up and time at which outcomes were assessed were highly varied in the included trials. Whilst our approach to combine data across trials, which assessed outcomes at different times in the 28‐day period after birth, may have added uncertainty to our estimates, it is unlikely that our approach would have led to biased estimates. We used an intention‐to‐treat analysis for all but three trials. This approach is likely to have led to an underestimation of effect in some instances of our meta‐analyses. We chose this approach because an available‐case analysis would have limited the data only to the subgroup of trial participants who were followed up. </p> </section> <section id="CD001862-sec-0176"> <h3 class="title" id="CD001862-sec-0176">Agreements and disagreements with other studies or reviews</h3> <p>Another detailed systematic review on the subject of ophthalmia neonatorum has been published (<a href="./references#CD001862-bbs2-0042" title="DarlingEK , McDonaldH . A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. Journal of Midwifery and Women's Health2010;55(4):319-27. ">Darling 2010</a>). This review was conducted with methods similar to Cochrane methodology, and the inclusion criteria were similar to those specified for our review. However, <a href="./references#CD001862-bbs2-0042" title="DarlingEK , McDonaldH . A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. Journal of Midwifery and Women's Health2010;55(4):319-27. ">Darling 2010</a> included trials only reporting data on gonococcal and chlamydial ophthalmia neonatorum. In contrast, our systematic review included these outcomes, but also included the outcomes of BC, culture‐negative conjunctivitis, and all clinical conjunctivitis cases irrespective of aetiology. The data reported by <a href="./references#CD001862-bbs2-0042" title="DarlingEK , McDonaldH . A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. Journal of Midwifery and Women's Health2010;55(4):319-27. ">Darling 2010</a> for the outcomes of CC and GC were similar to those identified in our review. <a href="./references#CD001862-bbs2-0042" title="DarlingEK , McDonaldH . A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. Journal of Midwifery and Women's Health2010;55(4):319-27. ">Darling 2010</a> concluded that the evidence supports the use of ophthalmia prophylaxis where there is high prevalence of maternal gonorrhoeal and chlamydial infection at birth. However, the review questioned the current evidence for North American laws mandating universal neonatal eye prophylaxis and suggested a "reexamination of this policy". The <a href="./references#CD001862-bbs2-0042" title="DarlingEK , McDonaldH . A meta-analysis of the efficacy of ocular prophylactic agents used for the prevention of gonococcal and chlamydial ophthalmia neonatorum. Journal of Midwifery and Women's Health2010;55(4):319-27. ">Darling 2010</a> review served as a major catalyst reference for the revised 6 March 2015 (and reaffirmed in 28 February 2018) Canadian Pediatric Society Position Statement on Preventing Ophthalmia Neonatorum, which states: "Paediatricians and other physicians caring for newborns should advocate to rescind ocular prophylaxis regulations in jurisdictions in which this is still legally mandated". </p> <p>The findings of our review are consistent with the evidence review supporting the recommendations provided by the World Health Organization (<a href="./references#CD001862-bbs2-0192" title="World Health Organization. WHO recommendations on newborn health: guidelines approved by the WHO Guidelines Review Committee. Vol. WHO/MCA/17.07. Geneva: World Health Organization, 2017. [CC BY-NC-SA 3.0 IGO]">WHO 2017</a>). This evidence review only examined the outcomes of CC and GC. This review also included randomised and non‐randomised studies. For all neonates, the May 2017 World Health Organization Recommendations on Newborn Health, and the 2016 World Health Organization Sexually Transmitted Infection guidelines "recommend topical ocular prophylaxis for the prevention of gonococcal and chlamydial ophthalmia neonatorum". The WHO based this recommendation on low‐certainty evidence, although categorised the recommendation as strong. </p> <p>The findings of our review are less consistent with the evidence review supporting the January 2019 updated recommendation published by the US Preventive Services Task Force (USPSTF) (<a href="./references#CD001862-bbs2-0131" title="Guirguis-BlakeJM , EvansCV , RushkinM . Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA2019;321(4):404-6.">Guirguis‐Blake 2019</a>; <a href="./references#CD001862-bbs2-0179" title="US Preventive Services Task Force. Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA2019;321(4):394-8.">USPSTF 2019</a>). The USPSTF recommendations were based upon a systematic review that only reported data on the outcome of gonococcal ophthalmia neonatorum. In this review, the USPSTF concluded "with high certainty that the net benefit of topical ocular prophylaxis of all newborns to prevent gonococcal ophthalmia neonatorum is substantial". Our review did not find high‐certainty evidence for prevention of gonococcal ophthalmia neonatorum but moderate‐certainty evidence of an effect on clinical conjunctivitis more generally. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001862-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram" data-id="CD001862-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Table of Trial Settings" data-id="CD001862-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-02.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Table of Trial Settings</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-02.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Table of Trials, Interventions, Method of Allocation, Settings" data-id="CD001862-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-03.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Table of Trials, Interventions, Method of Allocation, Settings</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-03.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001862-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001862-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Any prophylaxis versus no prophylaxis, outcome: 1.1 Gonococcal conjunctivitis" data-id="CD001862-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Any prophylaxis versus no prophylaxis, outcome: 1.1 Gonococcal conjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.1 Gonococcal conjunctivitis." data-id="CD001862-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.1 Gonococcal conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.2 Chlamydial conjunctivitis." data-id="CD001862-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 8 Erythromycin versus silver nitrate, outcome: 8.2 Chlamydial conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.1 Gonococcal conjunctivitis." data-id="CD001862-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.1 Gonococcal conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.2 Chlamydia conjunctivitis." data-id="CD001862-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.2 Chlamydia conjunctivitis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.3 Any conjunctivitis of any aetiology" data-id="CD001862-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 9 Tetracycline versus silver nitrate, outcome: 9.3 Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 17 Povidone‐iodine versus erythromycin, outcome: 17.1 Gonococcal conjunctivitis" data-id="CD001862-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plot of comparison: 17 Povidone‐iodine versus erythromycin, outcome: 17.1 Gonococcal conjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Prophylaxis of GC" data-id="CD001862-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-13.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Prophylaxis of GC</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Prophylaxis of CC" data-id="CD001862-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-14.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Prophylaxis of CC</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Prophylaxis of BC" data-id="CD001862-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-15.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Prophylaxis of BC</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Prophylaxis of ACAE" data-id="CD001862-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-16.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Prophylaxis of ACAE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-FIG-17" target="_blank"><b></b></a></p> </div><img alt="Prophylaxis of CUE" data-id="CD001862-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-17.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-FIG-17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Prophylaxis of CUE</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-FIG-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 1: Chlamydial conjunctivitis" data-id="CD001862-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 1: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 5: Nasolacrimal duct obstruction" data-id="CD001862-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 5: Nasolacrimal duct obstruction </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 6: Keratitis" data-id="CD001862-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Any prophylaxis versus no prophylaxis, Outcome 6: Keratitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Silver nitrate versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Silver nitrate versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Silver nitrate versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Silver nitrate versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Silver nitrate versus no prophylaxis, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Silver nitrate versus no prophylaxis, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Silver nitrate versus no prophylaxis, Outcome 4: Corneal abrasion" data-id="CD001862-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Silver nitrate versus no prophylaxis, Outcome 4: Corneal abrasion</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Silver nitrate versus no prophylaxis, Outcome 5: Nasolacrimal duct obstruction" data-id="CD001862-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Silver nitrate versus no prophylaxis, Outcome 5: Nasolacrimal duct obstruction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Erythromycin versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Erythromycin versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Erythromycin versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Erythromycin versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Erythromycin versus no prophylaxis, Outcome 3: Bacterial conjunctivitis" data-id="CD001862-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Erythromycin versus no prophylaxis, Outcome 3: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Erythromycin versus no prophylaxis, Outcome 4: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Erythromycin versus no prophylaxis, Outcome 4: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Erythromycin versus no prophylaxis, Outcome 5: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Erythromycin versus no prophylaxis, Outcome 5: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Erythromycin versus no prophylaxis, Outcome 6: Nasolacrimal duct obstruction" data-id="CD001862-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Erythromycin versus no prophylaxis, Outcome 6: Nasolacrimal duct obstruction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Tetracycline versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Tetracycline versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Tetracycline versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Tetracycline versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Tetracycline versus no prophylaxis, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Tetracycline versus no prophylaxis, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 3: Bacterial conjunctivitis" data-id="CD001862-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 3: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 4: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 4: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 5: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Povidone‐iodine versus no prophylaxis, Outcome 5: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Bacitracin‐phenacaine versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Bacitracin‐phenacaine versus no prophylaxis, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Colostrum versus no prophylaxis, Outcome 1: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Colostrum versus no prophylaxis, Outcome 1: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erythromycin versus silver nitrate, Outcome 1: Chlamydial conjunctivitis" data-id="CD001862-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Erythromycin versus silver nitrate, Outcome 1: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erythromycin versus silver nitrate, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Erythromycin versus silver nitrate, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erythromycin versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Erythromycin versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erythromycin versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Erythromycin versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Erythromycin versus silver nitrate, Outcome 5: Nasolacrimal duct obstruction" data-id="CD001862-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Erythromycin versus silver nitrate, Outcome 5: Nasolacrimal duct obstruction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Tetracycline versus silver nitrate, Outcome 1: Chlamydial conjunctivitis" data-id="CD001862-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Tetracycline versus silver nitrate, Outcome 1: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Tetracycline versus silver nitrate, Outcome 2: Nasolacrimal duct obstruction" data-id="CD001862-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Tetracycline versus silver nitrate, Outcome 2: Nasolacrimal duct obstruction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sulfacetamide versus silver nitrate, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Sulfacetamide versus silver nitrate, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sulfacetamide versus silver nitrate, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Sulfacetamide versus silver nitrate, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sulfacetamide versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Sulfacetamide versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sulfacetamide versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: Sulfacetamide versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Cetyl‐pyridinium chloride versus silver nitrate, Outcome 1: Bacterial conjunctivitis" data-id="CD001862-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: Cetyl‐pyridinium chloride versus silver nitrate, Outcome 1: Bacterial conjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Cetyl‐pyridinium chloride versus silver nitrate, Outcome 2: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: Cetyl‐pyridinium chloride versus silver nitrate, Outcome 2: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: Cetyl‐pyridinium chloride versus silver nitrate, Outcome 3: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: Cetyl‐pyridinium chloride versus silver nitrate, Outcome 3: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Penicillin versus silver nitrate, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: Penicillin versus silver nitrate, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Penicillin versus silver nitrate, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: Penicillin versus silver nitrate, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Penicillin versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: Penicillin versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-012.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: Penicillin versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-012.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12: Penicillin versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-012.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Penicillin IM versus silver nitrate, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: Penicillin IM versus silver nitrate, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Penicillin IM versus silver nitrate, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: Penicillin IM versus silver nitrate, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Penicillin IM versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: Penicillin IM versus silver nitrate, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: Penicillin IM versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: Penicillin IM versus silver nitrate, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 3: Bacterial conjunctivitis" data-id="CD001862-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 3: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 4: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 4: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-014.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 5: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-014.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14: Povidone‐iodine versus silver nitrate, Outcome 5: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-014.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Tetracycline versus erythromycin, Outcome 1: Chlamydial conjunctivitis" data-id="CD001862-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: Tetracycline versus erythromycin, Outcome 1: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: Tetracycline versus erythromycin, Outcome 2: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: Tetracycline versus erythromycin, Outcome 2: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: Colostrum versus erythromycin, Outcome 1: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: Colostrum versus erythromycin, Outcome 1: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Povidone‐iodine versus erythromycin, Outcome 1: Chlamydial conjunctivitis" data-id="CD001862-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: Povidone‐iodine versus erythromycin, Outcome 1: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Povidone‐iodine versus erythromycin, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: Povidone‐iodine versus erythromycin, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Povidone‐iodine versus erythromycin, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: Povidone‐iodine versus erythromycin, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-017.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: Povidone‐iodine versus erythromycin, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-017.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17: Povidone‐iodine versus erythromycin, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-017.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pencillin IM versus tetracycline, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Pencillin IM versus tetracycline, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Pencillin IM versus tetracycline, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Pencillin IM versus tetracycline, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Povidone‐iodine versus tetracycline, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Povidone‐iodine versus tetracycline, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Povidone‐iodine versus tetracycline, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: Povidone‐iodine versus tetracycline, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Povidone‐iodine versus tetracycline, Outcome 3: Bacterial conjunctivitis" data-id="CD001862-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: Povidone‐iodine versus tetracycline, Outcome 3: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-019.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Povidone‐iodine versus tetracycline, Outcome 4: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-019.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19: Povidone‐iodine versus tetracycline, Outcome 4: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-019.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Povidone‐iodine versus tetracycline, Outcome 5: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-019.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.5</div> <div class="figure-caption"> <p>Comparison 19: Povidone‐iodine versus tetracycline, Outcome 5: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-019.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Povidone‐iodine versus chloramphenicol, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Povidone‐iodine versus chloramphenicol, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Povidone‐iodine versus chloramphenicol, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: Povidone‐iodine versus chloramphenicol, Outcome 2: Chlamydial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Povidone‐iodine versus carbethopendecinium bromide, Outcome 1: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Povidone‐iodine versus carbethopendecinium bromide, Outcome 1: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 1: Gonococcal conjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 2: Chlamydial conjunctivitis" data-id="CD001862-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 2: Chlamydial conjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 3: Bacterial conjunctivitis" data-id="CD001862-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 3: Bacterial conjunctivitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-022.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 4: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-022.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 4: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-022.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 5: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-022.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.5</div> <div class="figure-caption"> <p>Comparison 22: Povidone‐iodine twice versus povidone‐iodine once, Outcome 5: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-022.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Penicillin IM versus topical penicillin, Outcome 1: Gonococcal conjunctivitis" data-id="CD001862-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: Penicillin IM versus topical penicillin, Outcome 1: Gonococcal conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Penicillin IM versus topical penicillin, Outcome 2: Bacterial conjunctivitis" data-id="CD001862-fig-0095" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: Penicillin IM versus topical penicillin, Outcome 2: Bacterial conjunctivitis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-023.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Penicillin IM versus topical penicillin, Outcome 3: Any conjunctivitis of any aetiology" data-id="CD001862-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-023.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23: Penicillin IM versus topical penicillin, Outcome 3: Any conjunctivitis of any aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001862-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/urn:x-wiley:14651858:media:CD001862:CD001862-CMP-023.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: Penicillin IM versus topical penicillin, Outcome 4: Conjunctivitis of unknown aetiology" data-id="CD001862-fig-0097" src="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_t/tCD001862-CMP-023.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23: Penicillin IM versus topical penicillin, Outcome 4: Conjunctivitis of unknown aetiology </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/media/CDSR/CD001862/image_n/nCD001862-CMP-023.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001862-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> any prophylaxis, including povidone‐iodine, erythromycin, tetracycline, silver nitrate, bacitracin‐phenacaine, colostrum </p> <p><b>Comparison:</b> no prophylaxis (none of the studies used a placebo or sham treatment) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with any prophylaxis</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.79<br/>(0.24 to 2.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>8229<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>In 2 of these 3 studies there were no cases of gonococcal conjunctivitis in either study arm. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 3) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(10 to 142) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.96<br/>(0.57 to 1.61) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4874<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="15" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(3 to 8) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>96 per 1000<br/>(57 to 161) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.84<br/>(0.37 to 1.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3685<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 6) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/>(19 to 97) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.65<br/>(0.54 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>9666<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 2) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000<br/>(162 to 134) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.75<br/>(0.37 to 8.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000<br/>(7 to 166) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>In a single study (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>), any prophylaxis (erythromycin 0.5% or silver nitrate 1%) did not appear to be associated with an increased risk of nasolacrimal duct obstruction compared with no prophylaxis (RR 0.93, 95% CI 0.68 to 1.28). </p> <p>A single study of 40 newborns comparing silver nitrate 1% with control reported that no events of keratitis were observed in the prophylaxis and no‐prophylaxis groups (<a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded (‐1) for risk of bias: studies were at high or unclear risk of bias.<br/><sup>2</sup>Downgraded (‐2) for imprecision: sparse data. </p> <p><sup>3</sup>Downgraded (‐1) for imprecision: 95% confidence interval includes no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any prophylaxis compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Physical characteristics of interventions studied in included trials</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions studied in included trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Physical characteristics/method of delivery</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver nitrate solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Translucent/white ointment, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Light‐yellow ointment, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxytetracycline hydrochlorate solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unknown colour/consistency, aqueous solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Orange‐red, clear solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hexarginum solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colour unknown, solution with 1 g silver nitrate + 36 g methylamine dissolved in 63 g sterile water, topical application </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin G ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear/white ointment, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin G intramuscular injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear, aqueous solution, intramuscular injection</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cetyl‐pyridinium chloride solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Solution of unknown colour/consistency, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacitracin‐phenacaine ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ointment of unknown colour, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfacetamide ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ointment of unknown colour, topical application</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clear, colourless to slightly yellow solution, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chloramphenicol ointment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colourless ointment; topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colostrum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yellowish, white or clear liquid, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbethopendecinium bromide solution</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yellowish to white powder in solution, solution colour unknown, topical instillation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mechanical cleansing</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eyes swabbed with clear, distilled water and wiped dry</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Physical characteristics of interventions studied in included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary results</span></div> <tbody> <tr> <td align="left" class="headercell" colspan="1" rowspan="2" valign="bottom"></td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Gonococcal conjunctivitis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Chlamydial conjunctivitis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Bacterial conjunctivitis</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Any conjunctivitis of any aetiology</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Conjunctivitis of unknown aetiology</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of trials</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk ratio (95% confidence interval)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any prophylaxis vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79 (0.24 to 2.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.57 to 1.61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.37 to 1.93)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.54 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75 (0.37 to 8.28)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Silver nitrate vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.06 (0.55 to 2.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.52 to 0.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.49 to 1.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.22 to 2.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.51 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.26 to 8.80)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.42 to 1.63)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.55 to 0.94)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00 (0.18 to 21.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.30 to 3.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38 (0.18 to 0.77)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00 (0.37 to 10.70)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacitracin‐phenacaine vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76 (0.20 to 2.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colostrum vs no prophylaxis</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.45 to 1.14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28 (0.88 to 5.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.51 to 1.09)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83 (0.69 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66 (0.21 to 2.05)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.40 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.66 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sulfacetamide vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88 (0.45 to 1.74)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54 (0.32 to 0.89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27 (0.11 to 0.66)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cetyl‐pyridinium chloride vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.79 (0.59 to 5.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.08 (0.40 to 2.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 2; IM penicillin: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 0.34 (0.18 to 0.65); IM penicillin: 0.75 (0.46 to 1.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 2; IM penicillin: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin:* <a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>: 0.15 (0.12 to 0.20); <a href="./references#CD001862-bbs2-0017" title="HarrisST . Silver nitrate in ophthalmia neonatorum prophylaxis. Sight Saving Review1957;27(3):152-3. ">Harris 1957</a>: 0.78 (0.35 to 1.70); IM penicillin: 0.26 (0.21 to 0.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 1; IM penicillin: 1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical penicillin: 0.13 (0.10 to 0.18); IM penicillin: 0.21 (0.17 to 0.27)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs silver nitrate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94 (0.60 to 6.29)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52 (0.38 to 0.71)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.61 to 0.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.63 to 0.84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 (0.55 to 0.89)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline vs erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.18 to 2.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72 (0.42 to 1.25)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>: 0.75 (0.54 to 1.02); <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a>: 1.38 (0.76 to 2.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colostrum vs erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (0.80 to 2.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (0.36 to 2.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.54 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.71 to 1.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78 (0.68 to 0.90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74 (0.58 to 0.93)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin IM vs tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 (0.48 to 1.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04 (0.99 to 4.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.01 (1.52 to 5.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs chloramphenicol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.77 (0.97 to 3.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine vs carbethopendecinium bromide</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (0.15 to 1.35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>No data were available.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Povidone‐iodine twice vs povidone‐iodine once</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.27 (0.26 to 6.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.69 (0.59 to 4.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.32 (0.99 to 1.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.29 (0.95 to 1.74)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Penicillin IM vs topical penicillin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No events reported in 1 or both arms.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.19 (1.14 to 4.24)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.71 (1.26 to 2.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.58 (1.12 to 2.25)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p><b>IM:</b> intramuscular </p> <p>*Indicates statistically significant heterogeneity precluding a meta‐analysis.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary results</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> silver nitrate<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2225<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in this study.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.06<br/>(0.55 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2225<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(3 to 10) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(55 to 202) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>2 of the 3 studies did not measure or report bacterial conjunctivitis (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>; <a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). 1 study measured bacterial conjunctivitis but did not report this outcome by study arm (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.67<br/>(0.52 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2713<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 per 1000<br/>(156 to 261) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>2 of the 3 studies did not measure did not measure or report conjunctivitis of unknown aetiology (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>; <a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). 1 study measured conjunctivitis of unknown aetiology but did not report this outcome by trial arm (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In a single study (<a href="./references#CD001862-bbs2-0002" title="BellTA , GraystonJT , KrohnMA , KronmalRA . Randomized trial of silver nitrate, erythromycin, and no eye prophylaxis for the prevention of conjunctivitis among newborns not at risk for gonococcal ophthalmitis. Eye Prophylaxis Study Group. Pediatrics1993;92(6):755-60. KrohnMA , HillierSL , BellTA , KronmalRA , GraystonJT . The bacterial etiology of conjunctivitis in early infancy. Eye Prophylaxis Study Group. American Journal of Epidemiology1993;138(5):326-32. ">Bell 1993</a>), silver nitrate prophylaxis appeared to be associated with an increased risk of nasolacrimal duct obstruction compared with no prophylaxis, but the variance in the estimate was imprecise with wide confidence intervals (RR 1.28, 95% CI 0.40 to 4.02). </p> <p>A single study comparing silver nitrate with control reported that no events of keratitis were observed in the prophylaxis and no‐prophylaxis groups (<a href="./references#CD001862-bbs2-0014" title="GrafH , RetkeU , SchillingC , SchmidtM . Reaction of the ophthalmic front region to the Crede-prophylaxis [Die reakton des vorderen augenabschnittes auf die Crede-prophylaxe]. Zentralblatt fur Gynakologie1994;116(11):639-42. ">Graf 1994</a>). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study with high risk of selection bias, unclear and high risk of performance bias, unclear risk of detection bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm of trial; study underpowered to assess relative effects of treatment on this outcome.<br/><sup>3</sup>Downgraded for imprecision (‐1): 95% confidence interval includes no effect.<br/><sup>4</sup>Downgraded for risk of bias (‐1): largest trial has high or unclear risk of bias; second‐largest trial has low risk of selection bias, but higher risk of performance or detection bias.<br/><sup>5</sup>Downgraded (‐2) for imprecision: sparse data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Silver nitrate compared to no prophylaxis for prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> erythromycin<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2526<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in these studies.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.93<br/>(0.49 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2526<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/>(2 to 9) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/>(49 to 177) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain.<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.80<br/>(0.22 to 2.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 9) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> <p>(11 to 145)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.68<br/>(0.51 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3509<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 per 1000</p> <p>(153 to 267)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/>(0.26 to 8.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/>(5 to 160) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In a single study of 269 people, there was no clear relationship between erythromycin and nasolacrimal duct obstruction (RR 0.83, 95% CI 0.56 to 1.23). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies were at high risk or unclear risk of bias. High loss to follow‐up in one trial, and unclear if follow‐up time is two weeks or one month in same trial. No placebo used in either trial.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm of trial.<br/><sup>3</sup>Downgraded for imprecision (‐1): 95% confidence interval includes no effect; very few events; one study; small sample size.<br/><sup>4</sup>Downgraded for risk of bias (‐1): study has high or unclear risk of bias with high loss to follow‐up. No placebo used.<br/><sup>5</sup>Downgraded for imprecision (‐2): very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Erythromycin compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> tetracycline<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2299<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in this study.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.82<br/>(0.42 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2299<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(7 to 26) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> <p>(42 to 163)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>1 study did not measure or report bacterial conjunctivitis (<a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a>), whilst the other study measured bacterial conjunctivitis but did not report by allocation group (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.72<br/>(0.55 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2519<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(2 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> <p>(1165 to 282)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>1 study did not measure or report conjunctivitis of unknown aetiology (CUE) (<a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a>), whilst the other study measured CUE but did not report by allocation group (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (‐3): no events in this trial.<br/><sup>2</sup>Downgraded for risk of bias (‐1): single trial with high risk of bias for sequence generation, allocation concealment, and masking, and unclear risk of bias for detection and attrition bias, which could affect outcomes considering the low event rates.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size not met, and confidence interval overlaps no effect in this single study.<br/><sup>4</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Tetracycline compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Povidone‐iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cases of gonococcal conjunctivitis were reported in this study.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 2.00<br/>(0.18 to 21.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(1 to 109) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> <p>(18 to 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture, smear, or Gram stain.<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.00<br/>(0.30 to 3.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/>(1 to 10) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> <p>(15 to 168)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.38<br/>(0.18 to 0.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(1 to 2) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114 per 1000</p> <p>(54 to 231)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.00<br/>(0.37 to 10.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>220<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(7 to 195) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for imprecision (‐3): no events in either arm of this study.<br/><sup>2</sup>Downgraded for risk of bias (‐1): the study is unclear regarding sequence generation and allocation concealment. Masking is a concern as there was no placebo. Very high losses to follow‐up.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> <p><sup>4</sup>Downgraded for imprecision (‐2): very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Povidone‐iodine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Bacitracin‐phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Bacitracin‐phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> bacitracin‐phenacaine<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with bacitracin‐phenacaine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.76<br/>(0.20 to 2.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>3355<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 per 1000</p> <p>(20 to 283 per 1000)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The 1 study does not seem to have measured or reported cases of chlamydial conjunctivitis (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>). Diagnostic methods for chlamydia would not have been readily available in 1959. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>It is unknown if bacterial conjunctivitis was measured in the 1 study (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>), as it categorises conjunctivitis only as "nonspecific conjunctivitis" and "gonorrhoeal ophthalmia". </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>It is unknown if all conjunctivitis were measured in the 1 study (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>), as it categorises conjunctivitis only as "nonspecific conjunctivitis" and "gonorrhoeal ophthalmia". </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The category of "nonspecific conjunctivitis" reported in the 1 study is undefined and may or may not also include bacterial conjunctivitis cases (<a href="./references#CD001862-bbs2-0025" title="PosnerAC , AndersonGD , PrigotA . Observations on the prophylaxis of ophthalmia neonatorum in a municipal hospital. In: Antibiotics Annual 1958-59. New York: Medical Encyclopedia Inc, 1958:552-5. ">Posner 1959</a>). </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial with high risk of selection bias, unclear risk of performance and detection bias, high risk of selective outcome reporting.<br/><sup>2</sup>Downgraded for imprecision (‐2): very wide confidence intervals, which include no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Bacitracin‐phenacaine compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> colostrum<br/><b>Comparison:</b> no prophylaxis </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no prophylaxis</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with colostrum</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No discussion of gonococcal conjunctivitis in this study (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). The trial excluded culture‐positive neonates before application of prophylaxis. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No discussion of chlamydial conjunctivitis in this 1 study (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). It is unknown if it was measured. Chlamydial conjunctivitis cases were not reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The 1 trial trial does not report bacterial conjunctivitis cases as distinguished from all conjunctivitis cases (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). It is unknown if bacterial conjunctivitis was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 0.72<br/>(0.45 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>186<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High risk</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216 per 1000</p> <p>(135 to 342)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>The 1 trial only reports all conjunctivitis cases, and does not distinguish bacterial conjunctivitis cases from cases of conjunctivitis of unknown aetiology (<a href="./references#CD001862-bbs2-0011" title="GhaemiS , NavaeiP , RahmiradS , BehjatiM , KelishadiR . Evaluation of preventive effects of colostrum against neonatal conjunctivitis: a randomized clinical trial. Journal of Education and Health Promotion2014;3:63. [DOI: 10.4103/2277-9531.134776]">Ghaemi 2014</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risks (low and high) in the comparison group were estimated from relevant prevalence studies (<a href="./appendices#CD001862-sec-0190">Appendix 8</a>).<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study at high or unclear risk of performance, detection, and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): 95% confidence interval includes no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Colostrum compared to no prophylaxis for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> erythromycin<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.28<br/>(0.88 to 5.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,855<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>In 2 of the 4 trials, there were no cases of gonococcal conjunctivitis in either study arm. </p> <p>Follow‐up: range 8 days to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 6) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.51 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13,472<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: range 4 weeks to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(11 to 23) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.69 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6333<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: range 9 days to 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(39 to 58) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9021<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A meta‐analysis was not conducted considering the considerable statistical heterogeneity (I<sup>2</sup> = 90%). Therefore, there was no pooled effect. </p> <p>Follow‐up: range 9 days to 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment of conjunctivitis</p> <p>follow‐up: 1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02<br/>(0.80 to 1.30) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4729<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After excluding 1 study (<a href="./references#CD001862-bbs2-0006" title="ChristianJR . Comparison of ocular reactions with the use of silver nitrate and erythromycin ointment in ophthalmia neonatorum prophylaxis. Journal of Pediatrics1960;57(1):55-60. ">Christian 1960</a>), I<sup>2</sup> declined to 51%, but was still moderate. A pooled effect was then presented for these 3 remaining studies. </p> <p>Follow‐up: range 9 days to 60 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/>(136 to 221) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.96<br/>(0.77 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2041<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133 per 1000<br/>(107 to 165) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In 1 study, erythromycin was associated with a reduced risk of nasolacrimal duct obstruction compared with silver nitrate. This association was not statistically significant (RR 0.81, 95% CI 0.55 to 1.20). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): very wide 95% confidence intervals including no effect.<br/><sup>3</sup>Downgraded for imprecision (‐1): 95% confidence intervals include no effect.<br/><sup>4</sup>Downgraded for risk of bias (‐1): one of the four studies, the smallest one (<a href="./references#CD001862-bbs2-0015" title="HammerschlagMR , ChandlerJW , AlexanderER , EnglishM , ChiangWT , KoutskyL , et al. Erythromycin ointment for ocular prophylaxis of neonatal chlamydial infection. JAMA1980;244(20):2291-3. ">Hammerschlag 1980</a>), was funded by the pharmaceutical company that produces erythromycin (Dista Pharmaceuticals). That trial favoured erythromycin, and was the only trial amongst four trials with no chlamydial conjunctivitis in the erythromycin arm (12 cases in the silver nitrate arm). There were 36 infants in the silver nitrate arm and only 24 in the erythromycin arm. Furthermore, 7 of 67 chlamydia‐positive mothers remained unaccounted for. Their distribution in the allocation arms is unknown. With a transmission rate of about 30%, low event rates, and small sample size, these missing mothers could have a significant effect on the results.<br/><sup>5</sup>Downgraded for inconsistency (‐1): confidence intervals do not overlap; point estimates vary widely and on either side of no effect; I<sup>2</sup> is 90%; and Chi<sup>2</sup> P &lt; 0.001. Heterogeneity could be explained by one older trial that did not define conjunctivitis, and review authors applied definition to eye reaction classifications. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Erythromycin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> tetracycline<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.66<br/>(0.21 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,501<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Amongst the 5 included trials, 3 had no events in either study arm.</p> <p>Range 4 weeks to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 2) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.64<br/>(0.40 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14,142<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Range 4 weeks to 19 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(3 to 7) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst 5 studies, 4 measured bacterial conjunctivitis but did not report the results (2) or the data could not be extracted (2). 1 study did not measure or report bacterial conjunctivitis. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.66 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>6229<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(42 to 63) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst 5 trials, 4 measured conjunctivitis of unknown aetiology (CUE) but did not report the results (2) or the data could not be extracted (2). 1 trial did not measure or report CUE. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>In 1 trial, tetracycline appeared to be associated with a higher risk of nasolacrimal duct obstruction, but the estimate was imprecise and included no effect (RR 1.57, 95% CI 0.63 to 3.91). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias.<br/><sup>2</sup>Downgraded for inconsistency (‐1): I<sup>2</sup> is 60%, Chi<sup>2</sup> P value is 0.11. Two trials had no events in either arm. Downgraded due to variable methods and length of follow‐up.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size is not met, but large sample size (7721 neonates in tetracycline group and 6780 neonates in silver nitrate group) with low baseline risk; however, confidence intervals are quite wide around relative effects, but around absolute effects relatively narrow. Outcome of gonococcal conjunctivitis is of critical significance and can affect vision. Therefore, downgraded one level for imprecision.<br/><sup>4</sup>Downgraded for imprecision (‐1): optimal information size is not met, but large sample size (7598 neonates in tetracycline group and 6544 neonates in silver nitrate group) with low baseline risk; confidence intervals are wide around relative effects, but around absolute effects relatively narrow. Confidence interval overlaps no effect. RR of 60% with tetracycline versus RR increase of 2% with tetracycline. Confidence interval fails to exclude important benefit. Chlamydial conjunctivitis outcome is important. Downgraded for imprecision.<br/><sup>5</sup>Downgraded for imprecision (‐1): confidence intervals include benefit and harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Tetracycline compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0012"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> sulfacetamide<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sulfacetamide</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study reported no cases of gonococcal conjunctivitis (<a href="./references#CD001862-bbs2-0007" title="CousineauGG , LloydLA . Preliminary report on prophylaxis of ophthalmia neonatorum. Transactions of the Canadian Ophthalmological Society1952;5:75-80. ">Cousineau 1952</a>). </p> <p>follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>It is likely that chlamydial conjunctivitis was measured in this 1952 study but not reported in this trial. It is described in other observational studies in the same paper ("virus inclusion bodies"). </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.88<br/>(0.45 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/>(24 to 92) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.54<br/>(0.32 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/>(39 to 109) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.27<br/>(0.11 to 0.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>640<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 3 to 9 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/>(8 to 46) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study with high risk of selection bias, high risk of performance bias, unclear risk of detection bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm of trial; study was underpowered to assess this outcome.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval overlaps no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Sulfacetamide compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0013"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Cetyl‐pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Cetyl‐pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> cetyl‐pyridinium chloride<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with cetyl‐pyridinium chloride</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis not measured and not reported. Study explicitly reported that there was no culture method used to detect <i>Neisseria gonorrhoeae</i>. </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>None of the studies reported the diagnosis of chlamydial conjunctivitis. None of the studies specified if chlamydia was measured, which was unlikely considering publication date of 1965. </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.79<br/>(0.59 to 5.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/>(10 to 92) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.08<br/>(0.40 to 2.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/>(11 to 78) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.14<br/>(0.01 to 2.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>599<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 2 weeks</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 27) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval overlaps no effect. Confidence intervals very wide.<br/><sup>3</sup>Downgraded for inconsistency (‐1): point estimates on opposite sides of no effect. I<sup>2</sup> is 60%, but confidence intervals overlap and and Chi<sup>2</sup> P value is 0.11. Borderline. Downgraded. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Cetyl‐pyridinium chloride compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0014"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2804<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study with this comparison measured gonococcal conjunctivitis but found no cases of gonococcal conjunctivitis in either study arm (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). follow‐up: 10 days </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Studies comparing penicillin to silver nitrate do not report the diagnosis of chlamydial conjunctivitis. They do not specify if chlamydia was measured, which is understandable considering 1950s publication dates. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.34<br/>(0.18 to 0.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2804<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a> </p> <p>follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(5 to 17) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5228<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Significant statistical heterogeneity, therefore meta‐analysis not conducted. Heterogeneity may be explained by differing definitions of conjunctivitis between trials. </p> <p>follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.13<br/>(0.10 to 0.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2804<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(26 to 47) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial with high risk of selection bias, unclear and high risk of performance bias, and high risk of attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either penicillin or silver nitrate arms of trial. Study was underpowered to assess this outcome.<br/><sup>3</sup>Downgraded for inconsistency (‐1): point estimates vary; confidence intervals do not overlap; I<sup>2</sup> is 93%; Chi<sup>2</sup> P &lt; 0.001. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Penicillin compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0015"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin IM </p> <p><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin IM</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study with follow‐up: 10 days measured gonococcal conjunctivitis but found no cases of gonococcal conjunctivitis in either study arm (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>1 study comparing penicillin IM to silver nitrate does not report chlamydial conjunctivitis and does not specify if chlamydia was measured, which is understandable considering the study was published in 1951. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.46 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up 10 days (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(12 to 32) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26<br/>(0.21 to 0.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>289 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(61 to 93) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.21<br/>(0.17 to 0.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2727<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Follow‐up: 10 days</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(45 to 71) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>IM:</b> intramuscular; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias: single trial with high risk of selection bias, unclear to high risk of performance bias, and unclear to high risk of attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm, likely not meeting optimal information size criteria.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met; confidence interval wide and crosses null effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Penicillin IM compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0016"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Povidone‐iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> silver nitrate </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with silver nitrate</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.94<br/>(0.60 to 6.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(3 to 25) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/>(0.38 to 0.71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(40 to 75) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.61 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132 per 1000<br/>(107 to 161) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/>(0.63 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>314 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226 per 1000<br/>(198 to 264) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.55 to 0.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2005<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0019" title="IsenbergSJ , AptL , WoodM . A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. New England Journal of Medicine1995;332(9):562-6. IsenbergSJ , AptL , WoodM . The influence of perinatal infective factors on ophthalmia neonatorum. Journal of Pediatric Ophthalmology and Strabismus1996;33(3):185-8. ">Isenberg 1995</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97 per 1000<br/>(76 to 124) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial has high or unclear risk of selection bias, performance bias, and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Povidone‐iodine compared to silver nitrate for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0017"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> tetracycline<br/><b>Comparison:</b> erythromycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.73<br/>(0.18 to 2.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,946<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 of 2 included studies did not identify any cases of gonococcal conjunctivitis (<a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/>(0 to 3) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.72<br/>(0.42 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10,946<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/>(3 to 8) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst the 3 studies comparing these interventions, <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> measured and reported bacterial conjunctivitis, but data could not be extracted, and <a href="./references#CD001862-bbs2-0016" title="HammerschlagMR , CummingsC , RoblinPM , WilliamsTH , DelkeI . Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. New England Journal of Medicine1989;320(12):769-72. ">Hammerschlag 1989</a> and <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> did not report and outcome was unlikely measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2539<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Data not pooled because of significant heterogeneity. I<sup>2</sup> is 69% and point estimates on opposite side of line of no effect. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Amongst the 3 studies comparing these interventions, <a href="./references#CD001862-bbs2-0005" title="ChenJY . Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatric Infectious Disease Journal1992;12(12):1026-30. ">Chen 1992</a> measured and reported conjunctivitis of unknown aetiology, but data could not be extracted, and <a href="./references#CD001862-bbs2-0016" title="HammerschlagMR , CummingsC , RoblinPM , WilliamsTH , DelkeI . Efficacy of neonatal ocular prophylaxis for the prevention of chlamydial and gonococcal conjunctivitis. New England Journal of Medicine1989;320(12):769-72. ">Hammerschlag 1989</a> and <a href="./references#CD001862-bbs2-0013" title="GhotbiN . Comparison of the effect of tetracycline 1% and erythromycin 0.5% ophthalmic ointments for prophylaxis of ophthalmia neonatorum. Scientific Journal of Kurdistan University of Medical Sciences2012;17(3):20-5. ">Ghotbi 2012</a> did not report and outcome was unlikely measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at unclear or high risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, but sample size is large at 5624 in tetracycline group and 5322 in erythromycin group. However, confidence interval includes no effect, confidence intervals wide, and one trial has no events.<br/><sup>3</sup>Downgraded for inconsistency (‐1): significant statistical heterogeneity. Point estimates on either side of line of no effect. I<sup>2</sup> is 69%. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Tetracycline compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0018"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> colostrum<br/><b>Comparison:</b> erythromycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with colostrum</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Gonococcal conjunctivitis was not reported, and there is no evidence that it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Chlamydial conjunctivitis was not reported, and there is no evidence that it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Bacterial conjunctivitis was reported, but data could not be extracted. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.49<br/>(0.80 to 2.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>171<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236 per 1000<br/>(127 to 442) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study excluded neonates with any positive cultures before administration of prophylaxis. Conjunctivitis of unknown aetiology was not reported, and there was no evidence that it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial at unclear or high risk of performance bias and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Colostrum compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0019"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Povidone‐iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> erythromycin </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with erythromycin</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.85<br/>(0.36 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 of the 2 studies had no cases of gonococcal conjunctivitis in intervention or control arm (<a href="./references#CD001862-bbs2-0001" title="AliZ , KhadijeD , ElaheA , FatemeN , MohammadM , FatemeZ , et al. Prophylaxis of ophthalmia neonatorum comparison of Betadine, erythromycin and no prophylaxis. Journal of Tropical Pediatrics2007;53(6):388-92. ">Ali 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/>(3 to 18) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.54 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 per 1000<br/>(37 to 70) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.87<br/>(0.71 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/>(101 to 152) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78<br/>(0.68 to 0.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 per 1000<br/>(187 to 248) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.58 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2408<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/>(72 to 115) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): studies at high or unclear risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): confidence interval overlaps no effect and optimal information size criteria not met.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criterion not met. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Povidone‐iodine compared to erythromycin for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0020"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin IM<br/><b>Comparison:</b> tetracycline </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin IM</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32,058<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study with this comparison measured gonococcal conjunctivitis but reported no cases in either study arm (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>). </p> <p>follow‐up: 41 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.75<br/>(0.48 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32,058<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a> </p> <p>follow‐up: 41 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/>(1 to 4) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>In the 1 study with these 2 interventions (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>), it is uncertain whether all cases of bacterial conjunctivitis were measured. Bacterial conjunctivitis was not reported in this study. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Total conjunctivitis cases of any aetiology (ACAE) was not reported in the 1 study with this comparison (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>). It is uncertain whether ACAE was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>In the 1 study comparing these interventions (<a href="./references#CD001862-bbs2-0028" title="SiegelJD , McCrackenGH , ThrelkeldN , DePasseBM , RosenfeldCR . Single dose penicillin prophylaxis in neonatal group-B streptococcal disease. Conclusion of a 41 month controlled trial. Lancet1982;1(8287):1426-30. SiegelJD , McCrackenGH , ThrelkeldN , MilvenanB , RosenfeldCR . Single dose penicillin prophylaxis against neonatal group-B streptococcal infections. New England Journal of Medicine1980;303(14):769-75. ">Siegel 1982</a>), conjunctivitis of unknown aetiology was not reported, and it is uncertain if it was measured. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk taken from the study population in the included studies.<br/><br/><b>CI:</b> confidence interval; <b>IM:</b> intramuscular; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial has high risk of selection bias, high to unclear risk of performance bias, unclear attrition bias.<br/><sup>2</sup>We did not downgrade for imprecision even though number of events were low, sample sizes are very large (close to 16,000 in each group). Long follow‐up time of 41 months. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Penicillin IM compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0021"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Povidone‐iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> tetracycline </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with tetracycline</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study included in this comparison measured gonococcal conjunctivitis but did not find any cases in either study arm (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study included in this comparison measured chlamydial conjunctivitis but did not identify any cases in either study arm (<a href="./references#CD001862-bbs2-0008" title="DavidM , RumeltS , WeintraubZ . Efficacy comparison between povidone iodine 2.5% and tetracycline 1% in prevention of ophthalmia neonatorum. Ophthalmology2011;118(7):1454-8. ">David 2011</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.04<br/>(0.99 to 4.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000<br/>(49 to 209) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 3.01<br/>(1.52 to 5.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149 per 1000<br/>(75 to 296) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 20.4<br/>(1.2 to 345.8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>410<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There were no cases of conjunctivitis in the comparator group. The value of 1 per 1000 is the risk for tetracycline for illustrative purposes only. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(1 to 346) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): study has unclear or high risk of bias, which could influence outcome.<br/><sup>2</sup>Downgraded for imprecision (‐1): small trial size and lack of detection of any gonorrhoea cases.<br/><sup>3</sup>Downgraded for imprecision (‐1): small trial size and lack of detection of any chlamydia cases.<br/><sup>4</sup>Downgraded for imprecision (‐1): optimal information size criteria not met; confidence interval overlaps no effect; small trial size.<br/><sup>5</sup>Downgraded for imprecision (‐1): optimal information size criteria met, but one trial, wide confidence interval, low event rates, small sample size.<br/><sup>6</sup>Downgraded for imprecision (‐1): optimal information size criteria possibly met, but one trial, wide confidence interval, low event rates, small sample size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Povidone‐iodine compared to tetracycline for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0022"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Povidone‐iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> chloramphenicol </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with chloramphenicol</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2004<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 included study measured gonococcal conjunctivitis but did not find any cases in either study arm (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.77<br/>(0.97 to 3.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2004<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 per 1000<br/>(16 to 52) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study measured and reported cases of bacterial conjunctivitis, but data could not be extracted (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study measured and reported cases of any conjunctivitis of any aetiology, but data could not be extracted (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>The 1 study likely measured conjunctivitis of unknown aetiology, but data could not be extracted (<a href="./references#CD001862-bbs2-0026" title="Ramirez-OrtizMA , Rodriguez-AlmarazM , Ocha-Diaz LopezH , Diaz-PrietoP , Rodriguez-SuarezRS . Randomised equivalency trial comparing 2.5% povidone-iodine eye drops and ophthalmic chloramphenicol for preventing neonatal conjunctivitis in a trachoma endemic area in southern Mexico. British Journal of Ophthalmology2007;91(11):1430-4. ">Ramirez‐Ortiz 2007</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): masking not addressed or unclear; high losses to follow‐up, which can create plausible bias about results.<br/><sup>2</sup>Downgraded for imprecision (‐1): zero event rates, sample size small, and unable to determine relative effects; single trial.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size not met, and confidence interval overlaps no effect; single trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 21.</span> <span class="table-title">Povidone‐iodine compared to chloramphenicol for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0023"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Povidone‐iodine compared to carbethopendecinium bromide for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Povidone‐iodine compared to carbethopendecinium bromide for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> povidone‐iodine<br/><b>Comparison:</b> carbethopendecinium bromide </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with carbethopendecinium bromide</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make any reference to gonococcal conjunctivitis (GC). There is no reference to culturing. It is unknown if GC was measured. GC cases were not reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make any reference to chlamydial conjunctivitis (CC). It unknown if CC was measured. No reference to culturing. No CC cases were reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make reference to bacterial conjunctivitis (BC). It unknown if BC was measured. No reference to culturing. No BC cases reported. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44<br/>(0.15 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 trial only (<a href="./references#CD001862-bbs2-0030" title="ZbojanJ , DluholuckyS , ZacharovskaM . Credeization with povidone-iodine - efficiency and a possible influence on thyroid gland in newborns [Kredeizacia povidon-jodidom - ucinnost a mozny vplyv na stitnu zlazu novorodenca]. Cesko Slovenska Pediatrie2004;59(1):11-3. ">Zbojan 2004</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/>(27 to 243) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Translation of the 1 study does not make reference to conjunctivitis of unknown aetiology (CUE). It unknown if CUE was measured. No CUE cases were reported and CUE could not be calculated. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial with unclear risk of selection bias, performance bias, detection bias, and attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect; small trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 22.</span> <span class="table-title">Povidone‐iodine compared to carbethopendecinium bromide for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0024"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Double application of povidone‐iodine compared to single application of povidone‐iodine for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Double application of povidone‐iodine compared to single application of povidone‐iodine for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> double application of povidone‐iodine<br/><b>Comparison:</b> single application of povidone‐iodine </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with single application of povidone‐iodine</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with double application of povidone‐iodine</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study measured cases of gonococcal conjunctivitis, but no cases were found in either study arm (<a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.27<br/>(0.26 to 6.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001862-bbs2-0020" title="IsenbergSJ , AptL , Del SignoreM , GichuhiS , BermanNG . A double application approach to ophthalmia neonatorum prophylaxis. British Journal of Ophthalmology2003;87(12):1449-52. ">Isenberg 2003</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/>(2 to 44) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.69<br/>(0.59 to 4.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 per 1000<br/>(9 to 72) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.32<br/>(0.99 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243 per 1000<br/>(182 to 322) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.29<br/>(0.95 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>719<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218 per 1000<br/>(161 to 294) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single trial has high risk of selection bias, unclear risk of performance bias, and unclear risk of attrition bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): no events in either arm. <br/><sup>3</sup>Downgraded for imprecision (‐2): limited number of events in each arm, very wide confidence intervals. <br/><sup>4</sup>Downgraded for imprecision (‐1): optimal information size criteria not met, and 95% confidence interval includes no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 23.</span> <span class="table-title">Double application of povidone‐iodine compared to single application of povidone‐iodine for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001862-tbl-0025"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in newborn children</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in newborn children</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> newborn children<br/><b>Setting:</b> any maternity setting<br/><b>Intervention:</b> penicillin IM </p> <p><b>Comparison:</b> topical penicillin ointment </p> </td> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with topical penicillin ointment</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with penicillin IM</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blindness (visual acuity less than 20/200)<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any adverse visual outcome<br/>follow‐up: 12 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gonococcal conjunctivitis<br/>assessed with: <i>Neisseria gonorrhoeae</i>‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 1 study measured cases of gonococcal conjunctivitis, but no cases were found in either study arm (<a href="./references#CD001862-bbs2-0009" title="DavidsonHH , HillJH . Penicillin in the prophylaxis of ophthalmia neonatorum. Journal of the American Medical Association1951;145(14):1052-5. ">Davidson 1951</a>). </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chlamydial conjunctivitis<br/>assessed with: <i>Chlamydia trachomatis</i> culture, PCR, or direct fluorescent monoclonal antibody stain<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>This 1 study from 1951 did not report the diagnosis of chlamydial conjunctivitis, nor did the authors specify if chlamydia was measured. It is unlikely that techniques to detect chlamydia were used in this time period. </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bacterial conjunctivitis<br/>assessed with: any bacteria‐positive culture<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.19<br/>(1.14 to 4.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(10 to 38) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Any conjunctivitis of any aetiology assessed with: clinical assessment<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/>(1.26 to 2.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75 per 1000<br/>(55 to 102) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Conjunctivitis of unknown aetiology assessed with: culture negative<br/>follow‐up: 1 month </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.58<br/>(1.12 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2795<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>1,3</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(39 to 79) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>No studies reported this outcome.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). The assumed risk is taken from the study population in the included studies. </p> <p><b>CI:</b> confidence interval; <b>IM:</b> intramuscular; <b>PCR:</b> polymerase chain reaction; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High‐certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate‐certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low‐certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low‐certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded for risk of bias (‐1): single study at high risk or unclear risk of bias.<br/><sup>2</sup>Downgraded for imprecision (‐2): optimal information size criteria likely not met; no events.<br/><sup>3</sup>Downgraded for imprecision (‐1): optimal information size criteria not met. However, confidence interval excludes no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 24.</span> <span class="table-title">Pencillin IM compared to topical penicillin ointment for the prevention of ophthalmia neonatorum in newborn children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/full#CD001862-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any prophylaxis versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.57, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.37, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.54, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Nasolacrimal duct obstruction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Keratitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Any prophylaxis versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Silver nitrate versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.52, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Corneal abrasion <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Nasolacrimal duct obstruction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Silver nitrate versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Erythromycin versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.49, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.51, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Nasolacrimal duct obstruction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Erythromycin versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tetracycline versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.55, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Tetracycline versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Povidone‐iodine versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Povidone‐iodine versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bacitracin‐phenacaine versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bacitracin‐phenacaine versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Colostrum versus no prophylaxis</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Colostrum versus no prophylaxis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Erythromycin versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.51, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.80, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Nasolacrimal duct obstruction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Erythromycin versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Tetracycline versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.40, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Nasolacrimal duct obstruction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Tetracycline versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sulfacetamide versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sulfacetamide versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Cetyl‐pyridinium chloride versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.59, 5.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.40, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Cetyl‐pyridinium chloride versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Penicillin versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Penicillin versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Penicillin IM versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2727</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Penicillin IM versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Povidone‐iodine versus silver nitrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.5 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Povidone‐iodine versus silver nitrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Tetracycline versus erythromycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.42, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Tetracycline versus erythromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Colostrum versus erythromycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Colostrum versus erythromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0042"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Povidone‐iodine versus erythromycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.54, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.68, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.58, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Povidone‐iodine versus erythromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0043"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Pencillin IM versus tetracycline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Pencillin IM versus tetracycline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0044"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Povidone‐iodine versus tetracycline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.4 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.5 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Povidone‐iodine versus tetracycline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0045"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Povidone‐iodine versus chloramphenicol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Povidone‐iodine versus chloramphenicol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0046"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Povidone‐iodine versus carbethopendecinium bromide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Povidone‐iodine versus carbethopendecinium bromide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0047"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Povidone‐iodine twice versus povidone‐iodine once</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 Chlamydial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.4 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.5 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Povidone‐iodine twice versus povidone‐iodine once</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001862-tbl-0048"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Penicillin IM versus topical penicillin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 Gonococcal conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 Bacterial conjunctivitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.3 Any conjunctivitis of any aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.4 Conjunctivitis of unknown aetiology <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Penicillin IM versus topical penicillin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001862.pub4/references#CD001862-tbl-0048">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001862.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001862-note-0036">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001862-note-0034">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001862-note-0035">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001862-note-0033">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001862-note-0032">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001862-note-0031">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001862-note-0029">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001862-note-0030">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001862-note-0027">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001862-note-0028">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001862\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001862\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001862\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001862\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001862\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=KUoIaN9D&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001862.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001862.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001862.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001862.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001862.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717140752"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001862.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717140756"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001862.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db0a59fa2936e',t:'MTc0MDcxNzE0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 